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Mobile health (mHealth) applications (apps) are currently changing Australian healthcare. mHealth apps 
which have a therapeutic and diagnostic intended purpose are called mobile medical applications (MMA), 
and are being integrated into healthcare by patients and practitioners in Australia. MMAs have the 
potential to decrease the health burden of some chronic conditions as well as improve the delivery of 
healthcare. Any harms produced by the technology are mainly through the information provided and how 
it is used in clinical decision-making.  
 
The nature of apps presents unique challenges (such as their rapid lifecycle) to regulatory and 
reimbursement processes. There are currently no policies or frameworks available that can be used to 
conduct a health technology assessment (HTA) on MMAs. Therefore, the aim of this research was to 
determine what policy changes and assessment criteria are needed to facilitate the development of a 
system that evaluates MMAs for regulatory and reimbursement purposes in Australia. 
 
Methodology 
In order to achieve this overall aim, the research was divided into four parts. Firstly, I reviewed the 
Australian Therapeutic Goods Administration (TGA) regulation of MMAs by evaluating it against 
international counterparts and the International Medical Devices Regulator’s Forum’s (IMDRF) guidance 
document for clinically evaluating medical software. This was achieved through the use of a policy 
analysis and case studies. The policy analysis evaluated MMA regulations internationally to determine 
whether the regulatory bodies of the IMDRF members addressed the IMDRF guidance on clinically 
evaluating software as a medical device (SaMD). The case studies reviewed how different MMAs in 
Australia and the United States of America (USA) were regulated to determine to what extent the SaMD: 
Clinical Evaluation (2017) guidance was applied.  
 
The second section evaluated existing frameworks for assessing MMAs and determined whether any 
were suitable for use in HTA and reimbursement decision-making. This was achieved through a 
methodological systematic review. The systematic searches were conducted in seven bibliographic 
databases in order to identify literature on MMA evaluation frameworks published between 2008 and 
2016. Frameworks were only eligible for inclusion in the review if they evaluated one of the HTA domains 
of safety, cost-effectiveness and/or effectiveness of an MMA. Once a framework had been included into 




The third section detailed the creation and testing of an MMA HTA evaluation module which was used to 
modify the current HTA guidelines in Australia. The use of the module ensures that the technology specific 
characteristics of apps would be properly appraised during an assessment. The module’s transferability 
to comparable HTA jurisdictions was also assessed. This was achieved in two stages. The first stage 
were in-depth interviews with stakeholders (healthcare practitioners, application developers, and 
policymakers) to determine possible impediments and pathways to MMA reimbursement in Australia. The 
findings of the interviews were integrated with those from the first and second sections of this research 
on MMA reimbursement and regulation to create an MMA evaluation module. 
 
The fourth and final section determined the feasibility of MMA reimbursement in Australia through the 
integration and synthesis of all the evidence generated from the preceding three sections. 
 
Results  
The research found that there were policy gaps in the regulatory and reimbursement criteria used to 
evaluate MMAs. Regarding current regulatory policy, the TGA does not adequately evaluate MMAs 
according to the IMDRF criteria. Policy changes to current regulation processes should include an 
assessment of the harm from misinformation as well as potential risks associated with information and 
connectivity compatibilities, such as cybersecurity threats. Similarly, there were a number of policy 
changes that could be made to support the reimbursement of MMAs in Australia.  
 
The systematic literature review of MMA evaluation frameworks found that there was a greater need to 
evaluate the harms posed by MMAs (i.e. misinformation) as well as a fuller consideration of the likely 
comparator for the technology. Other considerations included, but were not limited to, equity of access to 
MMAs (i.e. by way of age, literacy, user disability, etc.), as well as the importance of secure and proper 
management of confidential data. Other technology specific concerns included: the possible effect of 
software updates on the effectiveness and safety of MMAs and possible variation in app performance on 
different operating systems (OS), mobile platforms, and generations of the same platform.  
 
Interviews conducted with stakeholders sought to explore possible pathways and impediments to MMA 
reimbursement in Australia and, highlighted a few policy challenges. These included: clarification around 
where the responsibly lies regarding data ownership, cybersecurity, and professional liability in the use of 
app data; the digital health literacy of healthcare practitioners, patients, and any other MMA users (i.e. 
carers); and finally, developing evaluative measures which address the technological evolution of MMAs, 
such as the technology’s rapid lifecycle and software updates. Contrastingly, the interviews indicated that 
stakeholders trust the evidence-based approach used by the Australian Medical Services Advisory 
xxiii 
 
Committee (MSAC) to conduct HTAs and make public funding decisions and felt it would be an 
appropriate evaluation mechanism for MMAs. 
  
Given these policy concerns, proper evaluation of MMA’s is needed before they can be reimbursed in 
Australia. To ensure that MMAs are properly evaluated, a module was developed which could modify the 
current HTA framework employed by MSAC. The module addressed both regulatory and reimbursement 
policy concerns. This is to ensure that the regulatory issues are addressed, as the current TGA process 
does not properly evaluate them.  
 
The utility of the MMA HTA evaluation module was assessed for adaptation to other comparable HTA 
jurisdictional bodies, such as the European Economic Area (EEA), Canada, and the United States of 
America (USA). Minimal modifications would need to be made to the module for it to be used by other 
HTA agencies in these jurisdictions. These adaptations would include the removal of any of the unique 
MMA items (e.g. software, updates, cybersecurity) that were already addressed by the jurisdiction’s 
regulatory authority. Adaptations to the cost-effectiveness domain would be dependent on the individual 
economic evaluations conducted by the respective jurisdictional HTA agencies, and their individual 
healthcare contexts. 
 
The development of the MMA HTA evaluation module, and the research that informed it, shows that MMA 
reimbursement in Australia is feasible. Thus, it is feasible to tailor the regulatory and reimbursement 
processes in Australia to evaluate MMAs properly. 
 
Conclusion  
In conclusion, it is possible to tailor regulation and reimbursement processes in Australia to address the 
evaluation of MMAs. These modifications to current processes can be made through a variety of key 
policy and process changes. One process change would be the adoption of the MMA evaluation module 
as it is capable of adapting the existing MSAC evaluation framework to assess this technology. Other 
policy changes would include: facilitating the digital health literacy of MMA users (i.e. healthcare 
practitioners, patients, carers, etc.); providing clarification around who and where the responsibility lies 
regarding use of MMAs (i.e. data ownership, professional liability, and cybersecurity), and, finally, 
stipulating evaluative procedures which address the challenges posed by the ongoing technological 










1.1 Introduction to thesis 
Electronic health (eHealth) has been revolutionising the Australian health system. A large contributor to 
this transformation is mobile medical applications (MMA).(2-5) MMAs are applications (apps) that have 
an intended purpose which is therapeutic or diagnostic and are available on mobile devices such as 
smartphones, tablets, and smartwatches.(6, 7) Currently, MMAs are being both used and recommended 
by healthcare practitioners (i.e. general practitioners, specialists, allied health workers, etc.) in clinical 
consultations.(2, 4-6, 8, 9)  
 
A possible impediment to the complete incorporation of MMAs into the Australian healthcare system is 
the fact that various apps can have costs attached to them.(2, 10-12) These costs can be direct or indirect. 
An outright cost includes the price the patient has to bear to purchase and download the MMA. Whereas, 
the indirect cost encompasses the in-app purchases (i.e. subscriptions) the patient has to cover in order 
to receive the medical services provided by the MMA for set period of time (e.g. 3 months). The direct and 
indirect costs associated with the MMA, may prevent some users from being able to access the medical 
services provided by the software. For example, a mental health MMA called MoodKit(13) costs AU$7.99 
outright and has no in-app purchases. While, Moodpath: Depression & Anxiety(14) is free to download 
and has in-app purchases which range from AU$6.99 to AU$70.99. Some MMA have costs which may 
seem negligible, however, others may require in-apps purchases (i.e. subscriptions), and/or accessories 
such as attachments (i.e. glucometer, electrocardiogram), implantable devices (i.e. implantable cardiac 
monitor), and wearables (i.e. external heart rate monitor).(15-18)  
 
In Australia, the government provides reimbursement for medical services provided or prescribed by a 
healthcare practitioner, through the universal health insurance system (Medicare). Reimbursement is 
available for patients and eligible healthcare practitioners. Patients are able to claim subsidies on 
receiving a medical service,(19-22) while healthcare practitioners can claim reimbursement for providing 
medical services as part of a clinical consultation.(14, 20, 21, 23-25)  For medical services that involve a 
medical device, to be eligible for reimbursement through Medicare they have to undergo two evaluations. 
The first evaluation is conducted by the Therapeutic Goods Administration (TGA) on the medical device 
for regulatory purposes. The review guarantees that the medical device can be sold in Australia. The 
second evaluation is a health technology assessment (HTA) which is conducted by an independent 
organisation to inform decision making by the Medical Services Advisory Committee (MSAC). A medical 
service is reimbursable only after it is approved by the both the TGA and MSAC and the Minister of Health 





Currently, there is no pathway for patients or health practitioners to claim reimbursement for any MMA-
based medical services, even though they are already being used and recommended in domestic 
healthcare.(2, 28, 29) Moreover, there are no evaluation criteria in Australia (or internationally), which can 
be used to review MMAs for reimbursement purposes. This is further complicated by the fact that MMAs 
present different harms to traditional medical devices.(22, 30-36) The dynamic nature of MMAs (i.e. 
software updates, rapid lifecycle and development) may require evaluative frameworks that are specific 
to the technology.(14, 22, 31, 32, 34-36)   
 
Thus, this thesis explores the feasibility of tailoring regulation and reimbursement processes in Australia 
to the evaluation of MMAs. 
1.2 Thesis outline  
This thesis is “by publication” and is comprised of nine chapters. Chapter 1 provides a brief introduction 
and background to this thesis. Chapter 2 features a detailed background to MMA reimbursement and 
regulation in Australia. Chapter 3 provides a rationale for the research and outlines the thesis aim, 
research questions and objectives. Chapter 4 details the complete thesis methodology used to address 
the overall thesis aim and each research question. Chapters 5, 6, and 7 discuss the findings of the 
research studies conducted to answer the research questions. Chapters 5 and 6 include the articles 
published on MMA regulation in Australia and assessing MMAs for HTA purposes in Australia, 
respectively. Chapter 7 has two sub-sections, a manuscript submitted for publication on developing an 
MMA evaluation module which can be used to adapt existing frameworks for HTA and reimbursement 
decision-making in Australia, and a small auxiliary study on the adaptability of the proposed evaluation 
module to comparable jurisdictions. Chapter 8 synthesises the results from the three preceding chapters 
(Chapter 5, 6, and 7) and explores the feasibility of MMA reimbursement in Australia in the current 
domestic healthcare context. Finally, Chapter 9 concludes the thesis by addressing the overall aim, 










2.1 Introduction  
This chapter provides a detailed background on MMA reimbursement and regulation in Australia.  
 
2.2 About mobile health (mHealth) 
Mobile health (mHealth) is a dynamic field which is developing rapidly and has great potential in Australia 
to change the health industry.(12, 37) A large contributor to this is the rapid penetration of smartphones 
and tablets throughout the country over the last decade. Currently smartphone penetration is around 89% 
(2018), and it is predicted that it will continue to increase until it plateaus at 95%.(12, 37-40) This combined 
with the increase in health and medical applications (apps), has resulted in a change within the Australian 
healthcare environment.  
 
There is debate about the definitions and categorisation of mHealth, electronic health (eHealth) and 
telemedicine/ telehealth.(41, 42) Over the past two decades, as the fields have developed, the names for 
these forms of healthcare provision have been used interchangeably and definitions can slightly change 
depending on country.(41) Thus the definitions and categorisations of eHealth, mHealth and telemedicine 
used in this thesis are the ones created and recognised by the World Health Organisation (WHO).(41-44) 
See Appendix A for detailed explanation of mHealth (A.1.1), eHealth and telemedicine (A.1.2).  
 
Thus, it is important to explore the parameters of what defines mHealth apps, the different platform and 
operation systems the technology is available on, as well as the benefits and harms they may present to 
healthcare provision. 
 
2.2.1 Defining mobile platforms 
A mobile platform is a handheld, commercially available computing platform that may or may not have 
wireless connectivity. The current embodiment of a mobile platform includes smartphones, tablets, and 
smartwatches.(4, 42, 44, 45) 
 
2.2.2 Defining operating systems  
An operating system (OS) is a software that is loaded on the platform by a boot program. The software 
directly controls all platform processing, including other software/applications, assigning platform memory, 
as well as controlling output and input functions.(42-47) A few popular OSs for mobile platforms include, 
Android (Google), iOS (Apple), Symbian (Nokia), and Windows Phone (Microsoft).(32, 45) 
 
2.2.3 Defining mobile applications 
A mobile app is a type of software extension developed specifically for a mobile platform. The applications 




platform’s specialised capabilities.(48-50) Mobile apps can be categorised into two overlapping groups of 
a ‘native’ app and/or ‘web-based’ apps. Native apps are software created to be executed on a mobile 
platform, whereas web-based software applications are tailored to mobile web browsers and are run on 
a server. As technology is developing there are single apps which can be categorised as both native and 
web-based.(48-50) This thesis focuses on native apps. 
 
2.2.4 Defining mobile medical applications (MMA)  
Mobile medical applications (MMA) are a subset of mHealth. The Therapeutic Goods Administration 
(TGA) defines a mobile application as meeting the regulatory authority’s criterion for a medical device 
(explained in Section 2.3 below).(51) Examples of MMAs in Australia are apps that are used for the 
diagnosis and treatment of medical conditions.(22) Thus, within this research, apps used for information, 
wellness (fitness, meditation, nutrition) were not considered to be MMAs as they did not have a therapeutic 
purpose. It is not clear how the TGA define therapeutic medical apps that have accessories. In this thesis 
apps that meet the TGAs definition of a medical device and have accompanying accessories were also 
considered MMAs. Figure 2.1 shows how MMAs fit in the broader electronic health context. 
 
Figure 2.1: MMAs in a broader electronic health (eHealth) context  
 
Source: a World Health Organisation (44), b World Health Organisation (42), c World Health Organisation 





2.2.5 Potential of MMAs to transform Australian healthcare  
MMAs not only have the potential to transform Australian healthcare, they are already doing it.(2, 52-55) 
The potential for eHealth technology, such as MMAs, to alter the landscape of Australian healthcare has 
been known since the 1990s.(3)  
 
Mobile platforms in the form of smartphones are the primary medium embodying and driving the eHealth 
revolution within Australian healthcare, through mHealth technologies such as MMAs.(2, 55, 56) The high 
penetration of smartphones is due to platform mobility, affordability, accessibility, and the available data 
storage, as well as the ability of installed apps to integrate with various devices and the internet. So much 
so, that in Australia, smartphones account for 40% (2018) of Australian internet access; compared to 49% 
(2018) for laptops and desktop computers.(57) The portable, personal and diverse platform has truly been 
embraced: within an hour of waking, over 80% of Australians will have checked their smartphone, with 
over half having done it within the first 15 minutes. Throughout a single day it is estimated that collectively 
Australians glance at their smartphone over 440 million times.(22) Even in the age group of 65 to 75 years 
age, where the platform has the least penetration at 68%, people check their smartphone within an hour 
of waking and on average will glance at it 10 times per day.(58, 59)  
 
mHealth apps are already being used to deliver low cost health interventions to the population, particularly 
in rural and remote areas where there is limited health service delivery.(2-4, 60, 61) There is evidence 
that mHealth interventions – including those that include MMAs -- are effective in the management of 
chronic diseases (such as diabetes), as well as in health promotion (e.g. encouraging smoking 
cessation).(62, 63) MMAs could be especially beneficial as a medium to provide health services and 
chronic disease management, as residents of rural and remote areas are 40% more likely to have a 
chronic disease than those who reside in metropolitan areas.(64) Furthermore, the strain the increase in 
chronic health conditions has put on the domestic the health system is reflected in the increase in health 
expenditure.(65-67) With the average increase in health expenditure around 3.0% (2017) per year. Of this 
growth, approximately two-thirds was due to an increase in consumption of individual medical goods and 
services per person.(62) A large contributor to this increase was the broadening burden of chronic disease 
and the continued treatment and monitoring that accompanies the conditions.(63) The best way to reduce 
these increased budget pressures is through streamlined monitoring and prevention of chronic diseases. 






Examples where mHealth is being used in health care include:  
 
 e-Mental Health in Practice (eMHPac)(69): A programme funded by the Federal Government 
which teaches and encourages doctors and allied health professionals about software-based 
mental health resources (websites and MMAs). The programme aims to train healthcare 
professionals so these resources can be incorporated into primary care services to assist patients 
in receiving continual effective treatment regardless of time and place.(69)  The programme 
facilitates the use of MMAs in Indigenous Australian communities, due to the high take up rates 
of mobile phones and social media among Indigenous young people.(70)  eMHPac also provides 
training for doctors, nurses, and allied health workers working with Indigenous peoples.(69)   
 
 Additionally, an eMHPac affiliated project called StayStrong has designed and uses an app to 
assist doctors, nurses, allied health workers and Aboriginal health workers in to provide culturally 
appropriate wellbeing support to Indigenous clientele in both a clinical and community setting.(71) 
 
 The Commonwealth Scientific and Industrial Research Organisation (CSIRO) have successfully 
created and trialled an MMA that assists with the rehabilitation of cardiac patients.(72, 73)  
 
 In industry, SportsMed a healthcare provider, orthopaedic hospital, and specialist clinic in South 
Australia have created and trialled an MMA to assist with the rehabilitation, treatment, and 
management of patients before and after hip replacements.(74, 75) 
 
 iBobby  is an MMA that was developed and trialled by the Black Dog Institute, which was aimed 
at providing culturally appropriate evidence-based suicide prevention to young Indigenous 
Australians.(70, 76) 
 
MMAs may transform healthcare through a variety of mechanisms including: streamlining healthcare 
delivery (i.e. reduction of test duplication, improved coordination of the management of complex and 
chronic conditions); mitigation the challenges associated with treatment across distances in rural and 
remote areas; reducing escalating healthcare costs; remote monitoring of patients by health 
professionals; avoidance of hospital admissions; and a decrease in adverse events related to healthcare 





However, costs related to MMAs have the potential of act as a barrier to the access and provision of app-
enabled healthcare.  Possible cost- barriers include the purchase of MMAs, accessories or in-app 
purchases. For example if a doctor in Australia recommended a well-developed scientifically supported 
MMA like SkinVision –a skin-cancer detection app-- patients would have to pay between AU$5.99 to 
AU$41.99 every few months to monitor their skin health, due to the various in-app purchases.(80) These 
costs may be considered ‘low’, which could lead to the assumption that they are available to ‘everyone’. 
Yet, patients (mostly low socioeconomic status) could choose to use another skin-cancer detection app 
which is less effective and safe but is cheaper or free.(11, 34) Furthermore, there is currently no way for 
healthcare practitioners (i.e. general practitioners, GPs) to claim reimbursement for using the information 
provided by MMAs in a clinical consultation or for reviewing, assessing, and monitoring patient data 
produced by an MMA.(12) This could result in medical practitioners not utilising the MMAs, charging 
patients privately for the extra time it takes for them to review, assess, and monitor the MMA data, or 
billing Medicare for longer consultations (so the patient would have to pay a larger gap payment, as well 
as the costs associated with the app itself). If a patient could receive reimbursement for the application 
through a separate Medicare item number, there would be fewer out-of-pocket costs and the usage and 
effectiveness of app-based management could be monitored through claims data. Conversely, if a 
medical practitioner was reimbursed through Medicare for the time it takes to appraise the data produced 
by MMAs, as well as for its use in a clinical consultation, it could assist the uptake and transmission of 
digital health data and spare patients’ possible additional costs. Publicly funded, MMA reimbursement 
could ensure equitable and accessible healthcare that is provided through MMAs to all Australian 
residents regardless of socioeconomic status. 
 
2.2.6 Potential harms 
The potential harm posed by MMAs is different to that presented by traditional medical devices. Traditional 
medical devices pose mostly physical harms to users,(22, 36, 48) whereas the harms posed by MMAs 
(and similar digital health software) largely centre around the information produced and how it is used in 
decision-making by users.(22, 36)   
 
A major concern is how the user applies the information produced by the MMAs to inform clinical decision-
making by the healthcare practitioners or their patients. This is especially concerning when the information 
which underpins the MMA is outdated or not evidence based.(22, 32, 34, 36) It is not uncommon for MMA 
users to be exposed to misinformation. Aboms et al.(81) found low adherence to U.S clinical practice 
guidelines for treating tobacco use dependence among 47 mHealth apps aimed at assisting smoking 
cessation. A systematic review by Subhi et al.(33) concluded that mHealth apps do not adhere to medical 




available mobile platforms’ (i.e. smartphone or tablet) size and hardware features could affect the 
assessment and interpretation of medical information.(32, 48) For example, radiological image 
interpretation could be affected by the low contrast, back lighting, and screen size of device.(48) 
Misinformation is a serious harm. It can cause incorrect, unnecessary, or the withholding of a treatment. 
It can also cause patients direct psychological harm through causing unnecessary worry or indirect 
physical harm, through the effects of the clinical decision-making.(10, 22, 31, 34, 36, 82) 
 
An additional harm posed by MMA relates to information security (cybersecurity). Information security is 
about maintaining the users’ privacy and confidentiality, as well as protecting the user or their data from 
being the victim of malicious software. These harms are MMA-specific harms as traditional medical 
devices are not networked and have limited or connective capabilities. In order for a traditional medical 
device to be ‘hacked’ or for personal medical information to be sold or illegally obtained, it has to be done 
physically.(83) However, the dynamic and connective capabilities of MMAs results in increased 
vulnerablity to attacks (i.e. ‘hacks’) from malicious software (i.e. ransomware, viruses).(83-88) Attacks 
from malious software have been known to enable third party control of MMAs as well as altering the 
app’s safety and efficacy. In either case this can threaten the health of patients. (83-89)  These 
cybersecurity concerns increase concerns around the privacy of patient health data and who can access 
it. These concerns are compounded by companies that own apps who on-sell consumer data, both with 
and without the user’s consent.(89, 90) 
 
If MMAs become a permanent fixture in Australian clinical consultations, the software will alter how 
patients receive treatment. Thus there is a need for the proper integration of MMAs into the national 
healthcare system, starting with determining whether MMA regulation can address the technology specific 
harms posed by the software. This would need to be followed by deciding if MMA reimbursement as part 
of a clinical service is possible and feasible.  
 
2.3 MMA regulation in Australia 
In Australia, the first step towards a health technology with a therapeutic or diagnostic purpose being 
available for reimbursement is its approval by the TGA for domestic use and sale.(19, 26) Thus, for MMAs 
to be eligible for public funding they have to be regulated by the TGA.  Currently, the TGA is attempting 
to regulate MMAs using pre-existing software regulation. (6, 7, 19, 26)  
 
2.3.1 Therapeutic goods regulation in Australia  
Therapeutic goods such as medical devices, medicines and biologicals are all subject to regulatory 




protect public health.(6, 7) The TGA is responsible for regulating goods that are used by humans for 
various health related purposes that include: diagnosing, preventing, alleviating or curing a disease, injury 
or defect; pregnancy testing; testing of a person’s susceptibility to a specific aliment or disease; or  
modifying, inhibiting or influencing a physiological process.(6) The TGA also regulates products that can 
modify or replace sections of human anatomy as well as items that are used as a component or ingredient 
during the manufacture of a therapeutic good.(6) The TGA regulates therapeutic goods to minimise the 
harm a product poses to the Australian population. In order to achieve this the organisation uses a ‘risk-
based’ approach to guide the assessment of the product. The level of risk assigned to the product depends 
on its intended purpose and the manner of supply. If a therapeutic good passes the TGA’s assessment 
for efficacy and safety, and the evaluation determines that the risks can safely be managed with the 
correct regulatory oversight, the product it is registered on the Australian Register of Therapeutic Goods 
(ARTG), which is available online. Once a product is registered on the ARTG is available on the domestic 
market.(6, 7, 91)  
 
2.3.2 Software regulation in Australia 
The TGA currently regulates software as an active medical device1. A therapeutic good is considered a 
medical device if it is to be used on a human with the aim of: diagnosing, treating, alleviating, monitoring 
or compensating for a disability or injury; diagnosing, preventing, treating, alleviating or monitoring a 
disease; modifying, replacing, or  investigating a physiological process or anatomy; birth control; and/or 
does not achieve its intended purpose of action in a human body through immunological, pharmacological 
or metabolic means, but could be assisted through such means.(6, 7)  In specific situations software can 
be regulated as an in vitro diagnostic medical device (IVD) (see Appendix A.1 for definition).(92, 93) There 
are varying ways in which the active medical device and IVD regulation policy can be applied to software; 
for more information see Appendix A.2.(6, 92) 
  
Software risk-classification  
Different risk-based approaches have been used to regulate and classify active medical devices and IVDs. 
When software is regulated as an active medical device the risk-based approach classifies devices into 
Classes I, IIa, and IIb. However, when Software as a Medical Device (SaMD) directly interacts (i.e. 
controlling, directly influencing, monitoring) with an active implantable medical device (AIMD) (i.e. 
cochlear implant, pacemaker, etc.), it is classified an Class III.(6) The IVD classification categorises 
devices into Classes 1, 2, 3, and 4.(92-95) In both risk categorisations the lowest numerical classification 
poses the least risk  to public health.(6, 95) All medical devices and IVDs are required to meet the 
                                                     
 




Essential Principles for performance and safety characteristics.(6, 94)  Device compliance with the 
relevant principles ensures that the health and safety of users is not compromised as the benefits of the 
product outweigh the risks. Non-IVD medical devices that are classified as Class II and above are required 
to obtain Conformity Assessment Certification, which assesses therapeutic (or diagnostic) effectiveness, 
as well as the Essential Principles.(6) Appendix A.2.2 explains risk-classification, information on non-IVD 
medical devices and IVD risk-classification. 
 
2.3.3 Current state of MMA regulation in Australia 
Currently, Australia does not have any specific regulation for mobile health apps. The TGA is attempting 
to regulate this sub-set of mHealth application, as a software as a medical device (SaMD). As with other 
therapeutic goods, MMAs approved by the TGA are listed on the ARTG.(6, 7) Figure 2.2 provides a 







Concerns with MMA Australian regulation   
The regulation of MMAs as software may not be the best approach to accurately assess the risk that 
mobile technology poses to the population. MMAs present a different regulatory challenge compared with 
traditional medical software and devices. For example, with MMAs, the same app can be available on 
Figure 1.2: Simplified overview of MMA regulation by the TGA 




various mobile platforms (smartphone/ tablet) as well as across various operating systems (iOS/ Android) 
and the app may respond differently on the different platforms or systems (see Section 2.2.7).(22, 32) An 
MMA may also pose different risks to the user on different platforms. For example, on September 12th 
2016 the TGA issued a safety warning for an error that only affected Accu-Chek Connect Diabetes 
Management app on Apple’s iOS, but not for the same app that is available on Google’s Android 
platform.(96) Aside from issuing the warning, the TGA regulation is for the software but does not have 
any policies that account for differences across multiple platforms or operating systems. Furthermore, 
MMAs are regulated according to their intended purpose at the time of regulation. There are currently no 
clauses to address updates that could change an MMA’s intended purpose after it has been approved 
and listed on the ARTG.(6, 7, 92) Finally, unlike other medical devices, MMAs can be created by anyone, 
based on any type of information and be made available direct to consumers on global scale in stores 
that are only monitored by multinational corporations.(48) To counteract this, in June 2016 Apple instituted 
guidelines that enables them to refuse to upload MMAs to their iTunes AppStore that do not have the 
relevant jurisdictional regulators’ approval.(97, 98) The TGA has acknowledged the complexity presented 
by MMA regulation and is keeping up to date with medical device developments.(7)  
 
2.3.4 International comparisons  
The USA, the European Economic Area2 (EEA) and Canada also regulate MMAs.(48, 101-103) Each 
regulatory body in these jurisdictions takes a slightly different approach to the regulation of MMAs. The 
EEA and Canada attempt to regulate MMAs using pre-existing policy, while the USA implemented an 
MMA specific approach within their current medical device regulation.(48, 101-103) In the EEA an MMA 
that is regulated will receive a CE marking.(101, 104) There is no registry or list of all the CE marked 
medical products.(101, 104) However, MMAs that have a CE marking have this in their product 
description, as was done with the NaturalCycles – Contraception app.(105, 106) In Canada only MMAs 
that are classified as Class ≤II are registered on the Medical Device Active Licence Listing (MDALL).(102, 
107) This is because Canada’s Medical Device Bureau (MDB) does not require a medical device licence 
from Class I devices - Class I medical devices are monitored by the Health Products and Food Branch 
Inspectorate (HPFBI).(102, 107-109) 
 
                                                     
 
2 EEA includes the European Union(EU) member states as well as Norway, Iceland, and 
Liechtenstein.(99) After a referendum held on the June 23rd 2016 in which the citizens of the United 





Like Australia the US FDA also provides a list of registered medical devices, called the 510k database, 
which can be searched.(48, 110) To address the challenges presented by MMAs, the FDA is currently 
piloting a new software policy and the EEA will implement one in 2020.(60, 89, 111-113) 
 
The challenge presented by software risk-classification has been noted by the International Medical 
Device Regulation Forum (IMDRF)(114). The IMDRF is a global forum for medical device regulators of 
which Australia, Canada, the EEA and the USA are members.(114, 115) 
 
2.3.5 International medical device regulators forum (IMDRF) 
In 2013 the IMDRF created a working group to develop guidance on how to support the innovation and 
adoption of safe and effective SaMD technology.(114) In September 2017 the IMDRF published a 
guidance document titled Software as a Medical Device (SaMD): Clinical Evaluation(22) in order to tackle 
the regulatory challenges presented by this technology.(22, 116) 
 
The SaMD: Clinical Evaluation document applies to software that fits the definition of a medical device, 
irrespective of the technology used (e.g. server, mobile app).(22) The document in its current form does 
not apply to software that does not meet the definition of a medical device. The software excluded are 
ones used for retrieving information from systems or devices; optimising the workflow of healthcare 
through automating care protocols; collecting and organising data; or providing a closed loop 
intervention.(22, 116) This is demonstrated in Figure 2.3 below. Incorporated into the guidance document 
are other relevant IMDRF SaMD guidance documents for Risk Categorization and Corresponding 
Considerations, Key Definitions, and Quality Management systems. The SaMD: Clinical Evaluation is 
meant to act as a guidance document, and by no means is intended to modify or replace any existing 





Figure 2.3: Clinical evaluation of SaMD 
 
Source: SaMD: Clinical evaluation (116) 
 
The purpose of the clinical evidence guidance document is to simplify and to advise on the necessary 
level and type of clinical evidence which is needed to determine the safety and effectiveness of generic 
software that meets the definition of a medical device.(114) The document provides guidance on the 
acceptable methods for conducting a clinical evaluation of a SaMD, the relevant levels of evidence for the 
types of SaMD, and when an independent review of a SaMD is necessary. The guidance document also 
includes a SaMD framework that uses risk management principles to classify the risk posed by the 
software. The risk-classification for medical software has four classes; Class I, II, III, and IV. The higher 
the class the higher the risk posed by the software. A combination of two major factors affect the 
classification of the medical software; these are the significance of the information the software brings to 
the healthcare decision, as well as the healthcare situation or condition itself.(36, 114) How the two 
interact to determine the risk that the software poses to public health is shown in Figure 2.3. 
 
The IMDRF SaMD: Clinical Evaluation guidance document could be used to help develop and assist in 





2.4 Reimbursement of MMAs in Australia 
 
2.4.1 Health services reimbursement in Australia 
Australia has three overlapping avenues available for the reimbursement of diagnostic and therapeutic 
goods and services approved by the TGA. These are federal, state, and private.(117) 
 
Federal - Medicare (Universal health insurance) 
In 1984 the Federal Government (Commonwealth) implemented a universal health insurance scheme 
called Medicare to address the issue of access and equity in healthcare. In general Medicare provides 
Australian residents with access to hospital and medical services.(117)The insurance scheme was a 
response to widening the gap between different socioeconomic groups, which resulted in a large section 
of the population not having health insurance of any form.(20) Within Medicare there is the Medicare 
Benefits Schedule (MBS) which lists medical services that are eligible for governmental 
reimbursement.(20, 117) Through the MBS, Medicare provides subsided or free treatment from medical 
practitioners (general practitioners (GP), nurse practitioners, specialists, and optometrists). For treatment 
that occurs outside a hospital setting, reimbursement is available to patients for up to 100% of the MBS 
fee for a GP service, and up to 85% of the MBS fee for specialist services. In circumstances where a 
doctor bills Medicare directly (‘bulk bills’) the patient does not have to pay any fee for the service.(24, 117-
119) Medicare also covers 75% of MBS fee for private patients in private or public hospitals.(21, 24, 119) 
Health professionals may charge more than the MBS fee in which case the patient must pay the gap. 
There are special circumstances where Medicare can provide subsidised treatment for allied health 
practitioners (i.e. within the Chronic Disease Management Plan) and dentists (i.e. within the Cleft Lip and 
Cleft Palate Scheme).(21, 24, 118) 
 
State - Public hospitals 
Public hospitals throughout Australia are administered by the states. State run public hospitals have a 
network of health services available and treatment to public patients occurs in the institutions free of 
charge.  In 1984 an agreement was made that the States would maintain the responsibility for 
administration of public hospitals and that funding would be provided by the Federal Government 
(currently predominantly through goods and service taxation revenue). In cases where public hospital 
spending exceeds the allocated funding the states are responsible for difference. Conversely, if the states 
spend less than their allocation they are able to keep the savings.(25)  
 
Private health insurance 
In Australia private health insurance is available for permanent residents who choose to purchase it. The 
type and range of reimbursement and services available are dependent on the policy of the insurer. 




psychology, etc.), glasses, contact lenses, hearing aids, dental treatment, dental examinations, and home 
nursing. Regarding hospital cover, private insurance can cover the remaining 25% of the MBS fee in a 
private hospital, hospital accommodation, theatre fee, prostheses, diagnostic tests, pharmaceuticals, 
intensive care, consumables, and any additional doctors’ fees. It is important to note that private health 
insurance in Australia is also subsidised by the Federal Government.(21, 24, 120)  
 
Deciding reimbursement eligibility  
Currently, the Federal Government attempts to ensure that only evidence-based therapeutic and 
diagnostic services that are comparatively cost-effective, effective, and safe (in terms of health outcome) 
are available for governmental reimbursement through the MBS.(19, 121) In order to attain maximum 
health benefit at minimal expense and harm, the Federal Government uses health technology assessment 
(HTA) to determine if a medical service is eligible for governmental reimbursement.  HTA has 
subsequently become a cornerstone of Medicare.(19, 25, 26, 117, 121) 
 
2.4.2 HTA in Australia 
In Australia HTA is the instrument used by the Federal Government to deliver financially sustainable 
healthcare that is both safe and clinically effective.(19, 121-123) HTA enables the provision of high quality 
research to inform clinical decision-making and policy development. As HTA is a multidisciplinary field, it 
enables an assessment of the economic, social, ethical, legal and clinical impacts of a health 
technology.(122-127) HTA involves the systematic evaluation of a health technology’s potential impact, 
effect, and properties. The hallmarks of the HTA process is the evaluation and synthesis of all available 
evidence relating to a specific question(s) pertaining to the given health technology/intervention using a 
systematic and structured methodology that can easily be replicated. The HTA methodology can be 
adapted to different health system(s); however, the process should remain systematic, rigorous and 
transparent.(122, 124-127) 
 
The Australian government uses the HTA process to help decide what health technologies should be 
eligible for reimbursement/ public funding. A health technology assessed for reimbursement in Australia 
can be a pharmaceutical, medical device, prosthesis, medical procedure, medical or surgical procedure, 
vaccine, and/or diagnostic technology. HTA is also used to assess health technologies that combine the 
use of a test and treatment/procedure such as co-dependent technologies or hybrid technologies to 
determine eligibility for governmental reimbursement.(19, 121) The different types of health technologies 
can qualify for Governmental reimbursement under the MBS or the PBS. HTA is also used to assess an 
intervention’s eligibility for private health insurance subsidisation on the Prostheses List.(19, 121) The 
Medical Services Advisory Committee (MSAC) oversees the HTA of medical services (including devices) 




eligible for reimbursement through the MBS.(19, 121) Appendix A.3 has more information on MSAC. 
Similarly, the Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for overseeing the HTA 
of pharmaceuticals and makes recommendations to the government on which products should be listed 
on the PBS.(121)  
 
Apart from informing policy, the information obtained through the HTA process can be used by health 
professionals, consumers, and financiers, to make decisions regarding the benefits and value of the 
technologies and their use in specific situations.(19, 121, 124)  
 
2.4.3 MMA reimbursement in Australia  
Currently, reimbursement for MMAs is not available in Australia through universal or private insurance. 
The MBS does not have any items that cover MMAs or reimburse GPs, specialists or healthcare workers 
for utilising MMA capabilities or data.(2, 12) The MBS does have telemedicine items for video 
consultations.(121, 128-130) For further information on telemedicine reimbursement in Australia see 
Appendix A.4. Some Australian private health insurers do provide their policy holders with access to 
mobile apps that provide company related services (i.e. how to make a claim) or health information and 
prescription management.(131-133) Reimbursement under Medicare would be  preferable to private 
health insurance as it would allow doctors, specialists and other healthcare workers (where deemed 
necessary) to utilise MMAs without having to worry about the cost to themselves or their patients.  If MMAs 
were listed on the MBS it would enable the services provided to be reimbursable under Medicare and 
allow the benefits of the technology to be both accessible and equitable to all permanent residents of 
Australian irrespective of their socioeconomic status.  
 
2.4.4 MMA reimbursement internationally 
The USA and Germany provide MMA reimbursement within their respective health systems. Since 2013, 
selected US health management organisations (HMO) have reimbursed MMAs. The first MMA to be 
reimbursement by an HMO was an FDA approved diabetes management app called WellDoc.(134) 
Similarly, in Germany3 multiple public health insurers reimburse MMAs.(136) The first MMA to be 
reimbursed in Germany was an app that had received a CE mark called Caterna. The app treated 
amblyopia (lazy-eye).(137) The health insurers in the USA and Germany that reimburse these MMAs 
have not published how these apps where selected or assessed for reimbursement. However, it appears 
likely that one of the key criteria was that the MMA had received approval from the relevant jurisdictional 
regulatory body.  
                                                     
 





For MMAs to be eligible for public funding through universal health insurance or some types of private 
health insurance they will usually have to undergo an HTA. The first step towards ensuring that the 
benefits and risks of MMAs are understood prior allowing equitable access to them is to determine whether 
it is feasible for the government to reimburse them within current HTA processes. To do this there needs 
to be an objective evaluation framework to assess the HTA domains of comparative safety, effectiveness 
and cost-effectiveness of the MMAs, as well as methods to classify the apps and assess the risk they 
pose to the population. 
 
2.4.5 HTA evaluation frameworks for MMA 
 
Currently, there is no MMA evaluation framework that can be used specifically for HTA purposes. Ideally, 
an MMA evaluation framework would address the HTA domains of effectiveness, safety and cost- 
effectiveness which could determine if the app is eligible for reimbursement. Nonetheless, frameworks 
and/or criteria that evaluate mHealth apps for a variety of different purposes have been published. Popular 
frameworks were developed by Stoyanov et al.(138), Martinez-Prerez et al.(139) and Reynoldson et 
al.(140).  
 
2.5 Gap in knowledge  
Unlike the USA and Germany, Australia currently does not have a method for reimbursing MMAs.  In 
Australia, there is also no specific method to determine the comparative safety and clinical effectiveness 
of an app. This is concerning, as MMAs have been transforming healthcare delivery in Australia and could 
help in tackling the health, social and economic challenges presented by the increase in chronic diseases. 
Furthermore, the Australian Government and medical practitioners know the benefit of mHealth apps such 
as MMAs, as they are creating, recommending, and using the software. A reimbursement pathway with 
specific sections for MMA evaluation could help address this problem. Before MMA reimbursement can 
be implemented in Australia, a method or process for evaluating MMAs needs to be developed that is 
feasible and equally as rigorous as the current processes used to evaluate other health technologies. 
 
2.6 Publications and presentation of chapter findings  
2.6.1 Presentation(s) 
 September 2016, Presentation, Moshi* M, Tooher R, Merlin T, Determining the feasibility of 
reimbursing mobile health apps in Australia, PHAA 44th Annual Conference & 20th Chronic 





 May 2016, Presentation, Merlin* T. and Moshi M, Getting a grip on new technologies: AHTA’s 
journey into m-health and mobile medical applications (MMAs), Health Technology Assessment 










3.1 Rationale  
There is currently no ability to claim reimbursement through Medicare for MMA use in Australia. Medical 
practitioners cannot claim the interpretation of health data derived from MMA or the use of an app during 
a clinical consultation. Similarly, patients cannot be subsidised through Medicare for out-of-pocket 
expenses (in-app-purchases or the cost of the MMA) related to the use of an MMA recommended by a 
medical practitioner to assist with their health condition. MMA reimbursement is not available through 
private health insurance providers in Australia. There is also currently no HTA method that can be used 
to evaluate MMAs to determine their safety, effectiveness and cost-effectiveness, to inform 
reimbursement decision-making. Thus, there is a need to determine if is it possible to adapt or create 
government reimbursement processes to include the use of MMAs by medical practitioners and patients 
through Medicare. The aim, research questions, and objectives are listed below, and how they interact 
with each other is illustrated in Figure 3.1. 
 
3.2 Aim(s) 
The overall aim of this thesis is to determine the feasibility of tailoring regulation and reimbursement 
processes in Australia to the evaluation of MMAs. 
   
3.3 Research questions 
1. Do changes need to be made to the current Australian regulatory model for software as a medical 
device (SaMD) to enable assessment of the possible health risks and benefits posed by MMAs? 
 
2. Is reimbursement for MMAs feasible in Australia within the current health technology assessment 
(HTA) system? 
 
3. What key policy changes and assessment criteria are needed to facilitate the development of a 




1. Assess whether the current Australian regulatory framework is suitable for the assessment of MMAs.  
 





 Test if the IMDRF guidance for clinical evaluation of SaMD can be feasibly applied 
to MMAs. 
 
 Identify the changes that would need to be made to the regulatory process in 
Australia to properly evaluate MMAs. 
 
 
2. Review existing evaluation frameworks for MMAs and determine their suitability for use within the 
HTA processes currently used to inform reimbursement decision-making. 
 
 Determine if there are tools available to assess: 
 The clinical effectiveness and safety of MMAs, 
 The credibility of MMAs. 
 
3. Determine whether reimbursement of MMAs is feasible in Australia and develop possible 
reimbursement implementation pathways. 
 
 Identifying possible pathways and evaluation processes for the reimbursement of 
MMAs in Australia. 
 
 Identify impediments to the reimbursement of medical applications (e.g. barriers to 
implementation).  
 
4. Determine the applicability of the possible MMA assessment criteria for reimbursement purposes 
in Australia to other jurisdictions. 
 
 Assess the HTA criteria used in: 
 Canada 
 European Economic Area (EEA) 
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4.1 Framework of the research overall  
In order to achieve the overall aim and address the proposed research questions, the overall project was 
divided into four sections. The first three sections addressed each individual research question and the 
corresponding objectives. While the fourth section addressed the overall aim of this thesis, which was to 
determine the feasibility of MMA reimbursement in Australia. Figure 4.1 illustrates the individual studies 
that form this thesis, and the respective methodologies undertaken to address the corresponding research 
question(s)/ aim. This figure also indicates which chapter addresses each respective research 
question(s)/ aim.   
 
The first section (Section 4.2) reviews the Australian regulation of MMAs (and SaMDs) by evaluating it 
against international counterparts and the IMDRF guidance document for clinically evaluating medical 
software. The second section (Section 4.3), evaluates existing frameworks for MMAs and determines if 
any are suitable for use within HTA and reimbursement decision-making. The results of the first and 
second sections indicated the need for a criterion which can evaluate the MMAs for reimbursement and/or 
HTA decision-making purposes, as it provides a possible evaluative mechanism for MMA in Australia and 
in comparable jurisdictions. Thus, the third section (Section 4.4) of this methodology details the creation 
and testing of an MMA HTA evaluation module which was used to adapt the current HTA guidelines in 
Australia. The use of the MMA evaluation module to adapt HTA evaluation frameworks, ensures that the 
unique challenges apps pose would be properly appraised during an assessment. The module’s 
transferability to comparable HTA jurisdictions (USA, Canada, EEA) and their evaluative methodologies 
was also assessed. The fourth (Section 4.5) and final section determined the feasibility of MMA 
reimbursement in Australia through integrating and synthesising all the evidence generated from the 
preceding three sections. 
 
It is important to note, that the aim of this chapter is to summarise the methodology used to address the 
thesis aim and research questions. To prevent the repetition of information throughout the thesis, the 
details provided below are generally not present in the study manuscripts or respective chapters; where 





  Aim 
To determine the feasibility of tailoring regulation and 
reimbursement processes in Australia to the evaluation of 
MMAs.  
3)   What key policy changes and assessment criteria are 
needed to facilitate the development of a system that 
evaluates MMAs for reimbursement purposes in Australia? 
1)   Do changes need to be made to the current Australian 
regulatory model for ‘software as a medical device’ to 
enable assessment of the possible health risks and 
benefits posed by MMAs? 
Methodological systematic review which appraises existing 
MMA evaluation frameworks to determine their suitability for 
use within the current HTA processes 
Case studies which tested 
if the TGA and FDA current 
regulation of MMAs 
addresses the challenges 
presented by the 
technology 
 
Policy Analysis which 
evaluated the regulation of 
MMAs (incl. SaMDs) in the 
IMDRF member 
jurisdictions  
 Comparing and contrasting the content of MMA 
evaluation module with that of the HTA guidelines 
of the respective jurisdictions 
Qualitative descriptions (interviews) to gain 




Synthesis all the findings from RQ 1 and 2 with 
the findings of the qualitative description 
(stakeholder interviews).  
Creation of MMA evaluation module for HTA and 
reimbursement purposes using synthesised 
information 
 Creation of a MMA evaluation framework through 
using the MMA evaluation module to adapt the 




Synthesising all of the evidence generated from the three 
research questions 
Chapter 5 Chapter 7 
Chapter 6 
Chapter 8 
Figure 4.1: Outline of studies and the methodologies undertaken to address the research question(s)/ aim examined 
Published: Moshi MR, Parsons J, Tooher R, Merlin T (2019) 
Evaluation of Mobile Health Applications: Is Regulatory Policy Up to 
the Challenge? Int J Technol Assess Health Care 35,351-60 
Published: Moshi MR, Tooher R, Merlin T (2018) Suitability of Current 
Evaluation Frameworks for Use in the Health Technology Assessment 
of Mobile Medical Applications: A Systematic Review. Int J Technol 
Assess Health Care 34,464-75 
Submitted (22 Oct 2019): Moshi MR, Tooher R, Merlin T 
(Unpublished) Development of a health technology assessment 
module for evaluating mobile medical applications. Int J Technol 
Assess Health Care. 
 
2)   Is reimbursement for MMAs feasible in Australia within the 
current health technology assessment system? 
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4.2 Evaluating the domestic regulation of MMAs 
A policy analysis and a case study analysis were undertaken to critically review the regulation of MMAs 
in Australia.  
 
4.2.1 Policy analysis  
A policy analysis was conducted to determine how MMAs are evaluated for regulatory purposes in 
Australia and throughout the other IMDRF member jurisdictions (Brazil, Canada, EEA, Japan, Republic 
of Korea (south), Russia, Singapore, and the USA).(114) The MMA regulatory policies of IMDRF member 
jurisdictions were compared and contrasted against the SaMD: Clinical Evidence(22) guidance document. 
In situations where the SaMD guidance documents were unclear, the agencies were contacted via e-mail 
for further clarification. For the policy analysis, the FDA and Canadian MDB were contacted, see Appendix 
B for a summary of the correspondence. More information on the complete policy analysis method utilised 
is available in Moshi et al.(141) and its supplementary information in Chapter 5. A policy analysis was 
selected as the method to conduct this section of the study as it enabled the identification of potential 
international and domestic policy options which address MMA regulation in the English-speaking IMDRF 
member jurisdictions, as well as whether these options reflect the SaMD: Clinical Evidence(22) guidance 
document that they had produced - providing insight as to whether the guidance document can be 
practically implemented.(142, 143) 
 
4.2.2 Case studies 
The case studies were conducted to determine how the MMA regulatory policies identified during the 
policy analysis are executed by two IMDRF member jurisdictions, Australia and the USA. Each case study 
appraised the MMA regulatory applications that were submitted by industry, reviewed, and approved by 
the respective jurisdictional authorities. Case studies were used because they provided the opportunity 
to gain insight into how MMA regulatory evaluation is being applied in Australia and the USA.(144) 
 
Acquisition of MMA regulatory submissions 
Regulated MMAs and/or relevant accompanying hardware for each of the possible Australian regulatory 
pathways (e.g. general, AIMD, or IVD) were identified by searching the ARTG in August 2017. The 
regulatory submissions and/or clinical evaluation reports (CER) for the identified MMAs and/or relevant 
hardware were then accessed through two Freedom of Information (FOI) Act 1982 requests to the TGA 
through the Australian Federal Department of Health in August 2017 and January 2018. Two FOI requests 
were submitted to the TGA, as the first request did not locate the required documents. A tabulated 




To obtain the FDA evaluation of MMAs the FDA 510K database was searched for the same or similar 
MMAs to the ones identified through the ARTG. The selected MMA submissions and/or CERs were then 
downloaded from the 510K database.  
 
For more information on the acquisition of MMA regulatory submission to jurisdictional agencies see 
Moshi et al.(141) and in Chapter 5. 
 
Data extraction 
These submissions and/or CERs were assessed against a data extraction form developed from the 
IMDRF’s SaMD: Clinical Evaluation(22) guidance document. The relevant data was extracted by two 
people to improve reliability and reduce errors. The data extraction form is available in Appendix B. 
 
For more information on the data extraction methods and the creation of the aforementioned data 
extraction tool, see Moshi et al.(141) and its accompany supplementary material in Chapter 5. 
 
4.3 Reviewing existing MMA evaluation frameworks and determining their 
suitability for use within HTA and reimbursement decision-making 
A systematic literature review was conducted to provide information relevant to answering the second 
research question and its objectives. The overall aim of the systematic review was to review existing 
evaluation frameworks for MMAs and determine their suitability for use within the HTA processes currently 
used to inform reimbursement decision-making. The methodological systematic review was selected 
instead of other forms of reviews, as it enabled the identification and characterisation of all possible MMA 
evaluation frameworks that may be suitable for use in HTA.(145-148) A brief overview of the systematic 
review methods employed is outlined below. 
 
4.3.1 Study eligibility criteria    
Studies were included according to the following pre-defined criteria. The inclusion criteria are shown in 
Table 4.1.  
  
Table 4.1: Study selection criteria 
Characteristic  Criteria  
Types of Participants Anyone over the age of 18 that uses a mobile medical application (MMA) 
Types of Intervention Mobile medical applications (MMA)a 
Type of Comparator N/A – methodological systematic review   
Outcome Measure Framework(s) a that assess MMA effectiveness, cost-effectiveness and/or 
safety 
Language All literature was limited to English language only b 
Explanatory note(s) 
a Previously defined Section 2.2, 




If one framework was presented in several articles, the publications were collated and included as single 
study.  
 
The full study eligibility criteria and reasoning behind it, is available from Moshi, Tooher, & Merlin(149) in 
Chapter 6. 
 
4.3.2 Literature search methods 
The published literature searches were conducted in the electronic bibliographic databases listed in Table 
4.2. The searches had a cut-off date of 31st of October 2016. The minimum search date was the 1st of 
January 2008 (the first online application store opened in 2008).(10)  
 
Table 4.2: Electronic bibliographic databases 
Electronic Database Source Time Period 
Medical sciences bibliographic databases 
Cumulative Index to Nursing 
and Allied Health Literature 
(CINAHL) 
http://web.a.ebscohost.com.proxy.library.adelaide.edu.au/ 31th October  2016 
Embase http://www.embase.com.proxy.library.adelaide.edu.au 31th October  2016 
PubMed (including MEDLINE) https://www-ncbi-nlm-nih-gov.proxy.library.adelaide.edu.au/ 31th October  2016 
Psych INFO http://ovidsp.tx.ovid.com.proxy.library.adelaide.edu.au/ 31th October  2016 
The Cochrane Library http://onlinelibrary.wiley.com/cochranelibrary/search/ 31th October  2016 
Engineering bibliographic databases  
Business Source Complete  http://web.b.ebscohost.com.proxy.library.adelaide.edu.au/ehost/
search/advanced?sid=44187681-5977-443a-b76a-
e8d266c3c643%40sessionmgr106&vid=0&hid=125 
31th October  2016 
Compendex https://www-engineeringvillage-
com.proxy.library.adelaide.edu.au/search/quick.url 
31th October  2016 
  
Search terms and strategy   
Search terms  
The search terms included terms for MMA, mobile platforms, and evaluation. The search terms and 
strategy are explained in the supplementary document of Moshi, Tooher, & Merlin(149) in Chapter 6.  
 
Search strategy  
To identify the relevant published literature within the various databases the broad search only included 
keyword and indexing terms for MMAs and mobile platforms. ‘Evaluation’ and ‘framework’ related terms 
were not included in the search string because MMA assessment is an emerging field and it was expected 
there would be a variety of different synonyms used and limited or idiosyncratic ways in which 
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methodological frameworks would be indexed. I was concerned that additional terms would limit the 
searches, which could risk excluding relevant articles. 
  
The engineering bibliographic databases, Compendex and Business Source Complete, favour ‘key word’ 
searches over ‘indexing terms’. The lack of indexing resulted in the use of a slightly different strategy. The 
search strategy included key words for: mHealth applications and evaluation (assessment). The use of 
evaluation instead of smartphone related terms narrowed the search results to relevant literature. 
 
The search strategy used in PubMed (including MEDLINE) and Compendex are available in the 
supplementary document of Moshi, Tooher, & Merlin(149) in Chapter 6. The search strategies used in 
the remaining databases are available in Table C.1-C.5 in Appendix C.  
 
Grey literature searches were conducted to identify MMA evaluation frameworks that were not available 
in the published literature. The full strategy is available in the supplementary documents of Moshi, Tooher, 
& Merlin(149) in Chapter 6. 
 
4.3.3 Study selection  
There were seven stages to the study selection.  
1. Search results accompanying abstracts were downloaded from the included databases and 
imported into Endnote X7(150).  
 
2. Duplicates of references were removed. 
 
3. The citations and abstracts were exported from Endnote X7(150) to a screening database in 
Rayyan(151). This enabled blinded consideration of the eligibility of evidence by two independent 
screeners. 
 
4. The selection of a study in the database for inclusion in the systematic review was dependent on 
whether the citation or abstract information met the pre-defined eligibility criteria developed to 
address the research question (see Chapter 6). 
 
5. I (MM) applied the study eligibility criteria to all the database and this was checked by a second 
screener (TM).  The second screener reviewed 10% of the yielded literature to determine whether 




6. The studies that addressed the research question were exported from Rayyan(151) back to 
Endnote X7(150). 
 
7. I (MM) retrieved the included articles from stage 5 in full. The full text articles were screened 
against the pre-defined inclusion criterion in order to determine if they were eligible to be 
incorporated in the systematic review. Full-text articles were reviewed by a second researcher 
(TM) if eligibility was unclear.  
 
8. Reference lists of the included studies were reviewed and screened for any potentially relevant 
studies that could have been missed in the electronic database searches. Any studies that are 
identified were reviewed according to stages 4 and 6. 
 
The systematically reviewed evidence base consisted of articles selected from the sixth and seventh 
stages. Any disagreement in the selection process was resolved by the two reviewers through discussion. 
If consensus could not be reached, a third researcher (RT), was consulted to make the final decision. A 
PRISMA(152) diagram was used to illustrate the selection process. The list of included studies and the 
PRISMA diagram is available from Moshi, Tooher, & Merlin(149) in Chapter 6. 
 
4.3.4 Data collection and analysis  
Data extracted from the included studies was done using a pre-defined table detailed in Table C.6 in 
Appendix C). The information extracted included: author, year of publication, name of criteria/framework, 
outline of criteria/ framework, study methodology, intended user population, and the HTA domains 
addressed (current use of the technology, characteristics of the technology, effectiveness, safety, cost-
effectiveness, organisational aspects, legal aspects, social aspects). More information is available from 
Moshi, Tooher, & Merlin(149), in Chapter 6. 
 
To standardise the data extraction a checklist was created by MM. The use of this checklist enabled the 
traditional HTA domains addressed by each of the included MMA evaluation frameworks to be identified. 
The data extraction checklist was informed by Busse et al.(51) and Merlin et al.(153). The checklist was 
trialled and tested by myself (MM) and an HTA expert (DT) and found to have acceptable inter-reliability 
(Kappa 0.77). The full checklist is available in Appendix C. More information is available from Moshi, 
Tooher, & Merlin(149), in Chapter 6. 
 
Critical appraisal of evidence  
Since this was a methodological systematic review the included studies reporting on the evaluation 
frameworks were not critically appraised.  
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4.4 Creating an evaluation module and framework capable of conducting an 
HTA on MMAs 
Various steps were undertaken to address the third research question and its underlying objectives. Thus, 
the overall aim of this section was to determine what policy changes and assessment criteria are needed 
to facilitate the development of a system that evaluates MMAs for reimbursement purposes in Australia.   
The first step was to gain stakeholder (healthcare practitioners, app developer, and policymakers) insights 
on MMA reimbursement in Australia using semi-structured in-depth interviews. The second step was to 
synthesise all the information gained from the assessment of MMA regulation (Moshi et al.(141)  in 
Chapter 5), and, the systematic review of existing MMAs evaluation frameworks to determine their 
suitability to inform reimbursement decision-making (Moshi, Tooher & Merlin(149) in Chapter 6) with the 
stakeholder insights. This synthesised information was then used to create an MMA evaluation module 
which can be used to adapt current HTA frameworks so that they can be condut a HTA that will inform on 
whether an MMA is suitable for public funding. 
 
4.4.1 Qualitative description using in-depth stakeholder interviews 
Stakeholders were interviewed to identify any pathways and/or impediments to MMA reimbursement in 
Australia. The broad methodological approach used was a qualitative description. This approach is 
regularly used in the health sciences and creates a rich description of an event experience in the 
participants’ language. This enabled the data to reflect participants’ perceptions, sensitivities, inclinations 
and sensibilities.(154) The interviews were used to gain insight into stakeholders’ views and opinions on 
the use of MMAs in clinical practice and the technologies’ domestic future.(144, 154)  
 
Ethical considerations 
The ethical clearance (H-2017-039) for the in-depth interviews with stakeholders was received from the 
University of Adelaide Low Risk Human Research Ethics Committee (HREC). A copy of the ethical 
approval received is available in Appendix D. 
 
The main risk associated with participation was the potential for reputational and/or professional risk 
through disclosure of information about clinical or regulatory practices. To minimise this risk, steps were 
taken to maintain participant confidentiality and anonymity. For more information on the ethical 
consideration related to the in-depth interviews see Moshi, Tooher & Merlin(155) in Chapter 7. 
 
Recruitment  
Stakeholders were recruited purposively from stakeholder groups that were able to provide a rich insight 
and understanding of the topic.(144, 154) The stakeholder groups included healthcare practitioners, 
(general practitioners (GP) and allied health workers) policymakers, and mobile application developers. 
From each individual stakeholder group participants were recruited via email, using passive snowballing 
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(see Appendix D for the recruitment email and participant information sheet). An information power 
approach (instead of attempting to reach data saturation), guided sampling as participants could only be 
included if they could provide meaningful information on the topic.(27, 28, 156) The stakeholders were 
not offered any remuneration for their participation in the study and they were free to withdraw at any time 
prior to the completion of the publication(155). For more information about the recruitment process and 
information power, see Moshi, Tooher & Merlin(155)  and the supplementary information in Chapter 7. 
  
Data collection 
I collected the data using semi-structured interviews. The interview structure enabled the use of open-
ended questions and subsequent follow up and probing to further explore a topic when the interviewer 
deemed it necessary.(144, 154) The interview schedules were informed by the results of Moshi et al.(141) 
in Chapter 5 and Moshi, Tooher & Merlin(149) in Chapter 6. Different interview schedules were developed 
and used for the three stakeholder groups. I conducted the interview in person or via teleconference 
(phone/ videoconferencing). The interview schedules are given in Appendix D. Written and verbal consent 
was collected prior to the start of each interview. Examples of the consent forms used are given in 
Appendix D. Each interview was recorded using an electronic audio-recorder. All communication with 
participants, before and after the in-depth interview, was done solely via email. Detailed information about 
the data collection process is available in Moshi, Tooher & Merlin(155) and the supplementary information 
in Chapter 7. 
 
Data analysis  
A professional transcriber (Nicola Bennett) was employed to transcribe the interviews verbatim from the 
recordings. I analysed the interview transcriptions using thematic analysis (Braun and Clarke (157)) within 
the epistemology of pragmatism. NVivo 11(QSR international Pty Ltd)(29) was used to assist in the coding 
and the analysis, as well as to keep a log of the analysis and how and why decisions were made. The log 
was time and date stamped. Data triangulation was achieved using various quotes to demonstrate a 
finding as well as using participants from different jurisdictions throughout Australia.(30, 144) For more 
information on the data analysis process and the epistemology, see Moshi, Tooher & Merlin(155) and its 
supplementary information in Chapter 7. 
 
Reflexivity and context  
All of the interviews and the overall research project were based in Adelaide, Australia. I was born in 
Adelaide to an Australian born parent and another parent who migrated to Australia. I am a biracial woman 
and thus am always aware of my minority status and increased vulnerability to acts of discrimination in 
any given situation throughout the world. These lived experiences make me hyperaware and sensitive to 




I spent the majority of my childhood and formative years living as an expatriate with my parents overseas. 
All of my tertiary education has been conducted in Australia at a Group of 8 (research-intensive) 
University. I am a native English-speaker and it is my primary medium of communication. I also received 
all my primary, secondary, and tertiary education in English. The fact that I am a native English speaker 
meant that I was able to identify any subtleties in a conversation and/ or the transcripts that were 
assessed. During interviews, this meant I was able to understand the ‘subtext’ of a conversation as well 
as to naturally probe. It also resulted in an ability to correctly recognise humour and understand 
colloquialism. This enabled me to build rapport and trust with the interviewees. 
 
Given this was my first professional involvement in qualitative research, the entire process was a learning 
experience. Thus, there were a variety of factors which could have influenced my interpretation of the 
interviews. My main research training and experience within medical sciences is in HTA; a subset of 
evidence-based medicine. This resulted in a bias towards quantitative research, as well as being objective 
and detached from the research. It also meant that I had minimal experience and knowledge of theoretical 
paradigms and how to apply them. I kept a diary and wrote an entry after every individual interview of how 
I felt it went. Then with my meetings with my supervisor (Tooher) we would discuss how I felt during the 
interviews and review the audio-recording and transcripts to see if there was anything I could change in 
the next interview, such as probe in specific areas or use silence more effectively. My limited experience 
may have impacted the interpretation and analysis of the interviews as this was the first time I had used 
this method and I initially struggled to get into the ‘head space’ necessary to achieve a thorough analysis. 
I also worked with my supervisor on how to be subjective and aware of my biases as I undertook planning, 
data collection, and data analysis components of the qualitative description section of this thesis.  
 
My personal lived experiences may have created an unconscious bias during the interviews and analysis. 
Prior to the start of this research project I did not have any prior experience or training, with the design, 
development, or assessment of MMAs or eHealth technologies outside of being an end-user. Though, 
when I was conducting the interviews, there were moments when I did not understand specific terms or 
phrases and had to determine the concept from the context. This may have affected my interviews as I 
could have missed an opportunity to expand, probe, and/or seek clarification on a specific issue. I also 
could have developed unconscious biases towards eHealth technologies throughout my life, through my 
parents’ professions. One of my parents is a retired South Australian-trained electronics engineer, who 
throughout my childhood and formative years, worked with some of the largest technology and software 
companies in the world (at the time). So, I was exposed to the digital revolution from a unique perspective 
and learnt from a young age how its rapid evolution would disrupt multiple industries, as well as alter how 
people throughout the world lived and communicated. My other parent is a South Australian-trained and 
practicing Clinical Nurse Consultant (CNC). I have witnessed how their role in the healthcare workforce 
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and continual professional development (CPD) has dramatically changed with the healthcare industry’s 
adoption of eHealth technology. 
 
It is possible that my parent being a CNC who is actively involved in eHealth integration into the Australian 
healthcare system, unconsciously shaped my views on the technology and its adoption. I tried to keep 
their views separate when conducting interviews with healthcare practitioners. However, when they 
mentioned specific topics sometimes, I remembered my parent cited the very same issue, and I would 
use that opportunity to probe.  Similarly, this occurred when interviewing application developers, as prior 
to the start of this thesis, majority of my understanding of apps, was shaped from the perspective of my 
parent- someone who worked in the industry.  
 
Finally, during the interview(s), the issue of ethnicity and race occurred, where the research participant 
expressed discriminatory views. As an Australian biracial woman, I have developed the ability to look past 
a person’s biases and continue on a conversation with complete professionalism. However, after the 
interview I was shaken by the experience. I worked hard to limit how that experience could have affected 
my analysis and interpretation of the transcript(s) from the interview(s).  
 
4.4.2 Development of the MMA HTA evaluation module and framework for reimbursement 
purposes 
 
The results were integrated through prioritising and synthesising the research generated in the preceding 
sections (Sections 4.2, 4.3, and 4.4.1). A list of options to evaluate MMAs for HTA and reimbursement 
purposes was generated from the findings of the policy analysis, case studies, systematic review, and 
stakeholder interviews. These findings were synthesised to create the MMA HTA evaluation module. The 
MMA module was considered capable of adapting current HTA reimbursement assessment frameworks 
to ensure that the unique challenges apps present are properly appraised.   
 
Development of MMA HTA evaluation module  
In order to create the MMA HTA evaluation module that can be used for modifying current HTA 
frameworks, the key policy changes had to be identified. The policy changes were identified by 
synthesising and evaluating the findings from Chapters 5 and 6 with the results from the qualitative 
description detailed above in Section 4.3.1.(149, 155) The complete module and its detailed creation is 
available in Moshi, Tooher & Merlin(155) in Chapter 7. 
 
Development of MMA HTA evaluation framework 
The MMA HTA evaluation module was used to adapt the current MSAC technology evaluation guidelines 
to create an MMA evaluation framework for HTA and reimbursement purposes. A detailed description of 
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the steps taken to develop the evaluation framework is available in Moshi, Tooher & Merlin(155) and the 
supplementary information in Chapter 7 (Section 2). 
 
4.4.3 Applicability of MMA HTA evaluation module to comparable jurisdiction  
The applicability of the new MMA HTA evaluation module to comparable HTA jurisdictions (USA, EEA, 
Canada) was examined thorough comparing and contrasting its content with the that of the HTA 
guidelines of these jurisdictions. The USA, Canada, and EEA were selected as comparable jurisdictions 
as they have consolidated and comprehensive HTA guidelines available in English. The complete and 





Chapter 5: Regulation of mobile medical 






This chapter assesses the adequacy of TGA regulation of MMAs in Australia by investigating if changes 
need to be made to the current Australian SaMD regulatory model. To determine if the current domestic 
regulatory framework was suitable to address the challenges presented by MMAs, it was reviewed against 
the policies of international regulatory counterparts, and the IMDRF guidance document for the regulation 
of the technology.  
 
This chapter addresses the first research question and its respective objective(s) (listed below in Figure 
5.1). How this section relates to the overall thesis aim and other objectives and research questions is 












Figure 5.2: Structure of Chapter 5’s research question and objectives 
 
Research Question 1 
Objectives 
Sub-Objectives 
Do changes need to be made to the current Australian regulatory model for 
‘software as a medical device (SaMD)’ to enable assessment of the possible 
health risks and benefits posed by MMAs? 
Test if the TGA regulation on 
SaMD is relevant for MMAs 
Test if the IMDRF guidance for the 
clinical evaluation of SaMD can be 
feasibly applied to MMAs 
Identify the changes that would 
need to be made to the regulatory 
process in Australia to properly 
evaluate MMAs 
Assess whether the current Australian regulatory framework is suitable for the 
assessment of MMAs  
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This chapter addresses the above research question and objectives using a policy analysis and case 
studies detailed in the publication by Moshi et al.(141) and its corresponding supplementary 
documentation (see Section 5.2). For additional information on the methods used in Moshi et al.(141) see 
Chapter 4 Section 4.3.   
 
A tabulated summary of my correspondence with the jurisdictional regulatory agencies used during the 
policy analysis section of Moshi et al.(141) is supplied in Appendix B. Regarding the case studies, a table 
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To determine whether the approach used in Australia to regulate mobile medical applications (MMA) is 




The policies of members of the International Medical Device Regulator’s Forum (IMDRF) were analysed, 
to determine whether these regulatory bodies address IMDRF recommendations for the clinical evaluation 
of software as a medical device (SaMD). Case-studies of varying types of regulated MMAs in Australia 
and the US were also reviewed to determine how well the guidance in the IMDRF’s SaMD: Clinical 
Evaluation (2017) document was operationalised. 
 
Results 
All included jurisdictions evaluated the effectiveness of MMAs and addressed the majority of the key sub-
categories recommended in the IMDRF guidance document. However, safety principles concerning 
information security (cybersecurity) and potential dangers of misinformation (risk-classification) were 
generally not addressed in either the case-studies or in the policy documents of international regulatory 
bodies. Australia’s approach was consistent with MMA regulation conducted internationally. None of the 
approaches used by global regulatory bodies adequately addressed the risk of misinformation from apps 
and the potential for adverse clinical consequences.  
 
Conclusion 
The risks posed by MMAs are mainly through the information they provide and how this is used in clinical 
decision-making. Policy in Australia and elsewhere should be adjusted to follow IMDRF risk-classification 
criteria to address this potential harm as it examines the danger of misinformation. Australian regulation 
should also be updated to so it can comprehensively evaluate the harm posed by cybersecurity and the 
risk posed by connectivity capabilities. 
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Mobile medical applications (MMA) are software applications (apps) with a therapeutic or diagnostic 
purpose(1). MMAs are a part of larger group of software known as software as a medical device (SaMD); 
a class of medical software which can act as a medical device(1). These apps are increasingly being used 
globally by patients and health practitioners to treat and monitor chronic health conditions (such as 
diabetes)(2,3). Currently, software - including MMAs - in Australia is regulated as a general medical 
device, or an in vitro diagnostic (IVD) medical device, and when applicable as an active implantable 
medical device (AIMD)(2,4). MMAs are also subject to pre and post market regulatory oversight by the 
Australian federal regulatory agency, the Therapeutic Goods Administration (TGA)(2). All devices 
regulated in Australia are listed on the Australian Register of Therapeutic Goods (ARTG)(5).   
   
MMAs pose similar regulatory challenges to other forms of contemporary digital health software. These 
technologies are characterised by different methods for determining whether their intended purpose is 
achieved (software validation), as well as a fast and iterative design and development process, compared 
to more traditional forms of medical software and/or hardware(6-10). However, unlike traditional software 
forms, MMAs are easily accessible and installable software, and can be deployed on readily available 
non-specialised hardware (off-the-shelf) over various platforms. These platforms may also be 
interconnected with other datasets, systems and devices, via the internet and other networks(6-9). 
 
Current software regulation used by the TGA in Australia focuses on assessing the risks presented by 
traditional forms of software and/or hardware - predominantly direct physical harms such as infection(2). 
However, the risks posed by apps are mainly indirect, through the information they provide, and are thus 
more challenging to regulate(9). In this, MMAs resemble in vitro diagnostic medical devices (tests) as they 
do not directly improve health outcomes, but the output they provide has the ability to alter the 
management of the patient(11). Other jurisdictional regulatory bodies such as the United States (US) 
Food and Drug Administration (FDA)(3) and that of the European Commission(12) have experienced 
similar challenges with MMAs. In response, in 2013 the FDA implemented an MMA specific approach to 
regulatory evaluation(3). 
 
The regulatory challenges presented by MMAs and other contemporary software led the International 
Medical Device Regulator’s Forum (IMDRF) - to which Australia and the US are signatories - to create a 
working group aimed at harmonising the regulation of standalone medical device software(13). In 2017 
the IMDRF published a final guidance document on Software as a Medical Device (SaMD): Clinical 
Evaluation(13,14). The guidance document provides the level and type of clinical evidence needed to 




This study explores the regulation of MMAs in various international jurisdictions, and tests whether the 
approach used in Australia by the TGA to regulate MMAs (and/or accompanying hardware) is consistent 





Two methods were used to critically review international approaches to the regulation of MMAs and to 
benchmark the Australian approach against its international counterparts: a policy analysis and a review 
of case studies.  
 
Policy analysis  
The aim of the policy analysis was to identify policies for the evaluation of MMAs in the regulatory setting 
developed in the nine IMDRF member jurisdictions. These policies were then compared and contrasted 
relative to the SaMD: Clinical Evidence(13) guidance document (Supplementary material)(13,15).  
 
To identify documents for the policy analysis, documents available on the relevant jurisdictional regulatory 
agencies’ websites were reviewed (Supplementary material). Other relevant policy documents were 
identified through the snowballing of sources.  
 
Inclusion criteria  
The included policy documents had to be in English as well as published in or after January 2013 (IMDRF 
published its first SaMD guidance document in 2013) and before April 2018. The policy documents were 
limited to guidance documents that directly or indirectly addressed the regulation of MMAs and/or software 
within the IMDRF member countries. Legislative documents or Acts were excluded as they had not been 
enforced by the relevant jurisdictional regulatory agency (e.g. TGA). 
 
Case studies 
The case studies were used to assess to what extent these regulatory policies had been enacted in 
Australia and the US. The US was selected as companies’ regulatory submissions to the FDA were 
accessible. The case studies evaluated MMA applications which had been submitted, reviewed, and 
approved by the relevant jurisdictional regulators. Data were extracted from these documents using a 
form identifying elements of the IMDRF’s SaMD: Clinical Evaluation(13) guidance document 
(Supplementary material). The data extraction form is available upon request. 
 
Acquisition of submissions to regulatory bodies  
The ARTG was searched in August 2017 to identify MMAs and/or the accompanying hardware that were 
representative of each type of regulation pathway (i.e. general medical device, IVD and AIMD). 
Subsequently, Freedom of Information Act 1982 (FOI) requests to the Australian Department of Health in 
August 2017 and January 2018 to obtain the regulatory evaluation/ individual document but with sponsor 




The corresponding FDA evaluation of these MMAs were obtained through searching their 510K database 
and downloading the approved submissions(16). Unlike the TGA, the FDA reviewed the MMAs and/or 
any accompanying hardware together.  
 
Evaluation of submissions to regulatory bodies  
The TGA and FDA evaluation documents of the MMAs and/or their accompanying hardware (where 
applicable) that were used as case studies are listed in Table 1. Relevant information was extracted into 
to the data extraction form and by the first (MM) and second (JP) authors to determine what the regulatory 
bodies did and did not assess. Any disagreements between the evaluators was resolved by discussion, 




Table 1: Included MMAs and accompanying hardware (where applicable) 































Diagnostic  Unclassified 
iHealth Align 
Glucose Meter 
Clinical chemistry substrate 
IVDs 
(iHealth Align Gluco-













IVD Therapeutic IVD Class 3 
Class II 
Software IVDs 
(iHealth Gluco-Smart App) 
(44) 
279064 










Reveal LINQ Model LNQ11 – 
















Class II LINQ Programmer Application 
Model MSW001 – Implantable 
cardiac monitor programming 





Software Therapeutic Class III 
SkinVision 
SkinVision-Skin Cancer 
Detection App (42) 
 279238  
Emergo Asia 










AIMD – Active implantable medical device 
ARTG (Australian Register of Therapeutic Goods) – the databases used to catalogue all registered medical devices in Australia  
IVD -- In vitro diagnostic medical device 
MMA --  mobile medical applications 





Policy analysis  
Nine of the ten included regulatory bodies had policy guidance information on medical software regulation 
available, however only five were in English(2,3,17-23). The jurisdictions of Australia, Canada, the 
European Economic Area (EEA), Singapore and the US were included in the analysis(2,3,17-19).  
 
Independent review (e.g. internal non-conflicted experts, third parties, external experts) 
Policy documents from Australia, the EEA, and Singapore all recommend that the clinical evaluation of a 
medical device should be performed by a qualified individual(s). This is consistent with IMDRF SaMD 
clinical evaluation recommendations. The regulatory bodies also state the applicants should justify the 
choice of clinical evaluator(s) as well as provide evidence of the expert(s) experience and/or 
proficiency(24-26). The US and Canadian guidance documents did not include any clause to indicate that 
the submission to the jurisdictional regulatory body should involve a clinical evaluator(3,18,27,28). 
 
Continuous learning using real world performance data 
Also, in line with IMDRF guidance the five jurisdictional regulatory agencies require post-market 
surveillance of medical devices, encouraging the manufacturers to monitor the performance and safety 
(e.g. adverse events) of medical devices (29-33). However, contrary to the recommendation in SaMD: 
Clinical Evaluation(13)  these regulatory agencies do not review the device surveillance approach taken 
by the manufacturers, assess how burdensome the approach is, nor determine how the collected 
information could be integrated into the functionality of the regulated software in pre-market assessments. 
 
Description and current use of the technology 
All five regulatory agencies appraised the intended purpose of MMAs(1-3,17,24-26,28,34). However, only 
the EEA considered the input (e.g. physiological status, laboratory results, images, etc.), output (e.g. treat, 
diagnose, inform, etc.), and/or algorithm (e.g. model based logic, equations, rules, etc.), used by the 




All of the guidance documents recommend assessing the clinical effectiveness of SaMDs, in terms of 
clinical association and product performance. It was difficult to determine whether particular evidence was 
specifically required for the evaluation of MMAs, as this was not stated. Regarding clinical association, all 




that has been conducted on the product, and any performance data that the manufacturer possesses on 
the device (e.g. post-market data)(1-3,17,24-26,28,34). Regulatory bodies in Australia, Singapore, and 
the US verify whether the app/software meets the requirements of its specifications and whether it has 
been validated through testing as fulfilling its intended purpose(24,26,28,35). 
 
Safety 
Like Australia, the other jurisdictional members of the IMDRF use a physical risk-based (Table 2) 
approach for medical device software which aims to minimise the effect of physical harm from the device 
by balancing this against the benefits of its intended purpose. In all these jurisdictions, the higher the risk 
the medical devices poses, the more regulatory controls that are applied to the technology and the more 
systematic the clinical evaluation (Figure 1)(1-3,17,18,24-26,28,34,36-39). The system (risk-
classification) recommended by the IMDRF to classify the dangers posed  by SaMDs, assesses the harm 
posed by comparing the impact the software output will have on clinical decision-making against the 
severity of the condition being treated by the software(9,14). However, none of the included jurisdictions 
used the risk-classifications suggested in the IMDRF’s SaMD: Clinical Evaluation(13) guidance document.  
 
Similarly, none of the regulatory bodies included any aspects of information security (cybersecurity) for 









Type of Medical 
Risk Posed 




Non-IVD I IIa IIb III 
IVD 1 2 3 4 




Non-IVD I II III IV 
IVD I II III IV 






Non-IVD I IIa IIb III 
IVD General IVD High risk IVD 




Non-IVD A B C D 
IVD A B C D 














AIMD – Active implantable medical device 
IVD -- In vitro diagnostic medical device 
Non-IVD -- A medical device that is neither an AIMD nor IVD 
 
Technical characteristics 
Australia, Singapore, the US, and the EEA all clarify in their guidance documents that their jurisdictional 
influence only applies to MMA software and/or any relevant attachable hardware(1-3,17,19,27,34). These 
jurisdictions clearly conveyed that their jurisdictional authority does not extend to the mobile platforms 
(e.g. smartphone, etc.) or the devices’ operating system (e.g. Android, etc.) that interacts with the app 
and/or hardware (1-3,17,19,27,34).  
 
Summary of findings  
Regulatory agencies in Australia, the EEA, and Singapore all to some extent addressed four of the five 
recommendations within the SaMD: Clinical Evaluation(13)  guidance documents. The USA, and Canada 
did not assess if an independent reviewer (clinical evaluator) is necessary to appraise submissions. 
Canada was the only jurisdiction that did not assess technical characteristics of SaMD. Each of the five 
jurisdictions did not assess safety - as defined by the SaMD: Clinical Evaluation(13) guidance documents 
- both in terms of how risk is classified for software and in terms of cybersecurity.  
 
Case-studies  
We could not identify any standalone software versions of MMAs that were regulated by both Australian 
and American regulatory agencies. For Australia we selected the SkinVision skin cancer detection app 
(Class I), and for the US we selected DANA (unclassified), an MMA that assesses a person’s medical 
and psychological state(40,41). These MMAs where selected as they were two apps that acted as a 




hardware. For software that related to the IVD and implantable MMA regulatory pathways, we were able 
to identify apps that were regulated in both jurisdictions. We selected the iHealth Align Glucose Meter for 
the IVD pathway and the Reveal LINQ Insertable Cardiac Monitoring (ICM) System for the implantable 
MMA pathway.  In Australia the TGA classified the MMA and the attachable hardware of iHealth Align 
Glucose Meter as IVD Class 1 and IVD Class 3 respectively(42,43). The FDA classified the app and 
hardware together as Class II(44). As with the glucometer, the TGA classified the MMA and ICM hardware 
as Class III and AIMD respectively(45,46), while the FDA classified the devices together as Class II(47). 
See Table 1 for more information. 
 
Independent review  
The use of an independent reviewer in the case studies was only used by the TGA for high risk software 
and hardware submissions. The low risk TGA submissions of Class I (SkinVision) and IVD Class1 (iHealth 
app) did not require independent review of the device. These applications to the TGA were generally 
accepted within 24 hours of submission. The higher risk devices such as Class III (ICM app), IVD Class 
3 (iHealth Align Glucose Meter), or AIMD (ICM System), were all reviewed by TGA reviewers as well as 
professionals with clinical expertise whose curriculum vitae (CV) was provided with the submission 
(40,42,43,45,46). Regarding submissions to the FDA it was unclear if the reviewers had direct involvement 
with the development and/or testing of the product, or if the FDA ever reviews their CVs.  
 
Continuous learning using real world performance data 
Only the TGA considered how real world experience data could be integrated into the lifecycle of the 
medical device software and hardware within pre-market evaluations. In the Class III (ICM app) and AIMD 
(ICM System) submissions the TGA only assessed whether the manufacturers would continue to monitor 
the software after market authorisation(45,46). The TGA did not fully comply with IMDRF 
recommendations and examine if the MMA product performance was inferior or superior to the metric 
stated in the submission, and/or if the data could be used to enable or disable functions in the software. 
Unlike Australia, the FDA did not integrate any real world data into the jurisdictional regulatory process.  
 
Description and current use of the technology  
The TGA’s and FDA’s appraised submissions all reviewed the intended purpose of the software and 
hardware, the intended population, and output(s) of the technology (e.g. inform, treat, diagnose)(40-47). 
From the selected submissions, the TGA did not enquire about the input (e.g. digitized content such as 
laboratory results, symptoms, images). However, the TGA did review the software output (e.g. inform, 
treat, diagnose) for IVD Class 1 (iHealth app) and Class I (SkinVision) software, AIMD (ICM) and IVD 




reviewed the input for Class II (ICM and iHealth Align Glucose Meter) software and devices as well as the 
software’s algorithm (e.g. equations, model based logic, rules, knowledge base, reference base) 
(41,44,47).  However, the FDA only reviewed the output for IVD MMAs (iHealth Align Glucose Meter), not 
for the active implantable (ICM) or standalone (DANA) MMAs(41,44,47). 
 
Effectiveness  
Effectiveness in terms of clinical association or product performance (Table 3) was not assessed by the 
TGA in any of the software classified as Class I (SkinVision), or devices in IVD Class 1 (iHealth 
app)(40,42). Unlike the TGA, each MMA assessed by the FDA did evaluate valid clinical association and 
product performance in all submissions to some extent, including reviewing the clinical equivalency of all 
included MMAs. The FDA also examined if any scientific validity studies had been conducted on IVD 
(iHealth Align Glucose Meter) and active implantable (ICM) devices(41,44,47). The TGA evaluated the 
clinical association domain through the use of a literature review and experience data for its active 
implantable devices (ICM), whereas the FDA did not(41,44-47).  Regarding clinical validation, the FDA 
reviewed the relevance of the data used to demonstrate MMA effectiveness for all of the selected device 
types(41,44,47). Neither the TGA nor FDA assessed analytical validity for low risk (SkinVision and/or 
iHealth app) or unclassified devices (DANA). Only Class II (ICM and iHealth Align Glucose Meter) and 





Table 3: SaMD: Clinical Evaluation categories and sub-categories addressed by each submission 














































































































by the MMA to the 
healthcare decision 
Therapeutic Goods Administration (TGA) 
a SkinVision-Skin Cancer Detection App 
(42) 
Class I ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ~ ✘ 




a LINQ Programmer Application Model 
MSW001 – Implantable cardiac monitor 
programming application software (47) 
Class III ✔ ✔ ✔ ✔ ✔ ✘ ✘ ✔ ✔ ✔ 
b Clinical chemistry substrate IVDs 
(iHealth Align Gluco-Monitoring 
System) (45) 
IVD Class 3 ✔ ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ~ 
b Reveal LINQ Model LNQ11 – 
Implantable cardiac monitor (48) 
AIMD ✔ ✔ ✔ ✔ ~ ✘ ✘ ✘ ✘ ✔ 
U.S. Food and Drug Administration (FDA) 
c DANA (43) Unclassified ✘ ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✔ ✘ 
c iHealth Align Gluco-Monitoring 
System (BG1) (46) 
Class 2 ✘ ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
c Reveal LINQ Insertable Cardiac 
Monitor (Model LNQ11) (49) 
Class 2 ✘ ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Explanatory note: 
✔ Domain was addressed, ~ Domain was partially addressed, ✘ Domain was not addressed 
a Software, b Hardware (attachment to platform), c Software and hardware combined as a single device, 
AIMD -- Active implantable medical device, 
IVD -- In vitro diagnostic medical device 
Non-IVD -- A medical device that is neither an AIMD nor IVD 





The case-studies demonstrated that information required by the TGA and FDA changed depending on 
the risk-classification and the intended purpose of the device. For IVD Class 3 (iHealth Align Glucose 
Meter) devices the TGA determined whether the sponsor and/or manufacturer had been transparent with 
their information as well as if the device could withstand being configured in unintended ways. Unlike the 
FDA, the TGA also inquired about how the information is displayed by the software and how the 
technology could affect workflow for Class III (ICM app) devices. 
 
With respect to information security (cybersecurity), the TGA reviewed transmission data and if software 
could resist system interactions for Class III (ICM app) devices. The FDA did not appraise MMA 
cybersecurity in any form.  
 
Technical characteristics  
The case-studies demonstrated that there was limited consideration of information about the mobile 
platform or operating system. In Australia, for some classes of MMAs (not including hardware), the 
regulatory agency required information about the platform that the software was run on. However, for 
Class I (SkinVision) and IVD Class 1 (iHealth app) MMAs the submissions only stated that the devices 
were medical software, inferring use of an off-the-shelf device. The FDA assessed whether MMAs were 
run on non-specialised medical platforms (e.g. smartphones) for all the included devices. For the IVD 
device the FDA inquired about the type of platform and operating system that the attachment and app 
were to use.  
 
Summary of challenges 
The case studies have highlighted a number of challenges faced by Australian regulations of MMAs. 
When compared to IMDRF recommendations, the challenge revolves around how the Australian system 
should change its risk-classification system so that it is based on MMA content and information, instead 
of the physical risk it poses. Another challenge is integrating technology specific items (e.g. cybersecurity, 
analytical validity, etc.) into current regulation and ensuring that MMA regulatory submissions undergo 




In English speaking IMDRF jurisdictions the current regulatory oversight of MMAs and/or accompanying 
hardware does not completely comply with the IMDRF SaMD: Clinical Evaluation(13) guidance on the 





However, the Australian software regulation is consistent with the approaches used internationally. Most 
jurisdictions utilise a physical harm based risk-classification system, which determines how extensive and 
thorough (Figure 1) the clinical evaluation a MMA should be(2,3,24,26,30,36,37). Figure 1 illustrates the 
current Australian physical based risk classification. It is concerning that none of the IMDRF member 
jurisdictions review software safety using the method that they have recommended, i.e. that the risk-
classification should be based on the consequences to patients of the information supplied by the software 
(output). Much like medical tests, MMAs can produce health consequences for patients indirectly, if the 
patient takes a course of action (e.g. treatment) based on the information provided. The credibility of this 
information is critical. 
 






The challenges presented by digital health software to current device regulation is resulting in changes in 
regulatory processes internationally. In April 2017 the European Commission adopted new medical device 
legislation (implemented in 2020) to ensure that regulatory processes can adapt to the significant progress 
in technology and science that has occurred in the past two decades, and which will likely to continue in 
the future(12).  
 
Furthermore, the US has had to explore a different way of regulating SaMDs to address the unique 
challenges they present (3). The FDA is currently piloting a new method to regulate software (including 
MMAs)(10). It explores a pre-certification (based on SaMD: Clinical Evaluation) approach which assesses 
the SaMD developer for their software testing, designs, and other matters(7,10,48-50). The reason for 
exploring this new approach is because the existing method was considered inappropriate for the 
regulation of SaMDs, given the technology is easily adaptable with a fast life-cycle(10,50).  
 
Unlike the European Commission and the FDA, the TGA has not altered its approach to MMA regulation, 
but it does acknowledge the complexity of MMA regulation(51). Like the other regulatory agencies, the 
main reason that the TGA approach to regulation of MMAs is not compliant with SaMD: Clinical 
Evaluation(13,14), is because of the risk-classification approach used. Software has no direct physical 
interaction with the user (e.g. exchange or administer energy and/or supply energy for imaging, monitoring 
physiology processes), so the devices are generally classified as Class I (Figure 1)(2,26). Thus, 
submissions for MMAs will only have to provide a minimal level of evidence. An MMA which has direct 
interaction with an AIMD is automatically a Class III (this explains why the Reveal LINQ ICM app is Class 
III instead of Class I)(2,52). If the TGA measured the risk posed by software by reviewing the impact of 
the MMA content on the user, instead of its physical harm, as the IMDRF recommended for SaMD, the 
clinical evaluations and regulatory controls applied to medical apps may be more extensive. With regard 
to hardware that accompany MMAs, the current ‘physical risk’ approach of the TGA may be appropriate 
as these devices generally have direct contact with patients and as such pose physical harms(2).  
 
Technical considerations  
The TGA regulatory approach does not assess information security in MMAs or the applicable hardware. 
However, the TGA issued a Medical Devices Safety Update(53) in 2016 on medical device cybersecurity, 
in which it “advises medical device sponsors and asset owners to perform risk assessments by examining 
the specific clinical use of potentially affected products in the host environment”(53). Traditionally medical 
devices did not have the networking or connective capabilities and could only be ‘hacked’ through being 
physically altered(54).  However, with the networked and connective nature of MMAs and applicable 




59). This is particularly concerning as software enables third parties to remotely control the device (e.g. 
in 2017 the FDA issued a Safety Communication about cybersecurity vulnerabilities in Abbott’s 
implantable cardiac pacemaker), as well as alter the programming(54,56,57,60,61). The ability of 
malicious software to affect the safety and efficacy of the device could ultimately endanger the life of a 
patient(54,56,57,61). 
 
Areas for future research  
The development of a risk-classification process that can assess the downstream harms posed by SaMDs 
and accompanying hardware is needed. Methods for evaluating the cybersecurity of MMAs/SaMDs and 
accompanying hardware are also urgently required.  Research would also be helpful on the impact of 
commercially accessible non-specialised platforms on MMAs. Finally, further research could be 
conducted to investigate if our study findings are applicable to non-English language regulatory agencies.  
 
In the long term, research could explore the barriers to more robust regulation of MMAs to protect the 
Australian population from preventable harm. Better regulation of MMAs in Australia could also potentially 
create a pathway to reimbursement, as it is the first step to a device being eligible for government 
reimbursement schemes(62). If MMAs and/or the accompanying hardware are not properly regulated, it 
may prevent a device that could potentially provide benefits to the populations’ health from being publicly 
funded. This raises the question of how a health technology assessment (HTA)  
would be conducted on an MMA for reimbursement purposes, given the indirect impact of MMA 
information on patient health outcomes(63). Perhaps methods used in the evaluation of in vitro diagnostics 
could be adopted. 
 
Limitations 
There were various limitations to this research. Due to the policy analysis being limited to jurisdictional 
documents available in English, potentially important information was excluded. Furthermore, the case 
studies did not include FDA Class I or III software.  However, according to regulatory policy, the clinical 
evaluations conducted for FDA Class I or III are almost identical to the ones that we reviewed. The study 
used the SaMD: Clinical Evaluation(13,14)  as the benchmark (gold standard) to measure the regulation 
of SaMDs, and there may be differing views on the validity of this standard. 
 
Conclusion  
The Australian TGA’s regulation of MMAs is consistent with approaches used by similar international 




medical devices. However, unlike risks posed by traditional medical devices, the main harm posed by 
MMAs relate to the information provided and how this is subsequently used in clinical decision-making. 
At present, none of the approaches used by international regulatory agencies adequately assess the 
harms and risks posed by potential misinformation in apps. In order to protect the Australian public as 
well as global app users from the threats posed by MMAs - which mimic the challenges of IVDs – proper 
regulation that addresses the unique challenges of this technology is required. 
  
Policy implications  
To address the unique challenges presented by software as a medical device, the Australian TGA should 
adopt the risk-classification approach recommend by the IMDRF. Any hardware that accompanies the 
MMA should continue to be regulated in accordance with current TGA evaluation and risk classification. 
The TGA should also create a method for evaluating the information security of the apps, and other 
software and hardware with connectivity capabilities, due to cybersecurity threats. Other IMDRF 
jurisdictions should consider similar changes to their regulation of MMAs and medical device software 
more generally. With a clearer understanding of the information and connectivity risks and benefits 
associated with MMAs, there is a greater potential for the development of reimbursement pathway for 
these technologies.  
 
If the FDA’s software pre-certification program is successfully implemented and integrated into the US 
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5.2.3 Supplementary material 
 
IMDRF member jurisdictions 
Table S.1: Regulatory authorities' websites for IMDRF member jurisdictions  
 
Sources of data extraction form 
The data extraction form also incorporated elements from the IMDRF guidance document SaMD: Possible 
Framework for Risk Categorization and Corresponding Considerations(9)  when these details were 
referenced in the SaMD: Clinical Evaluation(13). The data extraction form excluded recommendations 
relating to the IMDRF guidance document SaMD: Application of Quality Management Systems(16) as 
these were not health system specific considerations. 
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a The FDA was directly contacted in April 2018 to clarify what regulations applied to medical apps, due agency being in a 




5.3 Postface  
 
5.3.1 Chapter summary 
This chapter addressed the first research question, which was to assess whether the TGA regulation of 
MMAs in Australia, using the current SaMD approach, properly assesses these technologies. This was 
achieved through a policy analysis and a review of case studies, which compared the Australian regulation 
of MMAs to its international counterparts and the IMDRF guidance document for SaMD regulation. Both 
analyses found that Australia and its international counterparts do not properly regulate MMAs. This is 
because the approaches used to regulate MMAs are the same as used to evaluate traditional medical 
devices and MMAs pose different challenges to usual technologies. The differences are related to the 
harms posed by the app, as well as how secure it is. The harms posed by MMAs are not physical, but are 
related to the information the apps produce and how this information is consequently used in clinical 
decision making. The security of a MMA is important as the technology’s connectivity, compatibility, and 
networking capabilities pose a threat to a patient’s personal medical information. Threats such as 
ransomware, and other types of malicious software, could affect the app’s safety and efficacy. In 
conclusion, the current TGA regulatory framework does not properly evaluate MMAs and the challenges 
the technology presents. Changes need to be made to the current TGA regulation of MMAs. Regulatory 
processes should address the harm of misinformation as well as the possible risks associated with 
information and connectivity compatibilities (cybersecurity threats). Improving Australian regulation of 




After the submission of Moshi et al.(141) to the International Journal of Technology Assessment in Health 
Care in November 2018, the TGA opened a consultation into proposed changes to SaMD regulation in 
Australia.(159, 160) The proposed changes to regulation were released in February 2019, and included 
changes on how to classify the risk posed by the technology, prevent personal importation of SaMDs, as 
well as to ensure that the performance and safety of SaMDs are properly evaluated.(159, 160) The 
consultation period closed at the end of March 2019, with a TGA brief summary of the findings relased in 
November 2019.(159, 160) The TGA will conduct additional consulations on the regulations in 2020.(159) 






5.3.3 Publications and presentation of chapter findings  
Between July 16th 2019 and December 5th 2019 --according to Cambridge University Press—Moshi et 
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Chapter 6: The suitability of mobile medical 
application (MMA) evaluation frameworks 







This chapter explores if reimbursement for MMAs is feasible in Australia within the current HTA system. It 
achieves this by examining existing MMA evaluation frameworks --available prior to 31st October 2016— 
to determine if they are suitable to be used for HTA purposes, specifically reimbursement decision-
making.  
 
The chapter is aimed at addressing the second research question and its respective objective(s) (see 
Figure 6.1 below). Figure 3.1 in Chapter 3 demonstrates how this section relates to the aim of this thesis 




Figure 6.3: Structure of Chapter 6’s research question and objectives 
 Research Question 2 
Objectives 
Sub-Objectives 
Is reimbursement for MMAs feasible in Australia within the current health 
technology assessment system? 
Review existing evaluation frameworks for MMAs and determine their 
suitability for use within the HTA processes currently used to inform 
reimbursement decision-making 
Determine if there are tools 
available to assess the credibility 
of MMAs 
Determine if there are tools 
available to assess the clinical 





This chapter addresses the above research question and objectives using a methodological systematic 
review detailed in the publication by Moshi, Tooher & Merlin(149) and the corresponding supplementary 
document (see Section 6.2). For additional, information on the methods used in Moshi, Tooher & 
Merlin(149) see Chapter 4, Section 4.3.  
 
The full search strategies used in the included bibliographic databases are described in Appendix C and 
the supplementary information of Moshi, Tooher & Merlin(149). Additionally, the data extraction 
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To identify and appraise existing evaluation frameworks for mobile medical applications (MMA) and 
determine their suitability for use in health technology assessment (HTA) of these technologies.  
 
Methods 
Systematic searches were conducted of seven bibliographic databases to identify literature published 
between 2008 and 2016 on MMA evaluation frameworks. Frameworks were eligible if they were used to 
evaluate at least one of the HTA domains of effectiveness, safety, and/or cost and cost-effectiveness of 
an MMA. After inclusion, the frameworks were reviewed to determine the number and extent to which 
other elements of an HTA were addressed by the framework. 
 
Results 
A total of 45 frameworks were identified that assessed MMAs. All frameworks assessed whether the app 
was effective. Of the 34 frameworks that examined safety, only seven overtly evaluated potential harms 
from the MMA (e.g. the impact of inaccurate information). Only one framework explicitly considered a 
comparator. Technology specific elements should be addressed in an HTA of MMAs. 
 
Conclusion 
None of the evaluation frameworks could be used, unaltered, to guide the HTA of MMAs. To use these 
frameworks in HTA they would need to identify relevant comparators, improve assessments of harms and 
consider the ongoing effect of software updates on the safety and effectiveness of MMAs. Attention should 
also be paid to ethical issues, such as data privacy and technology specific characteristics.   
 
Implications  
Existing MMA evaluation frameworks are not suitable for use in HTA. Further research is needed before 
an MMA evaluation framework can be developed that will adequately inform policymakers.  
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Mobile health (mHealth) has the potential to change health systems and how care is delivered.(1) One 
form of mHealth is mobile medical applications (MMAs), also known as ‘apps’. These are a type of 
software available for mobile platforms (e.g. smartphone, tablet, smartwatch).(1)  In a medical context, 
MMAs may be used by patients to self-manage and/or screen medical conditions, rather than presenting 
at hospitals or clinics for additional appointments. MMAs may also allow for medical practitioners and/or 
allied health workers to remotely monitor, screen and manage their patients.(2,3)  
 
A potential barrier to the successful integration of MMAs into health systems is that many come at a cost 
to the patient, or require in-app purchases, which some patients are unable to afford. While some MMAs 
may have a negligible costs - and thus will not warrant public funding - others may require subscriptions 
or come with accessories, such as wearables and implantable devices. Furthermore, medical practitioners 
and allied health workers that use MMA-based services during a clinical encounter are often unable to 
claim reimbursement for the interpretation of MMA output or for treatment guided by MMA results. 
 
Health Management Organisations (HMO) in the USA have reimbursed some MMAs since 2013.(4) 
Similarly, since 2014 private health insurers have reimbursed specific MMAs in Germany.(5,6) It is unclear 
how these apps were selected for reimbursement, although this may have depended on whether the MMA 
was approved by the relevant regulatory authority (e.g. the U.S. Food and Drug Administration (FDA)).  
 
Countries with tax funded universal healthcare like Australia and Great Britain currently do not reimburse 
the use of MMAs. However, the National Institute for Health Care Excellence (NICE) in Britain is currently 
investigating ways to assess MMAs and provide guidance on their use.(7,8) If the use of MMAs becomes 
routine in clinical consultations, MMA-guided care will need to be formally assessed.  
 
This systematic review is part of a larger research project to develop or adapt an evaluation framework 
for MMAs and determine the feasibility of a reimbursement pathway for MMAs in Australia. The aim of 
our review was to identify and appraise existing evaluation frameworks for MMAs and determine their 
suitability for use in health technology assessment (HTA). In this context an evaluation framework was 







Literature search  
We searched PubMed (MEDLINE), EMBASE, CINAHL, PsychINFO, The Cochrane Library, Compendex, 
and Business Source Complete between January 1st 2008 (when the first publicly accessible online 
application store opened) and October 31st 2016.(9) We used a broad search strategy including terms for 
MMAs (e.g. mHealth app*, telehealth app*), mobile platforms (e.g. cellular phone, mobile device) and 
evaluation (e.g. criteri*, apprais*). Grey literature sources were also searched to identify any relevant 
material that may have not been identified through the database search. The full search strategy is given 
in supplementary item 1. 
 
Study eligibility criteria 
Papers were selected for inclusion if they met the pre-determined eligibility criteria. The population of 
interest were participants aged 18 years or over that used an MMA. The intervention of interest was an 
MMA evaluation framework. This included frameworks that assessed all mHealth apps, as MMAs are a 
subset of these. MMAs were defined as mobile apps (including accompanying accessories or 
attachments) available on various platforms (smartphone, tablets, smart watches etc.) that have a 
therapeutic or diagnostic intended purpose. Framework(s) aimed solely at assessing pregnancy, health 
promotion, or disease prevention apps (e.g. medication management, smoking cessation, and weight 
management) were excluded as the apps’ intended purpose was not diagnostic or therapeutic. The 
outcomes of interest were the core HTA evaluation domains of effectiveness, safety, and/or cost, cost-
effectiveness. There was no comparator as the aim of the systematic review was not to determine the 
effectiveness of these evaluation frameworks but, rather, to identify the HTA domains that they address. 
Only frameworks available in English were included. Frameworks that were duplicated in several articles 
were collated and reported as a single record.  
 
Study selection  
Two reviewers (MM and TM) screened the literature separately and applied the inclusion criteria. MM 
reviewed all title and abstracts retrieved from the searches, while TM assessed 10%. The full text articles 
were screened against the inclusion criteria by MM. Any articles in which MM was unsure of eligibility, 
were discussed with TM and a consensus decision made. The reference lists of included papers were 
pearled to identify any additional relevant references. 
 
Data extraction 
The data extracted from the papers included:  Author and dates of publication, source affiliation, country 




MMA, framework scoring system, and HTA domains addressed. The included papers were not critically 
appraised for study quality as this was a methodological systematic review. 
 
Framework assessment 
A checklist was created to act as a tool to standardise data extraction. Using the checklist, each framework 
was assessed to determine if it included any of nine traditional HTA domains - six core domains 
considered essential for full HTA: current use of the technology; description and technical characteristics; 
effectiveness; safety; cost and cost effectiveness; organisational aspects - and three optional domains: 
legal aspects; ethical aspects; social aspects.(10,11) The checklist was trialled and tested by an HTA 






The systematic searches retrieved 12,690 citations. An additional 12 papers were identified from grey 
literature sources. Six additional frameworks were identified through the pearling of the included 
publications’ reference lists. Three frameworks were excluded as the information provided was not in a 
usable form. An evidence base of 46 papers met the inclusion criteria, and two of these papers published 
on the same framework. Thus, 45 frameworks were identified that assessed whether MMAs are safe, 
effective and/or cost-effective. Figure 1 illustrates the complete study selection process. Table 1 and Table 








Literature which remained after the removal of duplicates: 
n= 11,759 
Literature which was potentially relevant and was retrieved for further evaluation:  
n=454 
Literature which was excluded as it did not meet 
the predefined inclusion criteria: 
n= 11, 305 
Potentially relevant literature which 
was identified through other sources: 
n= 12 
 
Incorrect Intervention: n= 129 
Incorrect Language: n=19 
Incorrect Outcome: n=96 
Incorrect Population: n= 11 
Incorrect Publication Type: n=154 
Incorrect Publication Date: n=2 
Incorrect Study Design: n= 0 
Data not in a usable from: n= 3 




Literature included in the systematic review: 
n=46 papers (n=45 evaluation frameworks) 
Pearling of reference lists. 



































Figure 4: PRISMA Flow-chart of literature selection 
 
Potentially relevant literature was identified through systematic 
searches of: 
PubMed (MEDLINE), Embase, The Cochrane Library, CINCAL, 







Overview of frameworks 
All of the included frameworks addressed mHealth applications, with 73% (n=33) explicitly assessing 
MMAs. Most of the frameworks that evaluated MMAs were sourced from universities. The remaining 27% 
(n=12) were developed by private organisations, institutes, medical schools, or governmental 
organisations. 
 
The frameworks originated from three geographical regions. Most (49%, n=22) came from North America, 
while Europe contributed 40% (n=18) and the remaining 11% (n=5) originated from the Asia-Pacific 
region.  
 
The frameworks that assessed MMAs came in a variety of different formats. Some of these formats 
included questionnaires, data extraction criteria, flow charts, and varying types of lists. Due to the variety 
of formats, it was difficult to categorise the frameworks into types. Less than half of the frameworks had 





Author, date Intended  audience 






Country of origin1 
Albrecht, Von Jan & Pramann (20), 2013 Patients MMA Institute No Norway 
Anxiety and Depression Association of America 
(ADAA) (38), 2016 
Quality assurance for user protection MMA Private organization Yes USA 
Arnhold, Quade & Kirch (57), 2014 Quality assurance for research setting MMA University Yes Germany 
Aungst et al. (32), 2014 Health professionals MMA University No USA 
Basilico et al. (41), 2016 Quality assurance for research setting MMA University Yes Italy 
Beatty, Fukuoka & Whooley (15), 2013 Patients, health professionals MMA University No USA 
BinDhim et al (58), 2015 Regulators mHealth University Yes Australia 
Brooks et al. (39), 2015 Patients MMA University No USA 
Chan et al. (18), 2015 Patients, health professionals MMA University No USA 
Chomutare et al. (59), 2011 Quality assurance for research setting MMA University No Norway 
Demidowich et al.(60), 2012 Quality assurance for research setting MMA Medical school Yes USA 
Drinic et al. (16), 2016 Patients MMA University No USA 
Fairburn & Rothwell (33), 2015 Quality assurance for research setting MMA University No UK 
Ferrero-Alvarez-Rementeria (36), 2013 All stakeholders in mHealth mHealth Governmental organization No Spain 
Gautham, Iyengar, & Johnson, C. W (30),  2015 Health professionals MMA University No UK 
Gibbs et al.(25), 2016 Quality assurance for research setting MMA University No UK 
Grundy et al. (26), 2016 
Patients, health professionals, and app 
developers 
mHealth University Yes Australia 
Hacking Medicine Institute (HMi) (34), 2016 Quality assurance for user protection MMA Institute Yes USA 
Hoppe, Cade & Carter, (61) (2016) Patients MMA University Yes UK 
Huckvale et al. (27), 2015 Quality assurance for research setting MMA University Yes UK 
IMS Institute for Healthcare Informatics(62), 2013 Quality assurance for user protection mHealth Institute Yes USA 
Jin & Kim (63), 2015 Health professionals mHealth University Yes Republic of Korea 
Kassianos et al.(21), 2015 Quality assurance for research setting mHealth University No UK 
Lalloo et al.(47), 2015 Quality assurance for research setting MMA University Yes Canada 
Lee et al.(42), 2015 
Patients, health professionals, and app 
developers 
MMA University No New Zealand 
Martinez-Perez et al. (28,29), 2013/2015 Patients, health professionals MMA University Yes Spain 
McMillan et al. (19), 2016 Quality assurance for research setting MMA University Yes UK 





mHIMSS App Usability Work Group (31), 2012 Health professionals mHealth Private organization No USA 
Mobasheri et al. (64), 2014 Quality assurance for research setting MMA University No UK 
Murfin (24),  2013 Health professionals mHealth University No USA 
Pandey et al.(22), 2013 Quality assurance for research setting MMA University No USA 
Portelli & Eldred (17), 2016 Quality assurance for research setting MMA University Yes UK 
Powell et al.(14), 2016 Patients, health professionals MMA Private organization Yes USA 
Psyber Guide (65), Quality assurance for user protection MMA Private organization Yes USA 
Reynoldson et al. (43), (2014) Patients MMA University Yes UK 
Robustillo Cortes et al. (12), 2014 Patients MMA University No Spain 
Schnall et al. (44), 2015 Quality assurance for research setting MMA University Yes USA 
Shah, Jonassiant & Castro(66), 2014 Patients MMA University Yes USA 
Shaia et al. (45), 2016 Patients MMA Medical school Yes USA 
Shen et al. (46), 2015 Quality assurance for research setting MMA University No Canada 
Singh et al.(37), 2016 Quality assurance for research setting MMA University No USA 
Social Wellth (67), 2016 Quality assurance for research setting mHealth Private organization Yes USA 
Stoyanvo et al. (13), 2015 Quality assurance for research setting MMA University Yes Australia 
Walsworth (40), 2012 Patients mHealth University No USA 
Yasini & Marchard (23), 2015 Quality assurance for user protection mHealth Private organization No France 
Explanatory note:  
1 Based on first author affiliation.  





Intended audience  
The included frameworks had different intended audiences or purposes, such as: MMA developers (n=3), 
used for quality assurance for user protection (n=13), for patients (n=17), or used for quality assurance in 
a research setting (n=18). All of these frameworks assessed the HTA domains concerning the current use 
of the technology, description and technical characteristics, effectiveness, safety, and ethical aspects. 
 
Intended health condition  
The majority of the frameworks were aimed at evaluating MMAs that focused on the treatment, 
management or diagnosis of chronic health conditions. Diabetes and mental health were the most 
commonly addressed conditions with 13% (n=6) of the frameworks focused on MMAs for each condition. 
Cancer and pain were the next most frequently addressed conditions (7%, n=3, each). Three frameworks 
(7%) were aimed at MMAs managing sexuality transmitted infections (STI), with two of these focused 
specifically on the human immunodeficiency virus (HIV). 
 
Critical appraisal of the evidence-base underpinning the MMA 
The credibility of the information included in an MMA was assessed by 15 (33%) frameworks, including 
through: level of evidence or grade of the recommendation (12,13); assessment in a randomised 
controlled trial (RCT) (13-15); study design (i.e. clinical trial, controlled trial) (16,17); improved health 
outcomes (18); sample size, intervention fidelity and evaluation design (19); and publication in peer-
reviewed journals (20-23). Powell et al.(14), Beatty et al.(15), and Stoyonavov et al.(13) specifically 
question if the MMA was clinically tested using RCTs. Stoyonaov et al.(13) asked whether, the MMA has 
been verified through trialling/testing, ranking the responses with the lowest being no RCTs and the 
highest being multiple RCTs. One framework considered whether a systematic review or meta-analysis 
had been conducted about the MMA and topic area.(24) Furthermore, 27 (60%) of the included 






Health technology assessment (HTA) domains 
More than half of the assessed frameworks included the following HTA domains: MMA effectiveness; 
description of technical characteristics; safety; current use of the technology; and ethical aspects (Figure 
2). Five frameworks assessed 6 domains,(19,25-29) whereas two frameworks only assessed a single 





Core HTA domains  
Effectiveness 
Every framework assessed the effectiveness of MMAs in some capacity. Eleven frameworks (24%) 
evaluated user satisfaction. Thirty (67%) frameworks evaluated the technical efficacy of MMAs. Beatty, 
Fukuokam & Whooley.(15), Drinic et al.(16), and McMillan et al.(19) appraised efficacy of the applications, 
but did not provide any further detail of what they meant; it could interpreted as both therapeutic and/or 
diagnostic effectiveness. Only one framework explicitly considered comparative effectiveness.(32) Aungst 
et al.(32)’s framework asked whether an MMA already exists for the current reference condition (clinical 
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Author, date Health technology assessment (HTA) domains 
 
Domains addressed in a full HTA 
Auxiliary domains addressed in a 
full HTA 
Current use of the 
technology 















Albrecht, Von Jan & Pramann (20), 2013 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Anxiety and Depression Association of America 
(ADAA) (38), 2016 
✘ ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✘ 
Arnhold, Quade & Kirch (57), 2014 ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✔ ✘ 
Aungst et al. (32), 2014 ✘ ✘ ✔ ✔ ✘ ✔ ✘ ✘ ✘ 
Basilico et al. (41), 2016 ✔ ✔ ✔ ✔ ~ ✘ ✘ ✘ ✘ 
Beatty, Fukuoka & Whooley (15), 2013 ✘ ✔ ✔ ✔ ~ ✘ ✘ ✘ ✔ 
BinDhim et al (58), 2015 ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Brooks et al. (39), 2015 ✘ ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✘ 
Chan et al. (18), 2015 ✘ ✔ ✔ ✔ ✘ ✔ ✘ ✔ ✘ 
Chomutare et al. (59), 2011 ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Demidowich et al.(60), 2012 ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Drinic et al. (16), 2016 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✘ 
Fairburn & Rothwell (33), 2015 ✔ ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✘ 
Ferrero-Alvarez-Rementeria (36), 2013 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Gautham, Iyengar, & Johnson, C. W (30),  2015 ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Gibbs et al.(25), 2016 ✔ ✔ ✔ ✔ ~ ✘ ✔ ✔ ✘ 
Grundy et al. (26), 2016 ✔ ✔ ✔ ✔ ✘ ✘ ✔ ✔ ✘ 
Hacking Medicine Institute (HMi) (34), 2016 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Hoppe, Cade & Carter, (61) (2016) ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Huckvale et al. (27), 2015 ✔ ✔ ✔ ✔ ~ ✘ ✔ ✔ ✘ 
IMS Institute for Healthcare Informatics(62), 2013 ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Jin & Kim (63), 2015 ✘ ✘ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Kassianos et al.(21), 2015 ✘ ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✘ 
Lalloo et al.(47), 2015 ✘ ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✔ 
Lee et al.(42), 2015 ✔ ✔ ✔ ✔ ~ ✘ ✘ ✔ ✘ 





Martinez-Perez et al. (28,29), 2013/2015 ✘ ✔ ✔ ✔ ✘ ✔ ✘ ✔ ✔ 
McMillan et al. (19), 2016 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✔ 
mHIMSS App Usability Work Group (31), 2012 ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Mobasheri et al. (64), 2014 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Murfin (24),  2013 ✘ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Pandey et al.(22), 2013 ✔ ✘ ✔ ✔ ~ ✘ ✘ ✔ ✘ 
Portelli & Eldred (17), 2016 ✘ ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✔ 
Powell et al.(14), 2016 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Psyber Guide (65), ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ 
Reynoldson et al. (43), (2014) ✔ ✔ ✔ ✔ ~ ✘ ✘ ✔ ✘ 
Robustillo Cortes et al. (12), 2014 ✘ ✔ ✔ ✔ ✘ ✘ ✔ ✔ ✘ 
Schnall et al. (44), 2015 ✔ ✔ ✔ ✘ ~ ✘ ✘ ✘ ✘ 
Shah, Jonassiant & Castro(66), 2014 ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✘ ✘ 
Shaia et al. (45), 2016 ✔ ✔ ✔ ✔ ~ ✘ ✘ ✔ ✘ 
Shen et al. (46), 2015 ✔ ✔ ✔ ✔ ~ ✘ ✘ ✔ ✘ 
Singh et al.(37), 2016 ✘ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✔ 
Social Wellth (67), 2016 ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✔ ✘ 
Stoyanvo et al. (13), 2015 ✔ ✔ ✔ ✔ ~ ✘ ✘ ✔ ✘ 
Walsworth (40), 2012 ✔ ✘ ✔ ✔ ✔ ✘ ✘ ✘ ✘ 
Yasini & Marchard (23), 2015 ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✘ ✘ 
Explanatory note:  





The diagnostic accuracy of MMAs was assessed by 29% (n=13) of the frameworks. Martinez-Perez et 
al.(28,29) reviewed the accuracy of an MMA’s calculations. Stoyanov et al.(13), Powell et al. (14), Fairburn 
& Rothwell(33), Gibbs et al.(25), and Murfin(24), all assessed the accuracy or specificity of the information 
given in the MMAs, while HMi(34) reviewed the MMA’s clinical credibility. Powell et al.(14) included four 
response options which rated how the MMA was designed to improve a specific condition, whereas Gibbs 
et al.(25) ranked the accuracy of the information also using four options.  None of the 13 frameworks 
assessed subsequent changes in patient or decision-making management associated with use of the 
MMA (a necessary domain for determining the effectiveness of investigative interventions).(35) 
Furthermore, none of the included frameworks assessed the clinical utility of MMAs, i.e. the health impacts 
of an MMA that provides diagnostics information.  
 
Therapeutic MMAs 
Therapeutic effectiveness was assessed by 71% (n=32) of the frameworks. Three frameworks addressed 
primary patient-relevant outcomes including quality of life and mortality,(16,18,19) whereas, 25/32 (78%) 
made provision for the reporting of surrogate outcomes (e.g. physiological, biochemical, and/or behaviour 
change parameters); for example, a diabetes management MMA that could log glucose (HbA1C) 
readings, or  an HIV management app that could track T-cell counts.  
 
Safety 
Safety was addressed in 34 (76%) frameworks with 27 (79%) of these assessing the source of the 
information used by the MMA, and three appraising how the information sources were selected.  Only 
seven frameworks evaluated the harms of the app itself (e.g. adverse events).(14,18,19,26,32,36,37) Six 
frameworks addressed whether the MMA had been trialled or tested and whether safety concerns had 
been identified during the process.(15,16,20,22,38,39) 
 
Cost, cost-effectiveness  
Only one framework assessed the cost-effectiveness domain by asking whether a health economic 
evaluation had been conducted.(40) However, this domain was partially addressed by 11 (24%) 
frameworks that reviewed the cost of MMAs in terms of the price to download the application or to 





Current use of the technology 
The current use of the technology was assessed by 25 (55%) of the frameworks. Seventeen assessed 
(68%) usage of the MMA (e.g. rates, utilisation, trends), 16 (64%) assessed the intended user population 
and 15 (60%) considered the intended purpose of the app (e.g. diagnosis, management, or treatment).  
 
Description and technical characteristics  
Technical characteristics of MMAs were assessed by 78% (n=35) of the frameworks. The type of device 
(e.g. mobile platform, operating systems, software versions) was evaluated in 23 (67%) frameworks and 
19 (54%) evaluated whether experts were consulted during the development of the app. Eleven (31%) 
assessed whether the MMA had communicative capabilities (e.g. communication with personal health 
records, communication with electronic health records, and healthcare provider-patient communication), 
and 8 (23%) considered whether the MMA had personalisation capabilities. 
 
Organisational aspects  
Only three (7%) of the included frameworks assessed whether the MMA would have organisational 
implications. Two of the frameworks recorded if any training was needed to use the application and if 
adopting the MMA would alter the utilisation of existing services.(18,28,29) One framework assessed 
whether the MMA would alter the daily practices of clinicians.(32) 
 
Optional HTA domains  
Legal aspects 
Four (9%) of the identified frameworks assessed the legal implications of MMAs.(12,25-27) Three of these 
determined whether there were legal implications by asking whether the MMA had a disclaimer 
concerning clinical accountability.(12,25,26) Two of the frameworks required consideration of the 
possibility of copyright infringement.(26,27) 
 
Ethical aspects 
Ethical considerations were examined by 24 (53%) frameworks. Of these, 18 (75%) recorded whether the 
MMA had a privacy policy (though only four considered the individual content of the privacy policy); 18 
(75%) evaluated patient confidentiality provisions in the app; and 14 (58%) assessed conflicts of interest 
(e.g. affiliation, funding, third party sponsorship). Four (17%) frameworks appraised equity (e.g. 
socioeconomic status, disability, language, and age),(13,18,27,43) and an additional four (17%)   






Six (13%) frameworks assessed how the MMA provides social support to the users, (15,17,28,29,37,47) 
for example, whether the MMA provides psychosocial support, if the MMA can provide support through 






None of the included frameworks could be used “off the shelf” to evaluate MMAs in a full HTA requiring 
assessment across all six core HTA domains. Frameworks by Grundy et al.(26), Hacking Medicine 
Institute (HMi)(34), Huckvale et al.(27), Martinez-Perez et al.(28,29), and McMillan et al.(19) all assessed 
six HTA domains, but none of these addressed all of the six core domains. Ethical, social and legal 
considerations are frequently omitted in typical HTAs. However, we found that, for MMA specific 
evaluations, ethical issues were often addressed, whereas organisation of care, and cost and cost-
effectiveness domains, together with legal considerations, were the least likely to be addressed.(11) 
 
Safety 
Nearly a quarter of the evaluation frameworks did not assess safety in any capacity. Only five (16%) 
frameworks explicitly considered the MMA’s ability to cause harm or adverse events.  None of the 
frameworks explicitly assessed the comparative safety of the MMA with reference to other MMAs or 
current clinical practice without use of an MMA. It is possible that evaluators of MMAs do not find safety 
as important a concern as the effectiveness this technology. MMAs with attachments (such as 
glucometers, oximeters, or electrocardiogram leads) that have the potential to physically harm, may be 
more obvious candidates for safety assessment, rather than the individual MMA itself.  
 
A further concern regards the source of information on which the assessment of safety was based. We 
found that only one quarter of frameworks checked this factor. Lack of attention to information sources is 
problematic because of the potential harms caused by misinformation. The International Medical Device 
Regulators Forum (IMDRF)(48) states that the greatest risks and benefits posed by software which acts 
as a medical device (SaMD) - such as an MMA - relates to its output and how it impacts on a patient’s 
clinical management or other healthcare related decisions, not from direct contact with the device itself.  
Apps which utilise poor/weak evidence bases could present a range of clinical harms. For example, 
chronically ill patients using medication incorrectly due to inaccurate feedback from the MMA; 
rehabilitation patients doing inappropriate exercises; or, potentially more seriously, the long-term 
consequences to health of receiving a false negative diagnosis from an investigational MMA. However, 
both the physical harm and risks associated with misinformation are of interest in an HTA and may affect 
subsequent policy decisions, regarding access to, or reimbursement of MMAs. 
 
Effectiveness  
Normally to assess the effectiveness of an intervention in an HTA, the results of the intervention are 
compared to current practice or an existing intervention. However, only one of 45 frameworks considered 




of the condition without the MMA. Without a comparator identified it is impossible to adequately assess 
the effectiveness of an MMA or conduct a full HTA that could inform policy decision making. 
 
Investigative MMAs 
The safety and effectiveness of an investigative medical service can be determined through direct or 
linked evidence.(35,49-51) None of the included frameworks appeared to use a direct evidence approach 
to evaluate an MMA. Frameworks did address the diagnostic accuracy of an MMA, however, none linked 
this to subsequent changes in management or healthcare decision-making. In any case, those 
frameworks that assessed the diagnostic accuracy of MMAs did not collect sufficient information to enable 
a full assessment.  
 
Therapeutic MMAs 
In the evaluation of a therapeutic medical service safety and effectiveness can be determined through 
direct randomised trials (preferred), indirect comparisons of randomised trials, or non-randomised trials, 
and observational studies. The purpose of this evidence is to identify the best available clinical evidence 
for the primary indication relative to the main comparator.(50,51) None of the included frameworks 
adequately addressed the key elements evaluated to demonstrate the therapeutic effectiveness of an 
MMA, with only seven frameworks considering the quality of the evidence base (such as whether clinical 
trials were considered or what health outcomes eventuated from use of the MMA). 
 
Cost and cost-effectiveness and organisational Issues 
The frameworks did not consider the impact that the direct costs of an MMA would have on the current 
health system, or the potential effect on other medical services or devices (Table 2). Only one framework, 
by Walsworth(40),  addressed cost and cost-effectiveness and it only assessed if the value of the MMA 
justified the cost.  Formal economic evaluations of the value for money associated with the use of the 
MMA was not required by any of the identified evaluation frameworks. It may be that the cost impact of 
MMAs is considered to be trivial and therefore cannot justify a formal economic evaluation; the cost of 
some MMAs is small. However, costs do not just relate to the unit price of the MMA but also to downstream 
costs associated with behaviour affected by the MMA.  
 
Although no single framework addressed all of the information necessary for an HTA of an MMA, there 
were elements considered across the frameworks that if combined could produce a comprehensive 





Technology specific considerations  
There are a number of technology specific considerations that may need to be addressed when 
conducting an HTA on an MMA.  
 
The first is a requirement to assess ethical aspects, specifically data privacy. Over half of the frameworks 
identified had assessed ethical issues concerned with MMAs. Connectivity to the internet, networks and 
other devices through a portable handheld device (i.e. smartphone or tablet) is a unique vulnerability of 
apps that are used for medical purposes. If the MMA is jeopardised (e.g. hacked or viruses), there is the 
potential to compromise sensitive personal health information.(52,53)  The IMDRF(54) regards security 
concerns relating to the privacy and confidentiality of data (of an SaMD) as safety concerns. The 
accessibility, availability, and integrity of the device output are crucial  for patient treatment and 
diagnoses.(54) A further concern is that companies have been known to sell consumer data.(55) The 
FDA(52,53) has attempted to address cybersecurity concerns by publishing pre and post market guidance 
documents which provide recommendations for the management of cyber threats to medical devices.   
 
Secondly, compatibility and connectivity concerns are important for the evaluation of MMAs. MMA 
performance may vary between different platforms (i.e. smartphone, tablet, or smartwatch), with different 
operating systems (i.e. Android vs iOS), and for different generations of the same device (i.e. iPhone 5 
vs iPhone 6). Additionally the impact of software updates must also be allowed for, as MMAs are a 
dynamic technology which is constantly changing. One update that makes an incremental change to the 
MMA may not alter its intended purpose. However, multiple subsequent incremental updates may change 
the intended purpose of the MMA.(56) As highlighted by the IMDRF(54), if not managed systematically, 
any modification (e.g. updates) to the software throughout its lifecycle – including maintenance - poses a 
risk to the patient. A full HTA that is used to inform policy decisions regarding an MMA may need to 
assessing these compatibility and connectivity concerns to ensure that the app is consistent across 
various platforms, operating systems, and devices, as well as identify when software modifications such 
as updates, should trigger reassessment of the MMA.   
 
Key components of an MMA evaluation framework  
MMA evaluation frameworks intended to appraise apps for HTA purposes should include: consideration 
of a comparator; a complete assessment of safety and harms from misinformation; a more detailed 
evaluation of ethical issues such as equity and secure management of confidential data; a consideration 
of the impact of software updates on the safety and effectiveness of the MMA. It is difficult to determine 
from this systematic review whether social, legal, and organisational aspects, or the cost and cost 
effectiveness of MMAs should be evaluated. It would be helpful to identify indicators that could trigger an 




in an MMA evaluation framework for HTA purposes and what structure the framework could take. For 
example, would the structure of such a framework follow the HTA domains or use another categorisation 
method which is more suitable to address the unique challenges presented by MMAs (e.g. development 
quality, information security, technical considerations). 
 
 
The second stage of our research project is to conduct interviews with MMA developers, health 




As with any systematic review there were some limitations with the research. There is a risk of publication 
bias, although we attempted to limit this by conducting grey literature searches and including all 
frameworks in the review that met the selection criteria. Another possible limitation was that the checklist 
we created to standardise and identify which HTA domains the frameworks addressed, could have been 
idiosyncratic. The tool was pilot tested by an HTA expert and found to have fair inter-rater reliability. The 
use of the core HTA domains to assess the MMA evaluation frameworks may have limited the concepts 
identified. To address this, we have also highlighted a number of technology-specific considerations that 







In conclusion, none of the 45 identified frameworks could be used, unaltered, to assess an MMA in a full 
HTA to inform a policy decision. While several of the identified MMA evaluation frameworks addressed 
up to six of the HTA domains, there was a lack of detail that would be required to undertake a full HTA. 
To adapt these frameworks for use in the HTA of MMAs there would need to be greater consideration of 
the comparator, and a fuller assessment of the harms associated with MMAs. Our results also indicate 
that an HTA of an MMA should pay particular attention to the ethical issues associated with the 
technology, in particular to the secure handling of confidential data. The impact of MMA updates on overall 
conclusions of safety and effectiveness would also need consideration. 
 
Policy implications 
This research has various policy implications. Firstly, there is a need to develop an MMA evaluation 
framework that is compatible with HTA and addresses all of the relevant policy concerns. Further 
information is needed from developers and users of apps about the technology-specific characteristics of 
MMAs that would need to be addressed in a HTA evaluation framework to inform policy decisions on 
MMAs. Secondly, due to technology specific considerations, such as the app development cycle, varying 
platforms, and cybersecurity risks, regulatory and reimbursement authorities may need to work 
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6.2.3 Supplementary material 
 
Literature search terms and strategy    
Search strategy   
The search strategies used in all electronic bibliographic databases were based on the search terms 
described below. The search strategy in Table S.1 is an example of a strategy that was used in medical 
bibliographic databases and Table S.2 is an example of the one used in engineering databases.  
 
Search terms for mobile medical applications (MMA) 
Several search terms were used for mobile medical applications (MMA). These included terms used to 
describe MMAs, mobile health (mHealth) apps, and mobile apps in general. Search terms for telemedicine 
(including telehealth) and electronic health (eHealth) were also included as they are sometimes used 
interchangeably with mHealth.(1) 
 
Search terms for mobile platforms 
A variety of search terms were used for mobile platforms. Similar to the MMA strategy several terms were 
used to describe the devices. These terms include various names for cell phones, ‘smart’ devices, the 
operation systems the platforms run, and the commercial names of popular devices. It was important to 
include a wide array of search terms for cell phones and related devices as indexing terms for 
smartphones in some databases were only added recently (2016).  Indexing terms for mobile phones 
were implemented in 2003 – predating the 2008 cut-off.(2,3)  
 
Search terms for evaluation  
Additional search terms were included for evaluation (assessment).  
 
Table S.1: Search strategy for PubMed (MEDLINE)   
Mobile Medical Applications (MMA) Mobile Platform 
(mobile applications[mh] OR mobile app*[tw] 
OR portable electronic app*[tw] OR mHealth 
app*[tw] OR portable software app*[tw] OR 
mobile medical app*[tw] OR mobile health 
app*[tw] OR telemedicine[mh] OR telemedicine 
app*[tw] OR telehealth app*[tw] OR electronic 
health app*[tw] OR eHealth app*[tw])  
AND (cell phones[mh] OR cell phone*[tw] OR 
cellular phone*[tw] OR cellular telephone*[tw] OR 
mobile phone*[tw] OR mobile[tw] OR mobile 
device*[tw] OR mobile platform*[tw]  OR 
smartphone[mh] smartphone*[tw] OR smart 
phone*[tw] OR android*[tw] OR ipad*[tw] OR 
iphone*[tw] OR apple watch*[tw] OR smart 
watch*[tw] OR tablet*[tw] OR iOS[tw] 
Blackberr*[tw] OR windows[tw] OR Microsoft[tw] 






Table S.2: Search strategy for Compendex  
 
Grey literature search strategy 
In addition to the literature searches in electronic bibliographic databases several grey literature sources 
were searched to identify any relevant MMA related evaluation frameworks that were not available in the 
published literature. These sources are listed in Tables S.3, S.4, and S.5. 
 
Table S.3: Internet 
Source  Location 
IMS Institute for Health Informatics http://www.imshealth.com/ 
MIT Hacking Medicine Institute http://hackingmedicine.mit.edu/ 
Mobihealthnews http://www.mobihealthnews.com/ 
Mobile World Capital http://mobileworldcapital.com/ 
Sax Institute https://www.saxinstitute.org.au/ 
Science.gov http://www.science.gov/ 
The Commonwealth Fund http://www.commonwealthfund.org/ 
World Health Organisation (WHO)  http://www.who.int/en/ 
 
Table S.4: Speciality websites 
Source  Location 
Indigenous Australian HealthInfoNet http://www.healthinfonet.ecu.edu.au/ 
International Medical Device Regulator Forum  (IMDRF) http://www.imdrf.org/index.asp 
 
Table S.5: Sub-jurisdictional 
 
  
Mobile Medical Applications 
(MMA)  
Evaluation   Other 
("mobile medical app" OR 
"mobile health app" OR "mobile 
health application" OR "mobile 
health app" OR “telemedicine 
app” OR “telemedicine 
application” OR “mHealth app” 
OR “mhealth application”  OR 
“eHealth app” OR “eHealth 
application” OR “telehealth 
app” “telehealth application”) 






(tool* OR framework*) 
Source Location 
National Health Services (NHS), England http://www.nhs.uk/Pages/healthappslibrary.aspx 
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6.3 Postface  
6.3.1 Chapter summary 
The systematic review addressed the second research question of this thesis which was aimed at 
determining if it is feasible to evaluate MMAs within the current Australian HTA system. It achieved this 
by reviewing the existing MMA evaluation frameworks --available prior to 31st October 2016— to 
determine if any are suitable to be used to inform HTA purposes and/or reimbursement decision-making. 
The systematic review found that from the 45 MMA evaluation frameworks included, none of them could 
be used without any alterations to conduct a full HTA on apps. Of the frameworks which did review up to 
6 HTA domains, none of them evaluated MMAs with enough detail to properly undertake an assessment 
of the wider health and societal implications of apps. This was due to the lack of consideration of the 
harms presented by MMAs (i.e. misinformation) and the need for fuller consideration of a comparator (i.e. 
comparative safety, comparative effectiveness and comparative cost-effectiveness).  
 
The research also found that not only are current MMA frameworks unsuitable for conducting a HTA on 
MMAs, but, the current HTA system in Australia may also need to be adapted to properly review the 
dynamic nature of MMAs.  A large proportion of the technology specific MMA considerations identified 
related to ethical concerns. These considerations include, but are not limited to, concerns around the 
proper and secure management of confidential data. Additional technology specific concerns which need 
to be considered, are the effect of software updates on the safety and effectiveness of MMAs as well as 
how the app performance may be altered on different OS, platforms, and generations of the same 
platform. 
 
In conclusion, using current HTA processes in Australia, decision making regarding MMA reimbursement 
would be based on insufficient and potentially misleading information. The collation of current MMA 
evaluation frameworks has highlighted technology-specific information that is not incorporated in existing 
HTA guidance in Australia. Unfortunately, none of the identified MMA evaluation frameworks are fit-for-
purpose for informing policy decisions – the target audience was different. Changes need to be made to 
current Australian HTA processes to ensure that the methodology evaluates some of the technology 
specific challenges presented by MMAs.  
 
6.3.2 Update 
Since the publication of Moshi, Tooher & Merlin(149), no other systematic review has been conducted 





6.3.3 Publications and presentation of chapter findings  
Between September 11th 2018 and December 5th 2019 --according to Cambridge University Press-- 
Moshi, Tooher & Merlin(149) has accumulated an Altmetric of 5, 347 full PDF views, 48 HTML views, and 
1153 abstract views. On December 5th 2019 Moshi, Tooher & Merlin(149) had 3 citations and  was the 
second highest Altmetric of the 5th  issue of the 34th volume of the International Journal of Technology 
Assessment in Health Care.(162)  
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Chapter 7: Evaluative module for assessing 
mobile medical applications (MMA) 
 
Development of a health technology assessment (HTA) evaluative module for assessing 







This chapter explores the policy changes and assessment criteria needed to facilitate the development of 
a process for evaluating MMAs for reimbursement purposes in Australia. It achieves this through 
synthesising the findings from Chapters 5 and 6 with the results of newly conducted stakeholder (app 
developers, policymakers, healthcare workers) interviews. The findings of the synthesis and interviews 
were then used to create an evaluation module that could be used to adapt the current Australian HTA 
evaluation framework for the assessment of MMAs.  
 
This chapter is aimed at answering the third research question and its respective objective(s) as given in 
Figure 7.1. How the third research question and objectives relate to the other research questions is 
illustrated in Figure 3.1 in Chapter 3.  
 
  
Figure 7.1: Structure of Chapter 7’s research question and objectives 
 
Determine whether reimbursement of MMAs is 
feasible in Australia and develop possible 




processes for the 
reimbursement of 
MMAs in Australia. 
Identify 






Research Question 1 
Objectives 
Sub-Objectives 
Determine the applicability of the possible MMA 
assessment criteria for reimbursement purposes in 
Australia, to other jurisdictions. 
What key policy changes and assessment criteria are needed to facilitate the 
development of a system that evaluates MMAs for reimbursement purposes 
in Australia? 
Assess the HTA 
criteria used in 
Canada 
 
Assess the HTA 
criteria used in 
the USA 
 
Assess the HTA 







The publication included in this chapter combines and synthesises the results from Chapters 5 and 6 with 
the results of in-depth interviews undertaken to identify stakeholder groups’ (medical practitioners, 
application developers, and policymakers) views on possible pathways and impediments to MMA 
reimbursement in Australia. Moshi et al.(141) in Chapter 5 reviewed the Australian regulatory model for 
MMAs and identified the changes that are needed to properly assess the possible health risk and benefits 
posed by the technology. Moshi, Tooher, and Merlin(149) in Chapter 6 determined whether 
reimbursement of MMAs is possible within the current Australian HTA system. The findings from both of 
these chapters were used to scaffold interviews held with stakeholder groups to elicit their views on the 
feasibility of MMA reimbursement in Australia. The findings from Chapter 5, Chapter 6, and the 
stakeholder interviews were integrated to create an MMA module for evaluating MMAs for reimbursement 
and decision-making purposes. 
 
The interview schedules for the different stakeholder groups, the ethical clearance, the recruitment email, 
participant information sheet, as well as templates for consent forms for teleconference and in-person 
interviews are given in Appendix D. 
 
The second section of this chapter (Section 7.3) explores the second objective and explores the possibility 
of the MMA module being applied internationally. The focus was determining if the MMA HTA evaluation 
module developed for the domestic healthcare context could be transferred and applied to evaluate apps 
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Abstract   
Objective 
The aim of this study was to develop a module which could be used to facilitate the assessment of mobile 
medical applications (MMA) for regulatory and reimbursement purposes. 
 
Methods 
In-depth interviews were conducted with policymakers, healthcare practitioners, and application 
developers to determine possible pathways and impediments to MMA reimbursement.  These findings 
built upon with our previous research on MMA reimbursement and regulation in order to create a module 
which could be used with existing HTA methodological frameworks to guide the evaluation of MMAs.  
 
Results 
Stakeholders indicated that they trust how traditional medical devices are currently appraised for 
reimbursement and would like something similar for MMAs. They were concerned that there was a lack 
of clarity regarding which entity was responsible for app quality. There were also concerned about the 
digital health literacy of medical practitioners and patients. When evaluating MMA software changes, 
connectivity and cybersecurity of the app need to be considered. Additionally, the credibility of the 
information presented in apps must be assessed as it could potentially mislead patients and clinicians. 







An MMA evaluation module was created to adapt an existing HTA process for MMA technology. The 
adaptations included making provisions for an assessment of cybersecurity, consideration of the impact 
on MMA clinical utility of software updates, and compatibility issues. Items to address concerns around 
practitioner responsibility and the potential for app misinformation were also incorporated into the module. 
Keywords  
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Electronic health (eHealth) technologies such as mobile health (mHealth) applications (apps), electronic 
health records (EHR), and telemedicine are increasingly being used in healthcare(1-3). Apps with a 
diagnostic or therapeutic purpose are known as mobile medical applications (MMA) and have been 
growing in popularity over the past few years (4-7). MMAs are now being used and recommended by 
healthcare practitioners within clinical consultations (4-7). 
 
In Australia, government reimbursement of clinical encounters and prescribed interventions is available 
to healthcare practitioners (e.g. general practitioners (GP), medical specialists, allied health workers, 
dentists, optometrists) and patients through the national health insurance scheme called the Medical 
Benefits Schedule (MBS) (8,9). For a medical service or intervention to be reimbursable through the MBS, 
it has to first be approved by the Therapeutic Goods Administration (TGA), and then undergo a health 
technology assessment (HTA) to ensure it is safe, effective and cost-effective (5,6,9). After a medical 
service has undergone an HTA conducted by an independent body --under the guidance of the Australian 
Medical Services Advisory Committee (MSAC)-- and approved by the Federal Minister of Health, it is 
given an item number and listed on the MBS for reimbursement (8,9). Currently, there is no mechanism 
for MMAs to be reimbursed through the MBS, although other eHealth technologies, such as telemedicine, 
are reimbursed (10-12). 
 
MMAs pose different harms and risks than traditional medical devices or eHealth technologies, and 
therefore evaluation of them requires consideration of different dimensions than those used in a typical 
medical services evaluation (13-17). Unlike other technologies, MMAs: have a fast life cycle; are available 
on non-specialised off-the-shelf devices; are available on various operating systems (e.g. Android or iOS) 
and operating platforms (e.g. smartphone, smart watches, tablets); have software updates; can provide 
real-time post-market performance data or ‘real world data’; and connect to various databases and data 
systems via the internet and have other networking capabilities (14-17).   
 
MMAs do not currently undergo HTA evaluations in the Australian healthcare system (13).  The aim of 
this study, therefore, was to develop evaluation criteria (a module) that could be used to adapt current 
HTA frameworks for the assessment of MMAs.  
 
Methodology 
The need for a module capable of adapting HTA processes to enable them to properly evaluate MMAs 




developed by synthesising the results of the two previously mentioned studies with insights generated 
from semi-structured in-depth interviews with a range of stakeholders (healthcare practitioners, app 
developers, and policymakers).  The interviews sought stakeholder views on possible pathways and 
impediments to MMA reimbursement in Australia in order build on the findings from the two preceding 
studies and inform the creation of the HTA evaluation module. Patients were not interviewed as they are 
the end-users of the proposed HTA process.  
 
Since the complete methodologies utilised in the first two studies are available in their respective 
publications, only the methods related to the interviews and the creation and testing of the module are 
described below. 
 
In-depth interviews  
In depth interviews were undertaken with a sample of key stakeholders to support and inform the 
creation of the MMA evaluation module and to provide insight into issues identified in the two preceding 
studies. The study was not designed as a standalone qualitative study.    
 
Recruitment  
The stakeholders were purposively recruited by email (between April and December 2017) from those 
who have experience with MMAs in their professional careers. Potential participants were identified by 
scoping done by the first author (MM), as well as through contacts of the second (RT) and third (TM) 
authors. Passive snowballing via email was then used to identify further participants. All participants were 
emailed the participant information sheet in English prior to agreeing to the interview. The participants 
participated in the study on a voluntary basis and were free to withdraw prior to this publication. Adopting 
an information power approach, participants were only recruited if we identified that they could 
substantially add to the range of views about this topic (see Supplementary material A for more 
information) (19-21).   
  
Data collection 
The data were collected through semi-structured in-depth interviews with key stakeholders. The interviews 
were conducted by the first author (MM) in-person or via teleconference. The interviews were recorded 
using an audio-recorder. Verbal and written consent was sought before the start of each interview. In the 
case of in-person interviews, written consent was obtained before the interview, whereas with 
teleconferences a completed written consent form was returned via email before the start of each 





Data analysis  
The interviews were transcribed verbatim by a professional transcriber and were analysed through 
thematic analysis (Braun & Clarke(22)) using the epistemology of pragmatism (see Supplementary 
material A for more information). The assistive software NVivo 11 (QSR international Pty Ltd)(23) was 
used by the first author (MM) to aid in the analysis. The coding and analysis were checked by the second 
author (RT). Data source triangulation was achieved through the use of multiple participants with different 
expertise from five Australian jurisdictions (24-26). Quotations from participants are used below to 
illustrate the findings.  
 
Ethical considerations 
The stakeholder interviews (from the larger research project) were approved (H-2017-039) by the 
University of Adelaide Human Research Ethics Committee (HREC) Low Risk Human Research Ethics 
Review Group. 
 
To minimise any risk of reputational damage to the participants through disclosure of information about 
clinical or regulatory practices, we took extra steps to ensure that participants or their organisations could 
not be identified from any data extracts used as quotation(s), or from any example(s) included in this 
written publication. 
 
Development and testing of MMA evaluation module  
The module was developed by synthesising the results from the two aforementioned studies (8; 18) with 
the findings from the stakeholder interviews. This was achieved by the identification of the key policy 
changes and assessment criteria needed to enable the appraisal of MMAs. For example,  Moshi, Tooher, 
& Merlin (2018) identified the key considerations for conducting an HTA on MMAs for reimbursement and 
decision-making purposes (Table 1) (8). Moshi et al. (2019) identified critical regulatory considerations for 
MMAs which are not addressed the Australian regulatory authority (Therapeutic Goods Administration 
(TGA)) or by the other IMDRF member jurisdictions (Table 1) (18). On the basis of these studies, and 
informed by the insights generated from the interviews with stakeholders (Table 1), a module was 
developed.  
 
Pilot testing of the MMA evaluation module 
The MMA evaluation module was tested by applying it to the current HTA evaluation frameworks used by 
the Federal Department of Health to appraise medical services for public funding decisions. These 






Stakeholder Interviews  
Interview characteristics  
Nine semi-structured in-depth interviews were conducted between September and December 2017. The 
duration of each interview was approximately 1 hour.   
 
The participants included four healthcare practitioners (general practitioner(s) (GP), nutritionist(s), 
physiotherapist(s)), three policy makers, and two developers of health apps. Three different interview 




Stakeholders, particularly the healthcare practitioners, expressed trust in the HTA approach used by the 
MSAC. Trust in these processes is an enabler for the reimbursement of MMAs in Australia, as it aids in 
the creation of evidence-based policy. It requires that there be a rationale for use for the intervention in 
question.  
 
“So I think, if an app was listed on the MBS [Medicare Benefits Schedule] I think that would for me would 
indicate to me that oh well I would assume that there had been…it would be evidence based, there had 
been [a] quality check done on I guess the content and the process”  
Healthcare practitioner, 1   
 
The interviews reflected that there are unclear lines of responsibility with respect to jurisdictional oversight 
and practitioner accountability for MMAs.  
 
“I think one of the biggest challenges we have is actually working out what it is that we can regulate and 
we are able to regulate and I am aware that there are lots of complexities to this including kind of where 
it is that the actual app is being sold from impacts our ability to actually regulate things.”  
 
Policymaker, 1  
 
The ownership of the heath data produced by an MMA is a significant stakeholder concern as it affects 
patients’ rights to data privacy and confidentiality. For example, if the app data are owned by the company 





“there is an issue around who actually owns the data and monitors the data and is responsible for 




Stakeholders were also concerned about the impact of app use on the relationship between clinicians and 
their patients, including the clinician’s duty of care, and whether this would affect professional indemnity. 
The stakeholders suggested that bringing MMAs into the standard technology regulatory framework would 
help to address these concerns.  
 
“if there is a proper accredited process then that’s all you really need to know and then you are comfortable 
if your apps yeah put up to against the accredited process and passes then you know I think from a 
professional indemnity point of view you would have been seen to have done the…gone through the 
appropriate processes do it.” 
Healthcare practitioner, 4  
 
The stakeholder interviews also identified that the digital health literacy of both practitioners and patients 
is important. Healthcare practitioners were particularly concerned that the efficacy and safety of an MMA 
might depend on the fidelity of data entered by the user (i.e. patient) into the app and, further, that patient 
self-management might be compromised by a lack of knowledge about how to interpret the app’s output.  
 
“I’d still want to verify the data that has been inputted into it by the user I suppose, I guess my preference 
to sort of use my clinical judgement perhaps isn’t so much about the quality and strength of that app but 
more so the quality and completeness of the raw data that the clients inputting.” 
Healthcare practitioner, 1   
 
“user error you know often just by putting in say 100 kilograms instead of a 100 grams you know you can 
appreciate that could make a big difference”  
Healthcare practitioner, 2   
 
“I think it [digital health resources] gives people worry sometimes they get more confused rather than 
more enlightened .” 
 





The stakeholder interviews also highlighted the need for post-market surveillance of MMAs. These 
concerns were due to MMA’s fast lifecycle and the rapid technological evolution of digital health 
technologies. 
 
“The technologies are evolving fast and the policy just doesn’t have a chance to catch up”  
Policymaker, 1 
 
Stakeholders were particularly concerned about how post-market data and software updates might lead 
to changes which effectively created a new app or function that was not the subject of the original 
evaluation on which the regulatory and reimbursement approval was based (16,18,27,28).  
 
“they [apps] do work differently and even…so I’ve got a really old iPhone and everything will look 
different when a new iPhone comes out potentially and just the way the different buttons on Android 
verses iPhone” 






Table 1: Summary of findings from the preceding studies and the stakeholder interviews 
  
Regulation of MMAs (18) Reimbursement of MMAs 
internationally (Evaluation 
framework systematic review) (13) 
Pathways and impediments to 
MMA reimbursement (Stakeholder 
interviews) 
Effectiveness  
- Accuracy (i.e. consistency)1 
- Analytical (reliability)2 
validity 
- Precision (i.e. repeatability)3  
- Configuration  
- Communication and display  
 
Safety  
- The risk of misinformation 
(MMA credibility) 




- Operating system 
- Operating platform  
 
Post-market 
- Software changes (updates) 
- Post-market ‘real-world’ 
data on MMA effectiveness 
(process and health 
outcomes) 
- Post-market data monitoring  
Description and technical 
characteristics 
- Connectivity   
- Operating system 
- Operating platform   
- Software changes (updates) 
 
Effectiveness 
- Consider comparator 











- Confidentiality  




- Trust in HTA processes 
(MSAC) 
- Rationale for use 
- Evidence-based policy 
 
Impediments  
- Responsibility (i.e. 
indemnity issue, data 
ownership) 
- Technological evolution  
- Digital health literacy  
 
Explanatory Notes 
1Accuracy: Closeness of the quantity’s true value to its measured quantity. 
2Analytical validity: The MMAs ability to reliably and accurately produce the intentional output from the input data 
3Precision: Under unchanged conditions the degree to which the recurrent measurements generate the same result  (i.e. 
reproducibility, repeatability) 
HTA: Health technology assessment  
MMA: Mobile medical application 





Development of MMA evaluation module  
The complete evaluation module for MMAs is detailed in Table 2. The module is evidence-based and all 
of the domains are mandatory, with the exception of the social domain. Items that could fall under the 
jurisdiction of a regulatory authority were integrated into the module due to Moshi et al.(18) identifying that 
Australian and other international regulators do not properly assess MMAs. In Australia, regulatory 
approval is the first step to being eligible for reimbursement. Regulatory and reimbursement evaluations 
are independent of each other and typically focus on different aspects of the technology. However, if the 
criteria used by the regulatory authority to evaluate the MMAs do not cover all relevant concepts and/or 






Table 2: A module which can be used to adapt HTA and/or reimbursement evaluation frameworks to assess MMAs 
HTA domain HTA 
domain 
status 
MMA technology specific considerations 
Challenge posed 
by MMA 




Mandatory  Operating 
system(s) for 
MMA  




- Operating platforms of the MMA (i.e. smartphone, tablet, 
smartwatch) 
Current use of 
the technology 
Rationale for use  - The intended purpose of the MMA (i.e. diagnose, treat, inform 
clinical management, clinical management) 
- The healthcare condition or situation that the MMA addresses  
- MMA input (i.e. image, physiological status, symptoms, etc.)  
- MMA algorithm (i.e. equations, analysis engine model logic, 
algorithm, etc.) 




- Post-market software changes, that do not require the re-
evaluation of an MMA and are corrective, preventive, 
adaptive, and/or perfective (see Effectiveness for more 
information) 
- Post-market software changes that do require a re-evaluation 
of the effectiveness and safety of an MMA and  which enable 
or disable new MMA functions (see Effectiveness for more 
information) 
Effectiveness Accuracy (i.e. 
reliability) 
- Closeness of the output to the true value to the MMA’s output  
- Accuracy measures the effect of software errors on the MMA 
output  
- Total accuracy = ±(0.1% of input + x [relevant unit of measure 
(i.e. heart rate, blood sugar)]) 
Configuration - The MMA’s ability to withstand user configuration in an 
unintended way (i.e. results of fuzzing or fuzz  testing) 




- The design of the MMA user interface (i.e. level of complexity, 
type of platform, how information is displayed, etc.) 
- The appropriateness of the MMA interface as a means of 
information display (i.e. language translation, units displayed, 
clarity, etc.) 
- The MMA’s ability to communicate the relevant information 
(i.e. data quality, network availability, correct installation, etc.) 
Cybersecurity and 
connectivity 
- Formalised and safe methods have been implemented to 
convert, transmit, and/or store MMA data (i.e. results of 
fuzzing or fuzz  testing) 
- Users can safely implement information security updates 
- System supports ensure protection of  MMA system 
information  
- MMA software adheres to robust programming principles (i.e. 
paranoia, stupidity, dangerous implements, can’t happen) 
- Balances the availability of timely information and against 
privacy and security (i.e. results of fuzzing or fuzz  testing) 
- How MMA integrates with other software (i.e. results of 
fuzzing or fuzz  testing) 
- The need for MMA security software to be updated so it can 
be used alongside other systems, applications or in operating 




- Adaptive software changes (i.e. maintains software with 
dynamic environment) 
- Perfective software changes (i.e. recoding to improve 
performance) 




- Preventive software changes (i.e. corrects latent faults before 
they cause operational problems) 
Precision (i.e. 
repeatability) 
- Under unchanged conditions the degree to which the 
recurrent measurements input into the MMA generates the 
same output  (e.g. reproducibility, repeatability) 
- Values (in relevant unit) that are close together indicate that 
there is a high degree of software precision 
Analytical validity 
 
- MMAs ability to reliably and accurately produce the intentional 
output from the input data 
- The algorithm used by the MMA is a recognised standard (the 
current standard of care or described in the literature (i.e. 
insulin dosing)) 
- MMA accuracy is relative to reference standard (i.e. 
International normalisation ratio (INR)) 
- MMA comparable to another software or device that has an 
association between the software output and a health 
outcome 
Safety The risk of 
misinformation 
- How the MMA output (i.e. information) affects clinical 







- Considerations of applicability of the system, platform, 
licensing, attachable hardware, and versions of the MMA to 
those used in the health system 





- The training/education (i.e. digital literacy) which may be 
needed for user(s) (i.e. medical practitioners, patients, 
care givers) to effectively utilise the MMA. Examples 
include:  
 Continual professional development (CPD) 
courses for medical practitioner(s) could have to 
undergo to effectively learn how to utilise and 
recommend MMAs in clinical practice 
 Education that patient(s) have to undergo to 
effectively learn how to utilise MMAs 
Responsibility  - Accreditation that may be needed for professionals (i.e. 
medical practitioners, allied health workers, technicians) to 
prescribe and/or use the MMA 
Connectivity - The MMA interaction with current health informatics systems 
(i.e. hospitals and surgeries). Examples of health informatics 
systems include, but are not limited to, PROCURA and 
Enterprise patient administration system (EPAS) 
Technological 
evolution 
- How adopting the MMA could alter the current utilisation of 
services (i.e. workload, work force, compliance, etc.) 
- How adopting the MMA will change treatment location (i.e. 




and confidentiality  
- The presence of a privacy policy 
- The contents of a privacy policy  
Equity concerns 
 
- Considerations include: user disability (how could users’ with 
blindness use the MMA), language (users’ who have English 
as a second language), age, literacy, socio-economic status, 
etc. 
Access concerns  Considerations include: the cost of platform, in-app purchases, 
cost of MMA, geographical location, internet availability etc. 
Technological 
evolution 
Any possible conflicts of interest (i.e. developer or owner affiliation, 
sources funding, third party sponsorship, etc.) 
Legal aspects Responsibility - Litigation risks to the relevant person(s) associated with the 
use or recommendation of the MMA for healthcare 
practitioners (i.e. GPs, allied health workers, etc.) 
- How insurance(s) (i.e. professional indemnity, life, health, 





professionals, developers) could be affected through use or 
recommendation of the MMA 
- How possible professional registrations could be affected 
through the use or recommendation of the MMA (e.g. for 
medical practitioners with AHPRA)  
- Clarify which party owns the data related to the MMA (i.e. 
patient, third party, medical practitioners) 
- Clarity around which party (i.e. manufacturer, medical 
practitioner who prescribed it) is responsible for the medical 
advice provided by the MMA 
- Clarity around which party (i.e. manufacturer, medical 
practitioner, app developer) is responsible for monitoring and 
reviewing the patient data entered into the MMA 
Post-market 
monitoring   
Reappraisal - Post-market data that requires a full review of the 
effectiveness and safety of an MMA. These are performance 
data that alter the effectiveness measures of the MMA (i.e.  
inferior or superior to the original measures stated in the 
original HTA) and/or which change the harms posed by the 
MMA (i.e.  inferior or superior to the original measures stated 
in the original HTA) 
- How the manufacturer plans to monitor the MMA’s 
performance data (i.e. data includes user feedback, 
complaints, and adverse events, etc.) 
- How the data collection implemented has the least user 
burdensome approach to collect the MMA’s performance data 
- How the post-market data could be used to enable or disable 
new MMA functionalities (i.e. addition or removal of 
functionalities stated in the original submission, etc.) 
- How post-market data could affect the MMA’s cost-
effectiveness, safety, effectiveness 
- How post-market data could affect the ethical, legal, and/or 
organisational concerns associated with the MMA 
Social aspects  Optional None - How the use of the MMA may affect the patients’ care giver(s), 
including relationships with medical professionals 
- How the use of the MMA may affect the users’ relationships 
(i.e. family dynamics, friends, and other relevant social 
relations) 
- How the MMA may benefit patient autonomy 
Explanatory Notes 
1 Using a fee for service model 
APHRA: Australian Practitioner Regulation Agency 
GP: General practitioner  
HTA: Health technology assessment  




Description and technical characteristics  
Items were added to the module to identify and review the compatibility of the operating system (OS) and 
operating platform for the MMA. 
 
Current use of the technology  
Numerous items relating to the current use of the technology were included in the module. The first were 
items related to the intended purpose(s) of the technology, in terms of whether the MMA is aimed at 
informing, diagnosing, and/or treating a medical condition (13,18). Items to review the MMA input, 
algorithm, and output were also included in the module (18).  
 
Effectiveness  
 Multiple technology specific items were added in the module to ensure the proper appraisal of an MMA’s 
clinical effectiveness (Table 1). Previous research had found to that the technical evolution and dynamic 
nature of an MMA should be considered (13,18). To address this as well as the concerns raised in the 
stakeholder interviews, items were included to evaluate software changes (updates), information security 
(cybersecurity), communication and display, and connectivity (13,18). Items addressing regulatory 
concerns including analytical validity (reliability) of the software, software accuracy (consistency), 
software precision (repeatability), and software configuration. Furthermore, prior research found that a 
comparator should be considered for MMA evaluations, such as a clinical evaluation without the 
assistance of an app(or usual care).  
 
Safety  
Only one item was added to address safety concerns. This item was focused on evaluating the risk of 
misinformation in the app and how this could affect healthcare decision-making.  
 
Cost-effectiveness  
Module considerations relating to cost-effectiveness were minimal, and were made within a fee-for-service 
healthcare paradigm. These items include, a consideration of the applicability of the operating systems 
and platforms of the MMA being evaluated as well as the various versions of the MMA. The outright cost 
of the MMA and/or any possible in-app purchases were considered as unit costs. Change to subsequent 
care as a consequence of the MMA would be costed as part of the normal HTA process, along with 






To address data fidelity, organisational concerns were included into the module (Table 1). Organisational 
aspects that were incorporated included: if any training or education was needed for users (i.e. 
practitioners or patients); if any professional accreditation is needed for medical practitioners; if adopting 
the MMA will alter the current utilisation of services (i.e. work load, work force, compliance, etc.); if 
adopting the MMA will change treatment location (i.e. homebased, rural, remote, hospital, clinic, etc.); as 
well as an assessment of whether the MMA could interact with health informatics systems (i.e. Procura, 
Electronic Protocols Application Software (EPAS)) used in hospital, surgeries, and allied health clinics.  
 
Ethical aspects 
The ethical aspects added to the module included equity (i.e. disability, language availability, age, literacy, 
socio-economic status, etc.), patient confidentiality, and patient privacy, as these were raised in Moshi, 
Tooher & Merlin(13), Moshi et al.(18), and in the stakeholder interviews. Privacy is a major concern due 
to cybersecurity risks and that some companies that manage or produce MMAs do sell consumer data 
without consumers’ knowledge (13,18,29). Additional ethical considerations include access to the 
technology (i.e. cost of platform, in-app purchases, cost of app, geographic location, internet availability, 
etc.) and any potential conflicts of interest related to the app developer, app owner, third party sponsors, 
and funding sources.   
 
Legal aspects 
Legal aspect were included in response to concerns raised in the stakeholder interviews. The domain 
specifically evaluated responsibility.   To address this concern, items were added to review how MMA use 
and/or recommendations could affect personal insurance (i.e. professional indemnity, life, health, income, 
etc.), professional registrations (i.e. for healthcare practitioners), and risk of litigation. Furthermore, 
additional items were included to provide clarity around which party (i.e. manufacture, app developer, 
medical practitioner, etc.) owns: the data produced by the MMA; the medical advice produced by the app; 
as well as monitoring and reviewing the patient data. Legal concerns partially overlap with the Ethical 
domain above, in that it addresses some privacy concerns through seeking clarification around ownership 
(i.e. patients, medical practices, companies, etc.) of data produced by MMAs. 
 
Social aspects  
Moshi, Tooher & Merlin(13) and Moshi et al.(18) found that currently an evaluation of social issues are 
not considered an integral part of an evaluation of MMAs. Therefore, items included in the module allowed 
related social issues to be considered, such as whether the MMA can affect a care giver, the patient’s 






This newly added HTA domain has been created to address MMA specific challenges. The domain is 
aimed at evaluating post-market data as part of a HTA. Items were added to allow the post-market 
surveillance of MMAs, in terms of data monitoring (13,18). Including post-market data collection and 
utilisation (i.e. how the data could be used to modify the MMA) were also included (13,18). 
 
 
Testing the HTA evaluation module 
 
The MSAC technical guidelines were selected to test the HTA evaluation module, as these guidelines are 
used by the Australian Federal Department of Health to determine if both therapeutic and investigative 
medical services should be reimbursed through the national universal health system (27,28). These 
guidelines one of several different guidelines used in Australia to assess health interventions for 
reimbursement purposes.  
 
A range of adaptions were introduced to the MSAC guidelines from the MMA evaluation module (Table 
2).  Sections A through F of the original MSAC guidelines were modified to assess technology specific 
and pre-market (regulatory) evaluative concerns. Two new sections --G and H-- were added to incorporate 
additional technology specific items as well as any additional HTA information deemed relevant (27). All 
proposed adaptations made to the MSAC guidelines to ensure the proper assessment of MMAs are 
summarised in Table 3, with specific details given in Table 1 of the Supplementary material B. The 
complete adapted MSAC framework created using the evaluation module is available in Supplemently 
material B and is titled Framework for health technology assessment (HTA) of mobile medical applications 





Table 3: Module adaption of the MSAC technical guidelines  
Section 
letter(s) 
Technical guidelines for 
preparing assessment 
reports for the MSAC 
MMA evaluation framework for HTA and reimbursement purposes 
Technical guidelines 
section title(s)  
MMA evaluation 
framework 
section title(s)  
MMA specific modifications and adaption(s) 
A Details of the proposed 
medical services (therapeutic 
or investigative) and its 
intended use on the Medical 




the MMA used in 
the clinical service 
- Details of the MMA 
- Details of the MMA’s intended purpose 
- Details of the operation system (OS) 
- Details of the operation platform 
B Clinical evaluation for the 
proposed MMA (therapeutic 
or investigative) 
Evaluation of a 
clinical service 
involving a MMMA 
- Therapeutic MMAs 1 
- Investigative MMAs 2 
- Accuracy (i.e. consistency) 3 
- Analytical (reliability) validity 4 
- Connectivity  
- Configuration  
- Communication and display 
- Cybersecurity 
- Potential software changes (i.e. updates) 
- Post-market monitoring 
- Precision (i.e. repeatability) 5 
- The risk of misinformation (MMA credibility) 
C Translational issues 
 
Translational 
concerns for the 
economic 
modelling 
Considerations of applicability of system, platform, licensing, 
attachable hardware, and versions of the MMA to the 
Australian context  




evaluation of a 
clinical service 
involving a MMA 
Unit costs including MMA costs and in-app purchases 
E Estimated utilisation and 
financial implications  
Projected financial 
consequences of 
MMA utilisation  
 
No changes made 
F Option to present additional 
relevant information  
Evaluation of 
broader concerns 
with MMA use  
- Ethical considerations for MMAs (i.e. privacy, 
confidentiality, licensing, subscriptions, equity, 
access, etc.) 
- Legal considerations (responsibility) for MMA (i.e. 
medicolegal liability, data ownership, etc.) 
- Additional organisational considerations (i.e. 
training in digital health literacy) 
G N/A MMA post-market 
evaluation  
- How to evaluate MMA software changes (i.e. 
updates and determine the re-assessment trigger) 
- How and when to evaluate post-market 
performance data (real world data and incorporate 
into the re-assessment) 
H N/A Optional 
considerations for 
MMAs 
- Social considerations for MMAs 
- Other information considered relevant to specific 
MMA clinical evaluation  
Explanatory Notes 
1 Only applies to therapeutic MMAs 
2 Only applies to investigative MMAs 
3 Accuracy: Closeness of the quantity’s true value to its measured quantity. 
4 Analytical validity: The MMAs ability to reliably and accurately produce the intentional output from the input data 
5 Precision: Under unchanged conditions the degree to which the recurrent measurements generate the same result  (i.e. 
reproducibility, repeatability) 





This research aims to address the technology specific concerns of MMAs. The module that was developed 
was informed by HTA theory described in Busse et al.(30), a systematic review of MMA evaluation 
frameworks, guidance documents from the IMDRF’s working group on medical software, specifically 
SaMD: Clinical evaluation(16), together with insights gained from in-depth discussion with stakeholders.  
 
Many of the stakeholders’ concerns about MMA use in clinical practice pivots on the trustworthiness of 
the apps, the evidence-base underpinning them, and the regulatory and evaluative processes that support 
their use. Building stakeholder trust in the system for evaluating apps will strongly encourage integration 
of MMAs into the healthcare system and services. The module that has been developed attempts to 
address concerns about MMAs and increase trust in MMAs through a thorough evaluation of issues that 
are of particular concern for these types of digital health technologies. Doing so should allow MMAs to be 
accepted as part of standard clinical care alongside other more familiar medical and health technologies.  
 
However, there are broader policy issues outside the scope of HTA regarding the use of MMAs that need 
to be considered. These policy issues could possibly impact the nature of individual clinical consultations 
and the trust that clinicians and patients have in the interventions being used. Some of the concerns, in 
particular about the jurisdictional responsibility for apps, as distinct from the responsibilities of health 
practitioners, will need to be considered in a wider context than can be captured through an HTA (31). 
For example, in Australia uncertainties around data ownership and IP may fall under the jurisdiction of the 
Australian government department responsible for proprietary knowledge and ideas applied to inventions, 
trademarks and inventions (IP Australia(32)) rather than with the Federal Department of Health. 
 
Similarly, clinical liability matters may be best dealt with by authorities such as the Australian Health 
Practitioner Regulation Agency (APHRA)(33) and professional indemnity insurers. In particular, there 
needs to be clarity as to whether professional indemnity insurance can adequately deal with the use of 
apps in clinical consultations, or any other forms of malpractice that could occur through the professional 
use of the technology. 
 
Furthermore, in Australia concerns around patient privacy and the ownership of patient health data has 
been an significant contemporary national issue with the release of the Federal Government’s My Health 
Record in 2018 (11,34). The concerns were mainly around citizens’ personal medical information being 
sold to third parties, unauthorised healthcare practitioners reviewing data that is not relevant them (e.g. 
celebrities’ health records), and/or cybersecurity risks (34,35). In response, the Department of Health 




impending alterations to the privacy provision added to the My Health Record Act (2012)(12) may be able 




The limitations of the analysis and synthesis conducted to develop the MMA evaluation module is that for 
some sections the SaMD: Clinical evaluation(16) regulatory document was used as the gold standard for 
measuring specific indicators. Regulation and reimbursement have different aims, and thus the borrowing 
of concepts from a regulatory guidance documents may not be relevant for HTA processes developed in 
countries where there is a mature MMA regulation system (36,37). However, our review of regulatory 
processes in English-speaking countries found that only the US is close to having a mature regulatory 
system for MMAs (14,38-41). 
 
The limitations to the utilisation of interviews as a mechanism to identify possible pathways and 
impediments to MMA reimbursement is that the participants could have produced biased answers 
(25,42,43). The epistemology of pragmatism assumes that the participants will answer the questions 
truthfully (44-46). The questions prepared and asked by the facilitator were open-ended and single 
barrelled to avoid leading the participant(s) (25,42,43).  Only a limited number participants were recruited 
which could have affected result, however the study design attempted to address this by assessing the 
information power (see Supplementary material A) (19).  
 
The module was only tested by modifying the Australian MSAC HTA process. Further research needs to 





Conclusion and Policy Implications 
In conclusion, various steps need to be taken to facilitate the evaluation of MMAs. We have chosen to 
create a module that can be used to adapt existing HTA processes to address the unique technology-
specific characteristics of MMAs. The module recommends making provisions for the analytical (reliability) 
validity, cybersecurity concerns, software updates, incorporation of post-market performance data, 
assessment of compatibility issues (e.g. platform and operating systems), as well as MMA-specific ethical 
and legal considerations.  
 
Use of the MMA evaluation module in an HTA would enable policy-makers to decide if an app should be 
reimbursed or not, particularly when used in the context of a clinical consultation.  Thus the module could 
be used to inform policy decisions. 
 
Other implications are that broader policy changes are needed to ensure that the MMAs are evaluated 
properly and that the technology can be completely integrated into the health system. These policies need 
to improve stakeholders trust in MMAs, including through gaining clarity on professional liability for health 
practitioners who use or recommend MMAs during clinical consultations as well as who owns the heath 
data the apps produce and/or the IP (e.g. for the app or the code, or app content). Other considerations 
are around how policies should be adjusted to address the rapid lifecycle of MMAs, as well as 
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7.2.4 Supplementary material 
Supplementary material A 
 
S.1: Clarification of Methods used in the in-depth interviews with stakeholders 
Epistemology 
Pragmatism was the epistemology used, it views that all research is focused on answering the research 
question. It is frequently used in health systems research as it allows for abduction in research and aims 
at producing knowledge which is socially beneficial, and can be applied.(1-6) Pragmatism finds the truth 
through assuming that all knowledge is empirical and that there is one truth which differs due 
interpretations or perspectives.(1-3) This epistemology applies to the study as the research falls within 
health systems research, as well as there being a clear research question to be addressed that is part of 
a larger research project, i.e., to create an MMA evaluation module to adapt HTA frameworks. 
 
Information power 
The aim of the interviews was not to develop theory in the area but instead to identify barriers and 
facilitators to MMA integration into the Australian health system funding model. Since this is a developing 
area, there are a limited number of stakeholders with experience throughout the world. Rather than 
seeking data saturation,(7,8) we sought high information power to meet the aims of the study.(9) 
 
Background information on information power 
Information power is a qualitative research concept used to estimate the number of participants needed 
to ensure that the aim of the study can be achieved. There is an inverse relationship between information 
power and the number of participants needed in order to achieve the aim of the study. For example the 
higher the information power, the smaller the number of participants necessary.  
 
According to Malteured, Siersma,& Guassora(9) information power can be determined by five dimensions. 
These dimensions are: the aim of the study; the specificity of the participants used in the study; how 
established the theory used in the study was used; the quality of the dialogue between the facilitator(s) 
and the participant(s); and finally, the strategy utilised to analyse the interview. 
 
Information power in the in-depth interviews with stakeholders 
Information power used in the in-depth interviews with stakeholders to identify pathways and impediments 
to MMA reimbursement was high as the study design and method used the aforementioned dimensions. 




of the participants as they were purposefully recruited from a limited pool of ‘expert’ stakeholders who had 
experience with MMAs and health systems funding. As mentioned earlier, the theory used during the 
analysis was pragmatism.  This is an established epistemology which has been used within the 
communicative and dynamic technology in health system research.(1,4-6) There was a strong dialogue 
between the facilitator (MM) and the participants. Though the facilitator (MM) can appear shy, she had 
detailed knowledge of MMAs, as well as the Australian reimbursement and regulation structures. As these 
were semi-structured interviews, she was able to probe and adapt the interview schedule when required 
to attain the empirical data. Finally, the analysis strategy chosen was a case study. The case study was 
aimed at an in-depth exploration and analysis of selected patterns between MMAs and their relationships 
with the relevant selected stakeholders, and there was not an investigative cross-case appraisal of various 
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List of abbreviations  
 
APHRA: Australian Practitioner Regulation Agency 
 
ARTG: Australian Register of Therapeutic Goods 
 
FDA: U.S. Food and Drug Administration  
 
GP: General practitioner 
 
HTA: Health technology assessment 
 
MBS: Medicare Benefits Schedule  
 
MMA: Mobile medical application 
 
MSAC: Medical Services Advisory Committee  
 
PICO: Population, Intervention, Comparator, Outcomes  
 










Accuracy: Closeness of the quantity’s true value to the observed quantity that was measured.(1) 
 
Algorithm: A model, or set rules, or logic that the MMA is based on (e.g. inferences engine, equations, 
model based logic; affected by reference data, knowledge base, criteria, rules). 
 
Analytical validity: The MMA’s ability to reliably and accurately produce the intentional output from the 
input data.(1)  
 
Clinical utility: the benefits and risks which result from the use of the MMA.(2) 
 
Clinical validity: the ability of an MMA to identify a particular condition.(2) 
 
False negative(FN): MMA’s has incorrectly identified that the patient does not have the condition.(3) 
 
False positive (FP): MMA’s has incorrectly identified that the patient does have the condition (3) 
 
Fuzzing or fuzz testing: an effective automated method to identify software errors or ‘bugs’ in an MMA.(4) 
 
Input: Digitised content fed to the MMA (e.g. laboratory results, image, medical device data, physiological 
status, symptoms).(1,5)  
 
Investigative MMA: A MMA’s output that is intended to diagnose and/or drive clinical management by 
differentiating or monitoring patients or their physiological conditions (e.g. screening apps, diagnostic 
apps, risk predicting apps).(1) 
 
Linearity of associated transfer function: “Behaviour of output across the range of input data that is 
allowed”(1) by the MMA. 
 
Output: A product of the MMA that has the ability to affect the users health (e.g. inform, treat, 
diagnose).(1,5) 
 
Positive predictive value (PPV): The likelihood that the patient has the condition given the MMA result 
is positive.(1,3) 
 
Precision: Under unchanged conditions the degree to which the recurrent measurements generate the 
same result  (e.g. reproducibility, repeatability).(1) 
 
Reference standard: a standard that is used and widely accepted to determine the benchmark for a 
performance or presence/absence of a medical condition. 
 
Robust: An MMAs ability to deal with errors during software performance.(6)  
 
Sensitivity: MMA’s ability to correctly identify a patient with the condition.(1,7) 
 
Specificity: A MMA’s ability to correctly identify a patient as not having the condition.(1,7) 
 
Therapeutic MMA: A MMA’s  output that is intended to treat a healthcare condition or situation.(1) 






Verify (software verification): The MMA achieves its intended purpose without hindrances in the form 









This framework has been developed to provide some clarity on how to conduct a health technology 
assessment (HTA) on mobile medical applications (MMA) in the Australian healthcare context. MMAs are 
a subset or mobile health (mHealth) applications (app) that have a therapeutic of diagnostic purpose.(1,2)  
 
These guidelines address concepts which would generally be reviewed during the assessment of an MMA 
for regulatory purposes. As the Australian Therapeutic Goods Administration (TGA) does not review the 
MMA configuration, post-market monitoring, software changes, cybersecurity, and/ or communication and 
display, in their regulatory processes, these concepts were included in this HTA framework to ensure that 
they are addressed.  
 
The framework is aimed at policymakers and health technology evaluators. However, it can be utilised by 
any interested party and adapted accordingly. 
 
Context of framework 
 
This evidenced-based framework was developed to be used within the Australian healthcare context. 
Moreover, the studies that were conducted to assist in the development of research were conducted within 
the Australian healthcare context. The framework that has been adapted is based on the available 
guidance to evaluate health technologies by the Medical Services Advisory Committee (MSAC).(9, 10) 
 
Structure of framework   
 
A: Description and technical characteristics of the MMA used in the clinical service 
 
B: MMA clinical evaluation 
 
C: Translational concerns of the economic modelling 
 
D: Economic evaluation of a clinical service involving a MMA 
 
E: Projected financial consequences of MMA utilisation  
 
F: Evaluation of broader concerns with MMA use 
 
G: MMA post-market evaluation  
 









All MMAs – and attachable hardware – are to undergo a pre-market assessment (Section A, C, D, E and 
F). For MMAs that have a therapeutic intended purpose, complete sub-section B.1. For, MMAs that have 
an intended purpose that is diagnostic, complete sub-section B.2. In the situation where an MMA – and 
attachable hardware – have both a therapeutic and investigative intended purpose both sub-section B.1 
and B.2 should be completed. Sub-sections B.3 through B.7 should be addressed for all therapeutic or 
investigative MMAs – and attachable hardware. Section H is optional, and provides an area for the 
evaluation of relevant considerations that may have not been assessed in other sections of the framework 
(i.e. social considerations).The pre-market assessment is illustrated in Figure 1.  
 
Section G addresses post-market concerns and consists of two sub-sections. Each sub-section can assist 
in determining what software changes (i.e. updates) and/ or post-market performance data would be 







Figure 5: Order of the pre-market HTA evaluation of MMAs 













































B. 3: Reliability of MMA performance  
 
Section D: Economic evaluation of a clinical service 
involving a MMA 
Section C: Translational concerns of the economic 
modelling 
Section E: Projected financial consequences of MMA 
utilisation 
B.4: Configuration  
B.5: Communication and display  
 
B.7: Potential software changes (i.e. 
updates)  

















































 A.3: Possible sources of government 
funding 
A.4: Clinical management algorithm(s) 
A.1: Details on the MMA   
 A.2: Framing the research question(s) and 
search strategy 
 
B. 8:  Post-market monitoring 
F.2: Legal considerations for MMA 
  
 
F.1: Ethical considerations for MMA 
F.3 Additional organisational 
considerations 
 


































































H.2: Other information considered relevant 


























Does the MMA have therapeutic capabilities? 
Section B.1: Therapeutic medical services 
 
Does the MMA have investigative capabilities? 
B.2: Investigative medical services 









Figure 6: Order of the post-market HTA evaluation of MMAs 
  
Start 
G.1: How to evaluate MMA software changes (i.e. 
updates) 

























Changes which enable or 
disable new MMA 
functionalities 
Review of Section B and F 
The effectiveness and/or 
safety outcome measures 
ARE inferior or superior to 
the original measures 
stated in the original HTA 
submission 
Review of Section B and 
F 
The effectiveness and/or 
safety outcome measures 
ARE NOT inferior or 
superior to the original 
measures stated in the 
original HTA submission 
Changes which DO NOT 














Section A: Description and technical characteristics of the MMA used in the clinical service    
Framework item(s) Example(s) 
A.1: Details of the MMA  
1. Detail the question(s) relating to the 
MMA and its capabilities. 
 
 What is the effectiveness of a skin 
cancer screening app for 
Australian residents of working 
age (18 to 67 years of age) 
2. Provide information on the MMA’s 
registration – or application submitted - 




 ARTG entry number 26548 or FDA 
510k database entry number 
K842857.  
3. Detail the intended purpose of the 
MMA in which reimbursement is being 
sought. 
 
 The intended purpose of the MMA 
is to detect basal cell carcinoma or 
squamous cell carcinoma [insert 
details on the algorithm and other 
specifications] in Australian 
residents of working age (18 to 67 
years of age). 
 




 The intended medical purpose of 
the MMA is to… (i.e. diagnose, 
treat, inform clinical management, 
drive clinical management). 
 
 The healthcare condition or 
situation that the MMA addresses. 
  
 The MMA input, algorithm, and 
output. 
 
 The operating system(s) that 
reimbursement for the MMA is 
being sought for. 
 
 The operating platform(s) that 
reimbursement for the MMA is 






A.2: Framing the research question(s) and search strategy 
1. Provide a summary of the PICO criteria 




 Population (P): Australian 
residents of working age (18 to 67 
years of age). 
 
 Intervention (I): Assessment of 
skin lesion using a software 
application [insert details on the 
algorithm and other specification] 
on a mobile platform.  
 
 Comparator (C): Skin biopsy, skin 
exam (conducted by physician) 
without use of software 
application. 
 
 Outcome (O): Diagnostic 
measure(s) (sensitivity, specificity, 
false positive, etc.), or health 
outcome measures (e.g. 
remission, recurrence, cure rate, 
metastasis, mortality). 
 
2. Describe the intended population(s). 
 
 Australian residents of working 
age (18 to 67 years of age). 
3. Described any comparator(s). 
 
 
 The main comparators (e.g. 
comparator described in 1. 
above). 
 
 Relevant additional comparators. 
 
 Investigative MMAs: 
a. The reference standard a. 
 
b. In situations where there 
is no reference standard 
state this and provide 
information on app 







4. Describe the intended outcome(s). 
 
 
 The main outcome(s) (e.g. 
comparator described in 1. 
above). 
 
 Relevant additional outcome(s) 
(i.e. surrogate outcome(s)). 
 
5. Detail the included language(s).  
 Limited to the English language.  
 
6. Detail the time period.  
 Limited to 01 January 2008 to 31 
December 2017. 
7. Provide rationale (justification the 




8. Describe the differences between the 
intervention and the main comparator 
(i.e. indication, likelihood, 
contraindications, and adverse events). 
 
 Difference in contraindications, 
adverse events, mode of delivery, 
associated technologies, setting of 
use. 
A.3: Possible sources of government funding  
1. Detail the intended MBS listing (i.e. 
medical service item which receives 
government funding) for the MMA. 
 
 
 MBS item: Malignant skin lesion 
items;  
 
 MBS descriptor code: 31356, 
31358, 31359, 31361, 31363, 
31365, 31367 and 31369 
 
2. Detail any other possible pathways for 
the MMA to receive public funding that 
has been sought, or that has or is 
being pursued. 
 
 Through the Australian 
Department of Veteran Affairs 
(DVA). 
A.4: Clinical management algorithm(s) 




 Describe the clinical management 
algorithm(s) that demonstrates the 
context in which the MMA is 
intended to be used.  
 
 Describe the clinical management 





current management without the 
use of an MMA.  
 
 Summarise any changes between 
the two algorithms described in 
A.4 i. and ii. ie changes in clinical 
algorithms could be patterns in 
resource allocation, etc. 
 
Explanatory note 
a Applies to investigative medical devices only 
b In the absence of studies, Nil Return should be listed 
c Only relevant to MMAs when the intended purpose is for continuous use and/or monitoring 
ARTG: Australian Register of Therapeutic Goods 
FDA: U.S. Food and Drug Administration  
MBS: Medicare Benefits Schedule  
MMA: Mobile medical application 
PICO: Population, Intervention, Comparator, Outcomes  








Section B: MMA clinical evaluation 
 
Instructions: For therapeutic interventions complete section B.1, for investigative interventions complete 
section B.2, and for both therapeutic and investigative interventions complete section B.3-B.5 
 
Framework item(s) Example(s)   
Section B.1: Therapeutic medical services 
B.1.1: Literature identification   
1. Describe the search strategies used to 




 Should aim to be systematic and include 
all available resources. 
 
 Should include published and grey 
literature, as well as registers of clinical 
trials.  
 
 Should include the date(s) in which the 
searches were conducted. 
2. List all relevant studies b that have 
been included using the pre-
determined criteria from section A. 
  
 All direct randomised trials should be 
included.  
 
 List all randomised trials considered for 
inclusion in indirect comparison.  
 
 List all non-randomised studies. 
B.1.2: Identification of bias 
1. Describe the characteristics of the 




2. Provide an evaluation of the quality 
(internal validity) of the literature 
included in the assessment.  
 
 
 Describe the measures taken by 
investigators to minimise bias (i.e. 
randomisation, follow-up period, blinding) 
in the included literature. 
 
 The use of a reputable quality 
assessment tool is recommended (i.e. 
Cochrane Risk of Bias tool; Grading of 
Recommendations Assessment, 
Development and Evaluation (GRADE)). 
 
B.1.3: Effectiveness  







  Such as, primary outcomes (including 
quality-of-life instruments), or surrogate 
outcomes. 
B.1.4: Safety  




 The assessment should include an 
appraisal of how the MMA output (i.e. 
information) affects clinical decision 
making regarding management of a 
patient’s condition. 
 
 If relevant the assessment should include 
an appraisal of possible physical harms 







Instructions: ONLY complete this section for investigative medical services, SKIP this section if the 
medical service is therapeutic  
Framework item(s) Example(s)   
Section B. 2: Investigative medical services  
B.2.1: Literature identification   
1. Describe the search strategies used to 
identify the potentially relevant 
literature.  
 
 Should aim to be systematic and include 
all available resources. 
 
 Should include search of published and 
grey literature, as well as registers of 
clinical trials.  
2. Provide an overview of the linked 
evidence approach. Describe the basis 
for the linked evidence steps such as 
whether there is a reason to utilise the 




 Information on the basis for utilising a 
linked evidence approach. 
 
 A detailed summary of the treatment 
options that result from the use of the 
investigative MMA. 
 
 Sufficient evidence available on the 
health outcomes of the aforementioned 
treatment options and if they have been 
trialled in a comparable population.  
3. Report and list all of the MMA 
diagnostic accuracy studies b. 
 
 Possible examples include: MMA test 
conditions, demographics, recruiting 
strategy, follow-up, etc. 
4. Report and list all included change in 
management studies b. 
 
 The main outcome(s) (e.g. change in 
planned treatment). 
B.2.2: Identification of bias 
1. Provide an evaluation of the quality 
(internal validity) of the literature 
included in the assessment.  
 
 
 Assess risk of bias at each step of the 
linked evidence approach. 
 
 Use of a reputable quality assessment 
tool is recommended (i.e. QUADAS-2 for 
diagnostic accuracy studies; Grading of 
Recommendations Assessment, 
Development and Evaluation (GRADE)). 
B.2.3: Effectiveness  
B.2.3.1: Diagnostic accuracy 
1. Provide details on the diagnostic 
performance of the MMA.  
 
 Diagnostic measure(s) such as sensitivity, 
specificity, false positive (FP), false 






 Mention, reference standard, and indicate 
whether direct comparison studies, 
indirect comparison studies, meta-
analysis, concordance, etc. 
2. Provide details on the clinical validity of 
the MMA. 
 
 Measure of the clinical validity (i.e. 




 Clarify if the information provided relates 
to the predisposition or of any prognostic 
value of the MMA.  
3. Provide a systematic overview of the 
MMA accuracy studies results. 
 
 
 Primary analysis for each MMA accuracy 
study. 
 
a. The analysis for each primary 
measure in the form of tables or 
forest plots. 
 
b. Statistically combine (meta-
analyse) multiple MMA accuracy 
studies that used the same 
accuracy measures. 
B.2.3.2: Change in management  
1. Provide details on the clinical utility (i.e. 
net change in clinical management, 
clinical importance of false positive and 
false negatives) of the MMA. 
 
 
 Research on the impact of the changes in 
clinical management that result from 
investigative MMAs. 
 
 Clinical importance and impact of false 
positives (FP) and false negative (FN) 
finding from the MMA.  
 
 Health outcomes of the subsequent 
therapeutic treatment and how it links to 
the investigative MMA.  
 
B.2.3.3: Repeat testing and monitoring  
1. Impact of repeat testing/ use of MMA 
as part of a monitoring strategy (i.e. 
evidence supporting repeat use) c. 
 
 
 Evidence that supports the repeated use 
of the investigative MMA for monitoring 
purposes using the criteria below: 
 






c. Detectability of long term change 
d. Practicality 
B.2.4: Safety 
1. Provide extended assessment of 
comparative harms. 
 
 The assessment should include an 
appraisal of how the MMA output (i.e. 
information) affects clinical decisions 
regarding management of a patient’s 
condition. 
 
 If relevant the assessment should include 






Instructions: Complete sections B.3 to B.8 for BOTH therapeutic and investigative medical services  
 
Framework item(s) Example(s)   
Section B. 3: Reliability of MMA performance  
1. Assess the analytical validity of the 
MMA software.  
 
 
 The algorithm used by the MMA is a 
recognised standard (the current standard 
of care or described in the literature (i.e. 
insulin dosing)). 
 
 MMA accuracy is relative to reference 
material (i.e. International normalisation 
ratio (INR)). 
 
 MMA comparability to another software or 
device that has an association between 
the software output and a health outcome. 
2. Provide an assessment of the reliability 
of the MMA to generate the intended 




 Total accuracy = ±(0.1% of input + x 
[relevant unit of measure]). 
 
 Accuracy measures the offset and gain of 
the effects of software errors.  
3. Provide the precision (i.e. 
reproducibility, repeatability) of the 
MMA to generate the intended 




 Values (in the relevant unit) that are close 
together indicate that there is a high 
degree of software precision. 
Section B.4: Configuration d  
1. Describe the limitations of the MMA  
 
 
 The limitations could be in the, 
algorithms, clinical models, assumptions, 
and quality of the data. 
2. Assess whether the MMA is robust 
enough to withstand user configuration 
in an unintended way. 
 
 The results of fuzzing or fuzz testing. 
Section B.5: Communication and display d  
1. Assess the design of the MMA user 
interface. 
Provide finding from user testing: 
 
  The complexity of the user interface 






 Appropriateness of the user interface 
design for the intended platform (i.e. 
smartphone, smartwatch, tablet). 
 
 How dynamic the MMA data are (i.e. 
displaying appropriate information for an 
appropriate length of time). 
 
2. Assess whether the MMA has the 
appropriate means of information 
display.  
 
Provide finding from user testing: 
 
 Has the information been displayed in the 
MMA in a way that the target audience 
can understand it. 
 
 Item(s) to be considered are, the units 
displayed, language translation, etc. 
3. Assess whether the MMAs can 
communicate relevant information. 
 
Provide finding from user testing: 
 
 Can users utilise the MMA within the 
current facilities (in terms of available 
network, data quality input, competence, 
and hardware). 
 
 The correct installation and configuration 
of the MMA to enable the appropriate 
integration into clinical workflows. 
Section B.6: Cybersecurity d 
1. Consider whether formalised and safe 
methods have been implemented to 
convert, transmit, and/or store MMA 
data. 
 
 The results of fuzzing or fuzz testing, etc. 
2. Consider whether control measures to 
address data integrity are appropriate, 
in the circumstance where common 
information is accessed by multiple 
applications and users. 
 
Provide findings from user testing: 
 
 Can users safely implement information 
security updates? 
 
 Do system supports ensure protection of 
system information for the MMA? 
 
3. Consider whether MMA design 
includes robust and resilient measures 
to address potential adverse system 
interactions. 
Provide findings from user testing: 
 









c. Dangerous implements, 
d. Can’t happen. 
 
4. Consider whether the MMA balances 




 The results of fuzzing or fuzz testing, etc. 
5. Consider whether there are instructions 
for the user to safely manage MMA 
information security. 
 
6. Consider whether the MMA integrates 
with other software. 
 
7. Consider whether there needs to be 
updated security software for use of the 
MMA with other systems, applications 
or operating environments. 
 
Section B.7: Potential software changes (i.e. updates)  




 Adaptive software changes (i.e. 
maintains software within dynamic 
environment). 
 
 Perfective software changes could be 
(i.e. recoding to improve performance). 
 
 Corrective software changes (i.e. corrects 
problems). 
 
 Preventive software changes(i.e. corrects 
latent faults before they cause 
operational problems). 
 
 Determine when software updates should 
trigger re-assessment (see Section G) 
Section B. 8:  Post-market monitoring d 
1. Review of how the manufacturer plans 




 Performance data includes user 
feedback, complaints, and adverse 
events. 
 
 Include timetable for re-assessment 






2. Provide details on how the post-market 
data collection is to be implemented 





a Applies to investigative medical devices only 
b In the absence of studies, Nil Return should be listed 
c Only relevant to MMAs that’s intended purpose is for continuous use and/or monitoring 
d Regulatory domain-may be assessed by authority providing market access to the MMA. 





Section C: Translation concerns of the economic modelling  
Framework item(s) Example(s)   




 Applicability concerns - How the 
environment in which the intended 
population use of the MMA differs 
from the study circumstances in 
which the MMA was used (e.g. 
operating platform, operating 
system, version of the app, 
licensing, attachable hardware, 
versions of app, etc.). 
 
 Population characteristics - Any 
evidence which indicates a variety 
of risks for adverse clinical 
outcomes in the intended 
population.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
 Circumstances of use - Identify 
and assess direct randomised 
trials that demonstrate evidence 
of: the MMA being used alongside 
a method of delivery and/ or co-
administered therapies which have 
not received approval from the  
TGA (or other relevant 
jurisdictional regulatory bodies 
the); the MMA being used in an 
environment that does not meet 
the standards to be listed on the 
MBS (or other public funding 
bodies); and of the MMA being 
used in different situations than the 
intended listing on the prostheses 
and devices list or as part of a 
medical service on the MBS (other 
public funding bodies).     
 
 Extrapolation issues - Define any 







   Transformation issues - Define any 
concerns with the outcomes 
measured in the key studies that 
indicates that they need to be 
transformed for the economic 
model. 
2. Provide a focused analytical plan for 
each issue(s) identified above in C.1.  
 
 
 A focused analytical plan should 
include information on the:  
a. Data that will be used,  
b. Source of the information, 
c. Details on the method used 
by each pre-modelling study 
provided. 
 
3. Provide a presentation of results of 




4. Describe the relationship between the 
economic evaluation and each pre-
modelling study created in C.3.  
 
 
 Explain how the pre-modelling 
studies will be used in the 
economic evaluation. 
Explanatory notes 
MBS: Medicare Benefits Schedule  
MMA: Mobile medical application 






Section D: Economic evaluation of a clinical service involving a MMA  
Framework item(s) Example(s) 




 How the base case economic 
evaluation was generated (i.e. 
trial-based, stepped, modelled). 
 
 Type(s) of economic evaluation. 
2. Provide a description of the population 
and circumstance of use of the MMA 
utilised in the economic evaluation. 
 
 
 Justify characteristics of the 
patients as well as the 
demographics of the population 
used.  
 
 Justify the circumstances in which 
the MMA and its main comparator, 
are used.    
 
 Appraise the consistency across 
the population demographics and 
patient characteristics. 
3. Describe the structure and rationale of 
the economic evaluation. 
 
 
 A literature review of relevant 
information. 
  
 The software utilised. 
 
 Justify economic evaluation 
structure. 




 For each variable used in the 
evaluation, provide the following:  
a. Name and definition,  
b. Source,  
c. Quantity in units. 
 
 Direct health care resource items 
and costs (eg outright cost of an 
app, in-app purchases) in which an 





  the substitution of MMA for the 
main comparator. 
 
 Estimates of any direct healthcare 
costs and health outcomes.  
 
 Describe the insufficiencies in the 
evidence and the repercussions 
this will have on the economic 
evaluation.  




6. Provide sensitivity analyses. 
  
 
 Provide a univariate sensitivity 
analysis for each variable using 
extreme values. 
 
 Using the sensitive variables 
identified in the univariate 
analyses provide a multivariate 
sensitivity analysis. 
Explanatory notes 
MBS: Medicare Benefits Schedule  






Section E: Projected financial consequences of MMA utilisation  
Framework item(s) Example(s)  
1. Justify how the data was selected and 




2. Estimate the cost and use of the MMA.  
 
 
 Approximate the amount of 
patients the MMA will target. 
 
 Estimate the number of eligible 
patients the MMA is likely to be 
used by. 
 
 Estimate the amount of times the 
MMA will be downloaded per year 
for five years. 
 
 Estimate the cost for each MMA 
downloaded per year for five 
years. 
 
 Aggregate the MMA cost 
calculations per year for five years. 
3. Provide an estimation of how the MMA 
would cause changes to the cost and 
use of other medical services on the 




 MBS items affected by the 
proposed service,  
 Aggregate costs of affected 
service. 
4. Provide estimations of uncertainty and 
ways to reduce it. 
 
 
 Calculate and assess the possible 
sources of uncertainty. 
 
 Identify the type(s) of uncertainly. 
 
 Estimate the degree of uncertainty 
affecting the MMA utilisation and 








 Explore the nature of the 
uncertainty and how it impacts the 
overall estimates. 
 
 Estimates the uncertainty level and 
consider ways to reduce it.  
Explanatory notes 
MBS: Medicare Benefits Schedule  





Section F: Evaluation of broader concerns with MMA use 
 
Framework item(s) Example(s)   
F.1: Ethical considerations for MMA 
1. Assess if the MMA has a privacy 
policy. 
 
 The presence of a comprehensive 
privacy policy. 
2. Appraise the contents of the MMA’s 
privacy policy  
 
 
 Such as, if the data collected by 
the MMA can be sold without 
users’ consent, etc. 




 Such as the cost of platform, app, 
in-app purchase, internet 
availability (cellular or Wi-Fi), etc. 




 Such as user disability (how could 
users’ with blindness use the 
MMA), language (users’ who have 
English as a second language), 
age, literacy, socio-economic 
status, etc. 
5. Assess possible conflicts of interest  
 
 
 Such as, developer or owner 
affiliation, sources of funding, third 
party sponsorship, etc. 
F.2: Legal considerations for MMA   
1. Review litigation risks to the relevant 




 Possible litigation risks that 
medical professional(s) such as 
GPs or allied health worker(s) 
could be subject to due to the use 
of, or recommendation to use, 
MMAs in clinical practice.  
2. Review how insurance(s) (i.e. 
professional indemnity, life, health, 
income) for all stakeholders (i.e. 
patients, medical professionals, 
developers) could be affected through 
use of the MMA. 
 
 Review of insurance (i.e. 
professional indemnity, life, health, 
income) policies have clauses that 
are relevant to the use and/or 
recommendation to use MMAs. 
3. Review possible professional 
registration issues associated with the 




 Review how professional 
registration(s) boards/ 





Practitioner Regulation Agency 
(AHPRA)) view the use of MMAs. 
4. Assess which party owns the data 
related to the MMA (i.e. patient, third 
party, medical practitioners). 
 
5. Assess which party (i.e. manufacturer, 
medical practitioner who prescribed it) 
is responsible for the medical advice 
provided by the MMA. 
 
6. Assess which party (i.e. manufacturer, 
medical practitioner, app developer) is 
responsible for monitoring and 
reviewing the patient data entered into 
the MMA. 
 
F.3 Additional organisational considerations 
1. Assess if training/education (i.e. digital 
literacy) is need for user(s) (i.e. 
medical practitioners, patients, care 
givers) to effectively utilise the MMA. 
 
 Need for continual professional 
development (CPD) courses for 
medical practitioner(s) to 
effectively learn how to utilise and 
recommend MMAs in clinical 
practice. 
 
 Education that patient(s) have to 
undergo to effectively learn how to 
utilise MMAs. 
2. Describe how the MMA will interact 
with current health informatics systems 
(i.e. hospitals and surgeries) used in 
Australia. 
 
 How MMAs send and receive 
information from health information 
software such as PROCURA, 
Enterprise patient administration 
system (EPAS), etc. 
3. Describe if adopting the MMA will 
change treatment location  
 
 
 Such as, rural, remote, hospital, 
clinic, etc. 
4. Describe if additional accreditation will 
be needed for professionals (i.e. 
medical practitioners, allied health 
workers, technicians) to prescribe 







5. Describe if adopting the MMA will alter 
the current utilisation of services.  
 
 
 How the post-market MMA data is 
integrated into clinical workflows 
with appropriate use of safety (i.e. 
misinformation and cybersecurity) 
features. 
 
 Such as, workload, work force, 
compliance, etc. 
Explanatory notes 
APHRA: Australian Practitioner Regulation Agency 
GP: General practitioner  







Section G: MMA post-market evaluation  
 
  
Framework item(s) Example(s)   
G.1: How to evaluate MMA software changes (i.e. updates) 
MMA updates that do not require a review of Section A to F. 




 The software changes correct 
existing problems within the MMA. 




 The software changes correct 
latent faults before they cause 
operational problems. 




 The changes maintain the MMA 
software within a dynamic 
technological environment. 




 The software changes are 
recoding to improve MMA 
performance. 
MMA updates that do require a review of Section B and F 
v. Software changes that enable 
or disable new MMA 
functionalities. 
 
G.2: How to evaluate post-market performance data (i.e. real-world data) 
MMA post-market performance data that requires a full review of Section B and F.  
i. Post-market performance data 




 The effectiveness outcome 
measures (i.e. analytical validity) 
are inferior or superior to the 
original measures stated in the 
original HTA (i.e. MSAC) 
submission. 
ii. Post-market performance data 




 The safety outcome measures (i.e. 
harm, misinformation) are inferior 
or superior to the original 
measures stated in the original 
HTA (i.e. MSAC) submission. 
Explanatory notes 
HTA: Health technology assessment 
MMA: Mobile medical application 






Section H: Other considerations for MMA (Optional) 
  
Framework item(s) Example(s) 
H.1: Social considerations for MMAs  
1. Assess how the MMA may benefit 
patient autonomy. 
 
2. Asses how the MMA may affect the 
patients’ care giver(s). 
 
3. Assess how the MMA may affect the 
users’ relationships. 
 
 How the MMA could affect the 
users’ family dynamics. 
 
 How the MMA could affect the 
users’ friends and other relevant 
social relations. 
 
 How the use of the MMA may 
affect the patients’ relationships 
with their medical professionals. 
 
H.2: Other information considered relevant to MMA clinical evaluation 
1. Assess other information which was 
unable to be reported elsewhere.  
 
Explanatory notes 







Where the technology specific characteristic of an MMA was evaluated in this framework is summarised 
in Table 1 below. 
 
 Table1: MMA technology specific performance that needs to be evaluated in an HTA 
Item(s) Where the item(s) is addressed in the 
framework  
Section1  Page number 1 
Analytical validity (reliability)  B. 3 21 
Accuracy (i.e. reliability) B. 3 21 
Communication and display  B. 5 21 
Configuration  B. 4 21 
Connectivity B. 5 21 
B. 6 22 
F.3 32 
Consideration of a comparator (e.g. 
comparative effectiveness, safety)  
A.2 12 
Digital health literacy  F. 3 32 
Equity F. 1 31 
Access F.1 31 
Information security (cybersecurity) B. 6 22 
Operating platform(s) for MMA A. 1 12 
Operating system (s) for MMA A. 1 12 
Patient confidentiality B. 6 22 
F. 1 31 
Patient privacy B. 6 22 
F. 1 31 
Precision (i.e. repeatability) B. 3 21 
Post-market ‘real-world’ data monitoring B. 8 23 
G. 2 34 
Responsibility  F. 2 31 
F. 3 32 
Software changes (updates) B. 7 23 
G. 1 34 
Technological evolution  B. 6 22 
B. 7 23 
B. 8 23 
F.1 31 
G. 1 34 
G. 2 34 
The risk of misinformation  B. 1. 4 17 
B. 2. 4 20 
Explanatory notes 
1 Section in the framework where the item(s) is addressed 
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7.3 Applicability of the MMA HTA evaluation module to other jurisdictions 
 
7.3.1 Introduction 
Currently, there are no criteria that can be used to conduct an HTA on an MMA to determine whether it 
should be publicly funded. MMAs pose different risks than traditional medical devices and software. A few 
of these risks relate to the software having a fast lifecycle, being downloadable through off-the-shelf non-
specialised platforms, and potentially having cybersecurity vulnerabilities.(22, 23, 36, 149) The MMA 
evaluation module developed by Moshi, Tooher & Merlin(149) --detailed in Section 7.2-- outlines an 
approach that can be used to modify current HTA frameworks so that they can be used to evaluate apps 
for reimbursement and decision-making. The focus was on the Australian healthcare context. However, 
as the aforementioned module was only tested to be used within the Australian healthcare context, it is 
currently unclear if it can be applied to other healthcare jurisdictions in other developed countries. 
 
7.3.2 Aim 
The aim of this analysis was to determine if the MMA evaluation module (described in Section 7.2) could 
be used in other developed countries’ jurisdictions to adapt their HTA frameworks to enable the evaluation 
of apps for reimbursement and decision-making purposes.  
 
7.3.3 Methods 
Existing HTA frameworks and their methodologies for reviewing medical services for decision-making 
purposes were compared and contrasted to the MMA HTA evaluation module to determine whether the 
module included evaluative criteria that were not already present in the jurisdictions’ current HTA 
processes. 
 
To be included, the jurisdictions had to have an HTA agency with reimbursement policies, methodological 
documentation, and/or guidance documents available in English. The documentation needed to be 
available on the official HTA agency or network website (Table 7.1) and/or through snowballing of sources. 







Table 7.1: Sources of literature 
Jurisdiction  Health Technology 
Assessment (HTA) 
Agencies   
Websites  Time Period   
Canada Canadian Agency for 
Drugs and Technologies 
in Health (CADTH) 
https://www.cadth.ca/ 1st January 2008 to 










1st January 2008 to 
31st August 2018 
United States of 
America (US) 
Agency for Healthcare 
Research and Quality 
(AHRQ) 
https://www.ahrq.gov/research/ 1st January 2008 to 
31st August 2018 
 
The HTA methodologies were evaluated against a data extraction form to determine what the HTA bodies 
did and did not assess. The data extraction form was created by MM and was based on the domains 
included in the MMA HTA evaluation module for (Table 7.2).  
 
7.3.4 Results  
The USA, Canada, and EEA were selected as comparable jurisdictions as they have consolidated and 
comprehensive HTA guidelines available in English. In total, 25 guidelines and documents (Table D.1 in 
Appendix D) from the American Agency for Healthcare Research and Quality (AHRQ), Canadian Agency 
for Drugs and Technologies in Health (CADTH), and the European Network for Health Technology 
Assessment (EUnetHTA) all met the inclusion criteria.(163-179) None of the jurisdictional HTA bodies 
assessed all of the MMA technical characteristics evaluated in the HTA MMA module.(163, 167, 169, 171-
179) Table 7.2 (also the data extraction table) summarises the findings of this review. 
 
Description and technical characteristics 
None of the jurisdictional HTA bodies assessed the operating system (e.g. Android, iOS, etc.) or platforms 







Table 7.2: Detailed comparison between MMA module and HTA methodologies employed by the 
respective jurisdictional bodies 
 
Content addressed in framework categorised by HTA domain  


















Description and technical characteristics 
1. Operating systems the MMA can be run on (i.e. Android, 
iOS, etc.) 
✘ ✘ ✘ 
2. Operating platforms the MMA can be run on (i.e. 
smartphone, tablet, smartwatch) 
✘ ✘ ✘ 
Current use of the technology 
1. The intended purpose of the MMA (i.e. diagnose, treat, 
inform clinical management drive clinical management) 
✔ ✔ ✔ 
2. The healthcare condition or situation that the MMA 
addressed 
✔ ✔ ✔ 
3. MMA input (i.e. image, physiological status, symptoms, 
etc.), MMA algorithm (i.e. equations, analysis engine model 
logic, algorithm, etc.), MMA output (i.e. inform, treat, 
diagnose) 
✘ ✘ ✘ 
Evaluate MMA software changes (i.e. updates) 
1. Post-market software changes, that require the re-
evaluation of the MMA (i.e. changes that are corrective, 
preventive, adaptive, and/or perfective) 
✘ ✘ ✘ 
2. Post-market software changes that require the re-
evaluation of the effectiveness and safety of an MMA (i.e. 
changes that enable or disable new MMA functions) 
✘ ✘ ✘ 
Effectiveness  
MMA performance 
1. Accuracy (i.e. reliability) - Closeness of the actual output to 
the true value of the MMA’s output 
✘ ✘ ✘ 
2. Analytical validity - MMAs ability to reliably and accurately 
produce the intentional output from the input data 
✘ ✘ ✘ 
3. Precision (i.e. repeatability) - Under unchanged conditions 
the degree to which the recurrent measurements input into 
the MMA generates the same output (e.g. reproducibility, 
repeatability) 
✘ ✘ ✘ 
Configuration 
1. The MMA’s ability to withstand user configuration in an 
unintended way (i.e. results of fuzzing or fuzz testing) 
✘ ✘ ✘ 
2. Limitations of the MMA (i.e. assumptions, data quality, 
algorithms) 
✘ ✘ ✘ 
Communication and display 
1. The design of the MMA user interface (i.e. level complexity, 
clarity) 
✘ ✘ ✘ 
2. The appropriateness of the MMA interface as a means of 
information display (i.e. language translation, units 
displayed) 
✘ ✘ ✘ 
3. The MMA’s ability to communicate the relevant information 
(i.e. data quality, network availability) 
✘ ✘ ✘ 
Cybersecurity 
1. Formalised and safe methods implemented to convert, 
transmit, and/or store MMA data (i.e. results of fuzzing or 
fuzz  testing) 
✘ ✘ ✘ 
2. Users can safely implement information security updates ✘ ✘ ✘ 
3. System supports ensure protection of MMA system 
information  





4. MMA software adheres to robust programming principles 
(i.e. paranoia, stupidity, dangerous implements, can’t 
happen) 
✘ ✘ ✘ 
5. Balances the availability of timely information against 
privacy and security (i.e. results of fuzzing or fuzz testing) 
✘ ✘ ✘ 
6. Describes how MMA integrates with other software (i.e. 
results of fuzzing or fuzz testing) 
✘ ✘ ✘ 
7. The need for MMA security software to be updated so it can 
be used alongside other systems, applications or in 
operating environments (i.e. results of fuzzing or fuzz 
testing) 
✘ ✘ ✘ 
Assess the potential for changes to the software (updates). 
1. Adaptive software changes (i.e. maintains software within 
dynamic environment) 
✘ ✘ ✘ 
2. Perfective software changes (i.e. recoding to improve 
performance) 
✘ ✘ ✘ 
3. Corrective software changes (i.e. corrects problems) ✘ ✘ ✘ 
4. Preventive software changes (i.e. corrects latent faults 
before they cause operational problems) 
✘ ✘ ✘ 
Safety  
1. How the MMA output (i.e. information) affects clinical 
decision-making regarding management of a patient’s 
condition 
✘ ✘  ✘ 
Cost- effectiveness1 
1. Considerations of applicability of the system, platform, 
licensing, attachable hardware, and versions of the MMA in 
the evidence base to the target population 
✘ ✘ ✘ 
2. Unit costs including the MMA, attachments and in-app 
purchases 
✘ ✘ ✘ 
Organisational aspects 
1. Assess if training/education (i.e. digital literacy) is need for 
user(s) (i.e. medical practitioners, patients, care givers) to 
effectively utilise the MMA 
✔ ✔ ✔ 
2. Describe how the MMA will interact with current health 
informatics systems (i.e. hospitals and surgeries)  
✘  ✘ 
3. Describe if adopting the MMA will change treatment 
location  
✘ ✘ ✘ 
4. Describe if additional accreditation will be needed for 
professionals to prescribe and/or use the MMA 
   
5. Describe if adopting the MMA will alter the current utilisation 
of services 
✘ ✔ ✔ 
Ethical aspects 
1. Assess if the MMA has a privacy policy ✘ ✔ ✘ 
2. Appraise the content of the MMA’s privacy policy  ✘ ✘ ✘ 
3. Describe access issues related to MMAs  ✘ ✔ ✘ 
4. Appraise any equity issues related to the MMA  ✘ ✔ ✔ 
5. Assess possible conflicts of interest ✔   
Legal aspects 
1. Review litigation risks to the relevant person(s) associated 
with the use or recommendation of the MMA 
✘ ✔ ✘ 
2. Review how insurance(s) for all stakeholders would be 
affected through use or recommendation of the MMA 
✘ ✘ ✘ 
3. Review possible professional registrations to the relevant 
person(s) associated with the use or recommendation of 
the MMA 
✘ ✘ ✘ 
4. Assess which party owns the data related to the MMA ✘ ✘ ✘ 
5. Assess which party is responsible for the medical advice 
provided by the MMA 
✘ ✘ ✘ 
6. Assess which stakeholder is responsible for monitoring and 
reviewing the patient data entered into the MMA 






1. How the use of the MMA may affect the patients’ care 
giver(s) 
✘ ✔ ✔ 
2. How the use of the MMA may affect the users’ relationships 
(i.e. family dynamics, friends, and other relevant social 
relationships) 
✘ ✔ ✔ 
Reappraisal  
Post-market monitoring 
How the manufacturer plans to monitor the MMA’s performance data ✘ ✘ ✘ 
How the data collection implemented is the least user burdensome 
approach to collect the MMA’s performance data 
✘ ✘ ✘ 
How the post-market data could be used to enable or disable new 
MMA functionalities 
✘ ✘ ✘ 
Post-market data that requires a full review of the effectiveness and 
safety of an MMA i.e. performance data that alters the effectiveness 
measures of the MMA and/or which changes the harms posed by 
the MMA 
✘ ✘  
Explanatory notes: 
Item(s) addressed: ✔ 
Item(s) partially addressed:  
Item(s) not addressed: ✘ 
1 Using a fee for service model 
HTA: Health technology assessment  
MMA: Mobile medical applications 
 
Current use of the technology 
All of the HTA agencies reviewed the key concepts regarding the use of apps as part of the medical 
service. These concepts included the intended purpose of the medical service under evaluation, as well 
as the healthcare conditions or situation the services aims to address.(165, 167, 169, 170, 172-175, 178) 
Unlike AHRQ and CADTH, EUnetHTA did not review the MMA algorithm (software) of the medical 
services under review. (165, 167, 169-175, 177) None of the HTA agencies reviewed the MMA input, 
algorithm, or output.(163, 167, 169, 171-179) 
 
Effectiveness 
The additional assessment methodologies recommended for appraising the effectiveness of apps by the 
MMA HTA module, were not addressed by AHRQ, CADTH, and EUnetHTA. Specifically, none of these 
jurisdictions reviewed software performance measures (e.g. accuracy, precision, or analytical validity) of 
MMAs during HTA evaluations.(163, 167, 169, 171-179) Similarly, an MMA’s configuration, cybersecurity, 
and interface were not assessed. (163, 167, 169, 171-179)   
 
Safety 
All of the included HTA agencies and network(s) utilised various, but, similar methods to review the safety 
of a medical service. These methods included, but were not limited to, assessing the diagnostic accuracy 
of medical device.  However, none of the methods included any techniques that evaluated the harm of 
misinformation produced by any of the medical services, and how this information impacts on clinical 







None of the included HTA agencies made any concessions for MMAs (i.e. in-app purchases, applicability 
of operation system or platform, etc.) in their respective cost-effectiveness evaluations.(163, 167, 169, 
171-179) However, the respective agencies all have different requirements for economic assessments, 
and this needs to be taken into consideration. 
 
Unlike CADTH and EUnetHTA, AHRQ did not include an economic evaluation in their assessment of 
medical services.(165, 167, 169, 170, 172) The AHRQ does consider “Potential for significant economic 
impact: To reduce unnecessary or excessive cost”(167), however the methodological documents do not 
expand on how to evaluate or define a significant economic impact in the American healthcare context. 
CADTH and EUnetHTA review the type of, and rationale for, an economic evaluation, as well as the 
circumstance in which the medical service is used.(170, 172) Sensitivity analyses are also required by 
CADTH and EUnetHTA.(165, 167) 
 
All of the jurisdictions incorporated an estimation of cost and use of the medical services.(165, 167, 169, 
170, 172-177) However, CADTH did not estimate how the adoption of the medical service under review 
could affect the use and cost of other medical services or additional financial implications. AHRQ, CADTH, 
and EUnetHTA, did not evaluate the justification for the data source selection nor the steps taken to 
identify, estimate, or reduce uncertainty within a financial context. (165, 167, 169, 170, 172-177)  
 
Finally, none of the included jurisdictional HTA bodies thoroughly assess translational issues to the same 
extent that the HTA MMA module does.(26) AHRQ did not evaluate any translational issues; whereas, 
CADTH and EUnetHTA do identify whether any translational issues have been identified (e.g. population 
characteristics and circumstances of use).(169-177)      
 
Organisational aspects  
AHRQ, CADTH, and EUnetHTA all evaluated if additional training and accreditation is needed to properly 
deliver a medical service.(165, 169, 172)  However, only CADTH and EUnetHTA considered whether if 
implementation of a medical service may affect the utilisation of other services.(169, 170, 172) Whereas, 
CADTH partially appraised how a medical service interacts with the current health informatics systems as 
it reviews implementation issues such as operations constraints.(169) None of the HTA agencies 
evaluated if the adoption of a medical service may result in a change in treatment location. 
 
Ethical aspects  
MMAs present a number of ethical concerns. All of the agencies reviewed conflicts of interest (COI) to 





related to the authors of the submission and/ or the person conducting the HTA evaluation on the selected 
medical service.(167) CADTH reviewed the COI related to the submission authors and/ or the HTA 
evaluator, and EUnetHTA appraised COI related to the included studies.(169, 172) Regarding privacy 
and confidentiality, only CADTH reviewed the privacy policy of medical services as well as any access 
issues that may arise from implementation or use of a selected medical service.(169) None of the 
agencies reviewed the contents of the privacy policies. However, both CADTH and EUnetHTA evaluated 
any equity concerns that may arise from use or adoption of a particular medical service.(169, 170, 172) 
 
Legal aspects  
Unlike CADTH, neither EUnetHTA nor AHRQ reviewed any liability or other legal concerns related to the 
medical service under review.(169) Legal concerns are a major concern in MMA evaluation due to the 
lack of clarity around professional liability and responsibility as well as the ambiguity surrounding data 
ownership and data monitoring.  
 
Social aspects  
This domain is deemed non-compulsory and should be included in the optional section of the HTA 
guidelines. AHRQ, CADTH and EUnetHTA all had an optional section to review medical service 
capabilities.(165, 169, 172) The social implications of how an MMA may affect the patient or their carer 
(e.g. relationships, training, home care) domain were appraised by CADTH and EUnetHTA.(169, 172) 
 
Reappraisal  
The evaluation of post-market changes to medical services was only partially assessed by EUnetHTA. 
Their evaluation includes the re-assessment of a medical service using post-market ‘real world data’ 
and post-market RCT data to review the technologies’ relative effectiveness and safety after they have 
been implemented.(174, 175) Finally, the potential for software alterations --through updates—and their 






7.3.5 Discussion  
The MMA evaluation module could feasibly be used by international HTA agencies to assess whether 
apps should be reimbursed as part of a medical service. Where the international HTA agencies differed 
was with respect to addressing the cost-effectiveness of a medical service. AHRQ did not have 
comprehensive cost-effectiveness guidelines. Whereas, CADTH and EUnetHTA had comparable 
guidance on the evaluation of economic aspects. However, the assessment guidelines used by CADTH 
and EUnetHTA examine different concepts to the ones used in Australia by MSAC.(170, 172) AHRQ, 
CADTH, and EUnetHTA have comparable HTA methodologies to Australia for assessing clinical 
effectiveness of medical services to Australia’s MSAC guidelines.  
 
The difference in approaches to assessing the cost-effectiveness of medical services has provided 
challenges to the transferability of the MMA evaluation module to comparable jurisdictions. The module 
was created within the parameters of the Australian healthcare context and the fee-for-service funding 
model. Thus, to ensure that the MMA evaluation module can be used to adapt jurisdictional HTA bodies’ 
methodologies for assessing apps for reimbursement and decision-making purposes, it would need to be 
recognised that the recommended cost-effectiveness domains may not be relevant or achievable.  
 
For AHRQ to use the MMA evaluation module, the cost-effectiveness domain would need to be removed 
as the agency does not appraise it.(180) Whereas, CADTH and EUnetHTA would only have to make 
minimal adaptations to the MMA evaluation module to be able to employ it.(165, 167, 169-177) 
 
Other changes to the MMA evaluation module that would be needed to make it transferable to other 
jurisdictions are limited to the organisational, ethical, and legal domains. These adaptions would involve 
the removal of items within each domain that are already addressed, in order to prevent unnecessary 
repetition and re-evaluation of the same concept. 
 
Minimal content would need to be modified within the organisational domain. One of the concepts which 
could be removed from the module, if adopted, is the consideration of whether extra training is needed to 
be able to effectively utilise the app with a medical service. There is currently already provision for this. 
Finally, the need to assess utilisation of services would be unnecessary for CADTH and EUnetHTA, but 
required for AHRQ as it does not address this.  
 
 
Concerning the ethics, legal, and social domains, the majority of the module content would need to be 






Regarding the ethics domain, the assessment of possible conflicts of interest would need to be removed 
from the module by AHRQ, while EUnetHTA would need to remove the assessment of equity issues.(165, 
167, 169, 170, 172) CADTH assesses the majority of the relevant ethical concepts in their 
methodology.(169, 170) Thus, the only items which would be kept from the MMA module are the 
assessment of the content of MMA privacy policies, as well as a possible thorough review of any possible 
conflict of interests related to the app.(170) 
         
Only a minimal modification would need to be made to the legal domain of the module for it to be 
transferable to similar jurisdictions. CADTH is the only one of the three jurisdictional agencies that 
assesses legal concerns. The concept which would need to be removed is the one that reviews possible 
litigation risks associated with the use and recommendation of MMAs from the module.  
 
The assessment of the social domain is non-compulsory, so there is no pre-determined guideline of what 
concepts needs to be evaluated.(165, 167, 169, 172) However, common concepts from this domain 
evaluated by  both CADTH and EUnetHTA include how a medical service may affect the patients’ carer 
(e.g. relationship, training, home care).(169, 172)  
 
With some changes to the MMA evaluation module, the remaining evaluation criteria could be used by 
the respective jurisdictional HTA agencies to adapt their methodological guidelines to enable the proper 
evaluation of apps for reimbursement and decision-making purposes. Furthermore, the relevant HTA 
bodies could use this MMA evaluation module while they research into developing their own approach 
within their own healthcare context.  
 
This module is the first of its kind to enable an HTA evaluation of MMAs. The closest comparison is the 
Evidence Standards Framework for Digital Health Technologies (March 2019) by the National Institute for 
Health and Care Excellence’s (NICE) in the United Kingdom (UK).(181)  This framework provides 
standards of evidence that ought to be available and/or developed for a digital health technology. The 
evidence should include information on the effectiveness of the intended use of the software, as well as 
associated economic impact relative to any financial risk.(181)  This is done to demonstrate the health 
technology value to the healthcare system in the UK. This standards of evidence may not be applicable 
to MMAs globally as the Framework is aimed at evaluating digital technologies specifically commissioned 
for use with the UK health system and not for digital health software available direct to use through global 







There were two major limitations to this study. Since the HTA methodology documents from the included 
jurisdictions were compared and contrasted to the MMA evaluation module and all the documents were 
only evaluated by myself, hence, there is a risk that my conclusions may not be generalisable. The second 
limitation is that one source of information (publicly available methodological documentation) was used. 
There may well be methodological guidance documents used by these HTA agencies that are not in the 
public domain.  
 
7.3.6 Conclusion  
In conclusion, based on publicly available information, in its current form the MMA evaluation module is 
transferable to other comparable HTA agencies. Minimal modifications would need to be made to the 
module for it to be used by these agencies. Aside from the adaption and integration of the newly created 
reappraisal domain, most of the adaptations to the MMA evaluation module are small and many unique 
MMA items (e.g. post-market software, updates, cybersecurity) would remain. Those concepts being 
removed from the module are ones that are already evaluated in the current agencies’ guidelines, to 
prevent the repetition of elements. The modifications made to the cost-effectiveness domain, are 
dependent on the healthcare context and the methodologies employed by respective jurisdictional 





7.4 Postface   
7.4.1 Chapter summary 
This chapter addresses the third research question which was to determine what key policy changes and 
assessment criteria are needed to facilitate the development of a system that evaluates MMAs for 
reimbursement purposes in Australia. This was achieved through synthesising the findings from Chapter 
5 and 6 with the results of in-depth interviews with stakeholder groups. 
 
The results demonstrated that there were policy holes in the regulatory and reimbursement criteria used 
to evaluate MMAs. Regarding regulatory policy, the TGA does not adequately evaluate MMAs with 
respect to the unique challenges the technology presents. Policy changes to current regulation should 
include an assessment of the potential harm from misinformation, as well as possible risks associated 
with connectivity compatibilities, and cybersecurity threats. For more information, see Chapter 5. 
 
Similarly, there were a number of policy changes identified that could be used to facilitate reimbursement 
of MMAs as part of a medical service in Australia. The systematic literature review of MMA evaluation 
frameworks found that there was a greater need to evaluate the harms posed by MMAs (i.e. 
misinformation) as well as to undertake a more comprehensive consideration of the likely comparator for 
the technology. Other considerations included, but were not limited to, equity of access to MMAs (i.e. by 
way of age, literacy, user disability, etc.) as well as the importance of secure and proper management of 
confidential data. In addition, technology specific concerns would need to be considered.  These 
considerations include, the possible effect of software updates on the effectiveness and safety of MMAs, 
as well as variation in app performance on different operating systems (OS), mobile platforms, and 
generations of the same platform. For more information, see Chapter 6. 
 
Finally, the interview with stakeholders sought to explore possible pathways and impediments to MMA 
reimbursement in Australia, and highlighted the need for a few policy changes. These policy 
considerations could include: clarification around where the responsibility lies regarding various aspects 
of MMAs, such as data ownership and professional liability for using and prescribing apps; ensuring the 
digital health literacy of healthcare practitioners, patients, and any other MMA users (i.e. carers); and 
finally, providing evaluative measure which address the technological evolution of MMAs, such as the 
technology’s rapid lifecycle (e.g. updates). Current Australian policies which provide a pathway for MMA 
reimbursement are generally trusted by stakeholders as the HTA process ensures that there is rationale 






All the aforementioned policy concerns indicated that in order for MMAs to be reimbursed in Australia, the 
first step is to ensure that they are evaluated properly. To ensure that the harms MMAs pose are properly 
evaluated, a module was developed which could be used to modify the current HTA framework employed 
by MSAC. This adaption of the current MSAC approach ensures the technology specific harms are 
addressed and thoroughly appraised. The adapted process could be used to evaluate MMAs used as part 
of a medical service for a public funding decision.  It is important to note that the module addressed both 
regulatory and reimbursement policy concerns. This is to ensure that the regulatory issues are reviewed, 
as current TGA processes do not properly evaluate them.  
 
The MMA evaluation module could feasibly be adapted (in part) to be used by comparable HTA 
jurisdictional bodies (EEA, Canada, USA). Minimal modifications would need to be incorporated to the 
module processes. Most of these adaptations included the adoption of the newly added reappraisal 
domain, as well as the adjustment to review the unique MMA items (e.g. software, updates, cybersecurity) 
that were not already addressed in the jurisdictional HTAs’ agencies original processes. The remaining 
modification to the HTA MMA module addressed the cost-effectiveness domain. The adaptation to this 
domain would depend on the individual economic evaluations conducted by the respective jurisdictional 
HTA agencies and their individual healthcare contexts. 
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The chapter draws together the findings from all of my research to address the overall aim of this thesis, 
which was to determine the feasibility of tailoring regulation and reimbursement processes in Australia to 
the evaluation of MMAs. How the thesis aim interacts with the three research questions addressed in 
Chapter 5, 6, and 7, is detailed below in Figure 8.1. Figure 3.1 in Chapter 3 demonstrates how this section 




Figure 8.7: Structure of thesis aim and research questions 
Research Questions 
Aim 
To determine the feasibility of tailoring regulation and reimbursement 
processes in Australia to the evaluation of MMAs.  
3)   What key policy changes and 
assessment criteria are 
needed to facilitate the 
development of a system that 
evaluates MMAs for 
reimbursement purposes in 
Australia? 
2)   Is reimbursement for MMAs 
feasible in Australia within the 
current health technology 
assessment system? 
1)   Do changes need to be made 
to the current Australian 
regulatory model for ‘software 
as a medical device’ to 
enable assessment of the 
possible health risks and 





8.2 The feasibility of an MMA evaluation framework for HTA in Australia 
 
In order to determine whether it is feasible to tailor regulation and reimbursement evaluation processes 
in Australia to MMA technologies, the findings from Chapters 5, 6, and 7 and their respective studies were 
integrated and synthesised.  
 
8.2.1 Evaluation of MMA regulation in Australia 
In order to evaluate if regulation in Australia in its current form is capable of assessing the unique 
challenges posed by MMAs, a policy analysis and a comparative analysis of case studies was undertaken. 
The policies underpinning the Australian and international regulation of MMAs were compared and 
contrasted to the IMDRF’s SaMD: Clinical evaluation(22) guidance document. This policy analysis 
focused on the approaches used by IMDRF member jurisdictions to regulate MMAs and determined 
whether these were consistent with the guidance they had also formulated to regulate software as a 
medical device (SaMD: Clinical Evaluation(22)). The case-studies from Australia and the United States 
examined to what extent the observable regulatory processes followed policy, and also investigated 
whether these SaMD policies had been enacted.  
 
The Australian regulation of MMAs and/or any accompanying hardware is consistent with regulatory 
policies enacted internationally. However, it does not wholly comply with the IMDRF SaMD: Clinical 
evaluation(22) guidance document’s recommendations.(141) Four of the five categories recommended 
in the IMDRF’s SaMD: Clinical Evaluation(22) guidance document are addressed to some extent by the 
Australian MMA regulations. The fifth category that was not adopted by the TGA and other international 
jurisdictional regulatory agencies’ in the evaluation of MMAs was safety (as defined in SaMD: Clinical 
Evaluation(22)).(141) International and national regulatory agencies do not evaluate MMA safety in terms 
of the cybersecurity risks, and do not classify the potential risk/harms of the software.(141) SaMD: Clinical 
Evaluation(22) recommends the utilisation of a risk-classification system that assesses the harm posed 
by software in terms of how the information provided affects clinical decision-making. The risk is calculated 
by comparing the severity of the condition the software is treating, diagnosing, or managing against the 
impact the software output has on clinical decision-making.(22, 141)  
 
Internationally, the European Commission and the FDA have had to develop new medical device 
legislation to properly assess the challenges that SaMDs, like MMAs, present.(60, 89, 111-113) In April 
2017 a new medical device policy was released by the European Commission which allows provision for 
regulatory processes to adapt to momentous developments in technology and science.(111) The 





default risk-classification of IIa instead of the previous Class I.(182) These regulatory changes are to be 
implemented between 2020 and 2022.(111, 183) The FDA is currently exploring a software (including 
MMAs) pre-certification programme which is based on the guidance in the SaMD: Clinical Evaluation. 
This pilot investigates an approach which evaluates and pre-certifies the SaMD developers for their 
software designs, testing, and other matters.(60, 89, 112, 113) Similarly, in 2019 Health Canada put a 
draft guidance document for SaMD regulation out for public consultation.(184, 185) This draft guidance 
document details a risk-classification for SaMDs based on the one recommended by the IMDRF.(186) 
The aim of consultation is to discuss ways to better address the regulatory requirements for emerging 
technologies such as MMAs.(184, 185) 
 
Currently, there is no publicly available information which details why these recommendations from the 
IMDRF’s SaMD: Clinical Evaluation guidance(22) document have not been officially been adopted by the 
jurisdictional agencies which drafted them. However, since the recommendations were released in 2017, 
it appears that over time, the individual agencies are attempting to integrate aspects of the 
recommendations into their regulations. Nonetheless, the lack of adoption of the safety/risk classification 
system recommendation from the IMDRF guidance document by international regulatory agencies is 
concerning, particularly as these agencies drafted the IMDRF guidance document. 
 
This analysis suggests that proper regulation of MMAs is currently an evolving process. Concerns about 
the impact of MMA information on clinical decision-making are known and understood but are not currently 
reflected in international regulatory policy. The risk of misinformation (through poor quality control of the 
information included in apps, as well as the deliberate harmful manipulation of this data (cybersecurity 
risks)) is, therefore, not being monitored or assessed in the international regulation of MMAs (see Chapter 
5).(141) There does not appear to be comprehensive regulatory policies in place, domestically and 
globally, to prevent the harms posed by MMAs and their accompanying attachments; however current 
post-market measures are addressing any concerns that may arise. For example, the TGA issued a safety 
warning on MMAs, such as the one issued on the Accu-Chek Connect Diabetes Management app in 
September 2016 due to a programming error.(96) Similarly in June 2019, the FDA issued a safety warning 
on the Medtronic MiniMed insulin pump due to cybersecurity risks and patients were urged to cease use 
of the device and to change pumps. As with any other medical device Medtronic recalled the affected 
devices and replaced them with alternative insulin pumps.(187) 
 
8.2.2 Evaluation of MMA reimbursement in Australia  
Due to the fact that MMAs are such a dynamic technology which present different types of risks and 





Australian approach does not currently exist on how to provide the best evidence to decision-makers on 
the safety, effectiveness and cost-effectiveness of medical services that utilise MMAs. Thus, a systematic 
review of MMA evaluation frameworks was conducted to determine if any can be used to assess MMAs 
for reimbursement purposes.  
 
Assessment of other possible frameworks to evaluate MMAs for reimbursement purposes 
All existing MMA evaluation frameworks (published prior to 31st October 2016) were assessed to 
determine if MMA reimbursement within the current Australian HTA system is feasible.(149)  
 
In summary, none of the 45 MMA evaluation frameworks identified could be used, unaltered, to conduct 
an HTA of an app. These 45 frameworks did not address all six of the core domains that are needed to 
conduct a full HTA.(149)  Although, notably, a framework by Walsworth(189) did assess the effectiveness, 
cost-effectiveness, and safety, of an MMA.(149)  However, like the majority of the other frameworks, it did 
not evaluate the MMA parameters in enough detail – further information was needed on the comparator, 
as well as on the potential for harm.(149) 
   
This review of MMA evaluation frameworks indicated that there are technologically specific considerations 
that need to be taken in to account when assessing apps.  These include a more comprehensive 
evaluation of the ethical challenges associated with app use, as well as connectivity and compatibility 
issues.(149)  
 
Ethical concerns were primarily related to privacy and confidentiality, and the role of cybersecurity.(36, 
48, 60, 89, 113, 149, 190, 191) If the device is accessed by an unauthorised person (e.g. hacked) the 
users’ sensitive medical information would be available to others without their consent and could be used 
for malicious purposes. There is the potential that cybersecurity breaches could be harmful for the patient 
– not only through the misappropriation of confidential information but also through changing information 
stored in the app. These type of breaches might alter how the MMA functions, which in turn could affect 
the output of the app that is used in clinical decision making.(22, 36, 48, 60, 89, 113, 149, 190, 191) Lastly, 
companies have been known to on-sell patient data without their consent, in breach of jurisdictional 
laws.(46, 149) 
 
The connectivity and compatibility concerns identified through the systematic review of MMA evaluation 
frameworks relate to the dynamic nature of MMAs and how this affects the performance of an app. The 
fact that MMAs are available across a variety of operating platforms (i.e. smartphone, tablet, smartwatch), 





versus iPhone X), is a known cause for changes in app performance. An MMA may pose different risks 
to a user on different platforms.(22, 36, 48, 60, 113, 149, 192) For example, on September 12th 2016 the 
TGA issued a safety warning for an error that only affected Accu-Chek Connect Diabetes Management 
app on Apple’s iOS, but not for the same app that is available on Google’s Android platform.(96) Another 
concern is that MMAs have a fast lifecycle, which results in multiple software updates. One incremental 
update may not alter the intended purpose of the MMA; however, a variety of incremental updates over 
time may dramatically change the focus of an app and its output.(22, 48, 60, 113, 149, 192) For a full 
summary of the study see Moshi, Tooher & Merlin(149) in Chapter 6. 
 
As the review found that no existing MMA evaluation framework could be used to evaluate these 
technologies for reimbursement decisions, and so it may be more sensible to adapt existing HTA methods 
and processes to examine the specific characteristics of these technologies. Technology-specific 
elements relating to data ownership, privacy and data security, as well as information or algorithm 
credibility and stability, need to be incorporated into HTA processes when evaluating MMAs for a public 
funding decision both in Australia and elsewhere. 
 
8.2.3 Possible impediments and pathways to MMA reimbursement  
Stakeholder interviews were conducted to identify possible impediments and pathways to MMA 
reimbursement in Australia. The in-depth interviews involved healthcare practitioners (nutritionist(s), 
general practitioner(s) (GP), physiotherapist(s)), policymakers, and healthcare app developers.  
      
The stakeholders who were interviewed expressed a fundamental underlying trust in MSAC and the HTA 
evaluation that informs which medical service can be reimbursed through the MBS. Trust was centred 
around how the HTA process requires a rationale for use and enables evidence-based policy. This 
suggests that healthcare practitioners would be more comfortable using MMAs in clinical consultations, 
and recommending the devices to their patients, if apps were reimbursed through Medicare. Specifically, 
that this comfort was not due to the financial benefits to the healthcare practitioners of having the review 
of app information subsidised, but was rather due to an awareness of the underlying rigour and 
completeness of an evaluation that a medical service must to undergo before it can be listed on the MBS. 
Particularly, there was understanding of how this process protects patient safety and ensures that the 
reimbursed devices are clinically effective.    
 
Conversely, the stakeholders conveyed some concerns about MMAs and their integration into the current 
health system. These concerns were caused by the stakeholders’ inability to trust the technology because 





was the post-market surveillance of MMAs. Interviewees were aware of the technological evolution of 
MMAs. They were concerned by the software’s rapid lifecycle and the potential for multiple updates which 
could alter the various elements of how the health intervention could be delivered. A second major 
concern was that there were unclear lines of responsibility surrounding practitioner accountability and 
jurisdictional oversight of the advice provided on the basis of data collected through an app. Interviewees 
also wanted clarity around who owns the data produced by the MMA and how this could potentially infringe 
on patients’ rights to confidentiality and privacy. Finally, digital health literacy of healthcare practitioners 
and patients was identified as a concern. The main concern of the healthcare practitioner was the fidelity 
of the data inputted into the MMA by the patient and how this could affect the app’s safety and efficacy. 
Furthermore, practitioners raised concerns that patient self-management could be impaired by a lack of 
knowledge in how to interpret the MMA output. 
 
The interviews with stakeholders provided insights into the possible pathways and impediments into MMA 
reimbursement. The current HTA pathway for medical services (used by MSAC in Australia) was 
considered the right pathway, although it was acknowledged that for MMAs this needed to change to 
accommodate a range of other methodological and policy issues associated with the ownership, curation 
and interpretation of digital information, as well as the responsibilities and consequences associated with 
using this information. For the complete study see Moshi, Tooher & Merlin(155) in Chapter 7 (Section 2). 
8.3 Policy changes required for MMA reimbursement adoption and 
development 
If MMA reimbursement is going to be possible within the Australia healthcare system, various changes 
are needed within healthcare policy.(141, 149)  
 
Firstly, regulatory policy would have to be adapted so it is capable of evaluating the challenges presented 
by MMAs.(141) To address the unique dynamic technological challenges presented by MMAs and other 
types of SaMDs, the TGA should adopt the IMDRF SaMD risk-classification system.(141) Moreover, the 
TGA should work on creating a method which is capable of evaluating the cybersecurity threats posed to 
MMAs due to the connectivity of their operating platforms, the app’s software and/ or accompanying 
hardware.(141) Where there is a risk of physical harm, the current TGA risk-classification (Appendix A.2) 
should continue to be applied, e.g. for the hardware accompanying MMAs.(141) Since regulation is the 
first step to a medical service being eligible for Medicare reimbursement, a regulatory evaluative process 
that is capable of properly assessing the risk and benefits associated with MMAs, opens a reimbursement 







Secondly, a variety of policy implications arose from the review of MMA evaluation frameworks. There is 
a need to develop an MMA evaluation framework that is specific for policy purposes, and specifically for 
HTA.(149) The framework should be capable of assessing HTA matters in the required depth of detail, as 
well as the technology specific challenges that MMAs represent.(149) The HTA concerns that would need 
to be addressed in processes to evaluate MMAs include the formal consideration of a comparator (to 
assess comparative safety, comparative effectiveness and comparative cost-effectiveness), assess all 
harms (including misinformation and the possible consequences to clinical decision making and patient 
health outcomes), and proper assessments of the cost-effectiveness of a medical service utilising an 
MMA.(149) The technology specific issues that should be considered, both in the methodological 
approach used by the HTA evaluator, as well as by decision makers, include the fast lifecycle of MMAs, 
varying platforms, multiple operating systems, ethical concerns, and cybersecurity risks.(149) It is 
important to mention that, traditionally, the mandate to evaluate the harms of a software would fall under 
the authority of the TGA.(149)  
 
It is important to note that there are wider policy issues regarding ethical concerns related to the health 
data that MMAs produce. These issues could not be addressed in this thesis alone, however are still a 
major concern when undertaking an HTA on apps. The health data produced by eHealth technologies is 
changing the power dynamic in health research, in terms of data ownership, consent, privacy and 
confidentiality.(195, 196) For example, it is rather simple for corporations to gather a private individual’s 
health data and conduct their own unsupervised research on the collected data. Whereas, for researchers 
to generate the same data would require approval from human research ethics committees (HREC) - a 
rather difficult procedure - and significant oversight of the welfare of the study participants.  This change 
in ”the gatekeeper” of data collection and research could result in a decrease in patient rights. Regulatory 
oversight over how private corporations conduct their big data research is often lacking; a role that was 
traditionally overseen by HRECs within academic research infrastructure. This could be a concern as 
patients generally provide consent to access goods and services - not overtly to be the subject of research. 
(195-197) Thus, the consent of these individuals may not be fully informed and could be partly coerced 
by making availability of a good/service contingent on participant agreement to offer their data. As the 
research done by corporations is technically not for enlightenment, but rather for audit purposes and 
quality assurance, it therefore does not fall under the purview of HRECs. This means that there is currently 
no clarification – as occurs under the HREC process - on who owns the data that is collected.  
Considerably more research and clarification needs to be provided regarding the ethics of data collection 






Lastly, policies would have to facilitate an increased trust in apps by stakeholders. This could be achieved 
through ensuring apps are evaluated in a manner consistent with other health technologies i.e. evidence-
based policy development, and by also addressing stakeholder distrust. Addressing distrust could be 
achieved by increasing digital health literacy, monitoring technological evolution, and clarifying 
jurisdictional and practitioner responsibility regarding MMAs and the data they produce. What is most 
challenging about attempting to increase stakeholder trust in MMAs in Australia is that the mandate to 
address digital health literacy, technological evolution, and responsibility may not fall within the 
jurisdictional mandate of the federal or state health departments. Clarification on who has this mandate is 
needed. For example, ensuring the digital health literacy of health practitioners may fall under the 
responsibility of APHRA(54) (oversee healthcare practitioner registration), whereas the mandate to 
provide clarity around data ownership and intellectual property issues would come from IP Australia(53). 
Moreover, health practitioners’ concerns over malpractice and professional liability concerns could fall 
under the mandate of multiple entities. These include APHRA(54) and individual providers of professional 
indemnity insurance.(198, 199)  
 
Most of the policy concerns highlighted above could be addressed as part of the development of an MMA 
evaluation module. This module was created with the intent to modify existing HTA guidelines utilised by 
MSAC to inform reimbursement decision-making in Australia. The module could be used as a permanent 
or temporary answer to the evaluative challenges posed by MMAs until wider policy solutions are found 
that address the concerns highlighted earlier.  
 
8.3.1 Creation of MMA evaluation module  
The MMA HTA evaluation module was created to support an evaluation of MMAs for HTA purposes. The 
module was aimed at filling the holes in current domestic policy responsible for evaluating MMAs for 
reimbursement and regulatory purposes. For example, the module evaluates the technology specific 
challenges presented by MMAs, which current domestic regulatory and HTA guidelines do not address. 
Thus, the intention of this module was to inform evidenced-based decision-making with regards to MMAs 
in Australia, through modifying current domestic HTA processes. Therefore, the module was applied to 
the MSAC guidance on evaluating medical services and a modified HTA framework was produced that 
could be used in Australia to evaluate MMAs.  
 
Though the module is aimed at adapting HTA evaluation frameworks for reimbursement and decision-
making purposes, it appraises some MMA technology specific regulatory concepts. This is due to the 





be conducted prior to an HTA evaluation, and the TGA does not currently evaluate some MMA technology 
specific challenges. 
 
Since there is no consensus on what funding mechanism should be used for MMA reimbursement in 
Australia, and because the findings from stakeholder interviews indicated that the MSAC HTA process 
was trusted, it is assumed that the current fee-for-service model (through the MBS) would be used when 
adapting the MMA assessment framework to MMA-specific considerations.  
 
The complete version of the MMA HTA evaluation module and the subsequently created MMA evaluation 
module are available in Chapter 7 (Section 2).  
 
8.4 Recommendations  
 
8.4.1 Use the MMA assessment framework to evaluate these apps in Australia 
There is a gap in regulatory and reimbursement policies and processes in Australia with regard to the 
evaluation of MMAs. To make the assessment of these technologies feasible, and of use to policy makers, 
an MMA evaluation module was created. The subsequent adaption of the MSAC HTA process using this 
module meant that a way forward for evaluating MMAs for reimbursement or HTA purposes in Australia 
has been produced.  
 
The MMA evaluation framework is capable of assessing apps for reimbursement and decision-making 
purposes with or without the recommended regulatory changes to the Australian TGA’s SaMD policy. This 
is because the MMA evaluation framework has components that address MMA capabilities that are 
generally regulatory concerns. If the regulatory concerns are subsequently addressed by the TGA (i.e. 
their policies are changed), then these parts of the MMA evaluation framework can be removed, to avoid 
duplication.  
 
Contrastingly, the clinical evaluation elements integrated into the MMA evaluation framework –at the 
recommendation of the module-- should not be removed if the policy recommendations are achieved. The 
inclusion of these elements ensures that the original core HTA domains (e.g. description and technical 
characteristics, current use of the technology, effectiveness, safety, cost-effectiveness, organisational 
aspects) properly evaluate the new technology specific characteristics of MMAs.  
 
With the adoption of the MMA evaluation framework, it would be feasible for MMAs to be assessed 
properly to inform decisions on whether they should be marketed as part of a medical service, and whether 






8.4.2 Clarification of important policy issues 
Furthermore, clarifications about which organisations are legally responsible for various aspects of 
MMAs and the challenges presented by the software when used within the Australian healthcare 
context, is needed. There needs to be explanations of: 
 
 The clinical liability of healthcare practitioners who use or recommend MMAs, and how this 
affects insurances, 
 
 Who owns the data produced by MMAs, 
 
 Who owns the intellectual property associated with various aspects of the MMAs. 
 
8.4.3 Investigate whether it is feasible to apply the MMA evaluation module to other jurisdictions  
The findings from Chapter 7 (Section 3) indicated that, with minimal adaptions, the MMA HTA module 
could be transferred and applied to processes used by HTA agencies in comparable international 
jurisdictions (Canada, EEA, USA). More research has to be done within the respective healthcare contexts 
to determine the feasibility of using the MMA evaluation framework.  
 
8.5 Significance of research 
No other research has been identified globally that focuses on how to assess MMAs for governmental 
reimbursement within a healthcare system. With increasing levels of mobile platform use for health 
purposes, the outcomes from this thesis have considerable policy significance, as it has been determined 
that MMA reimbursement in Australia is feasible through existing processes (albeit modified). Pathways 
for the implementation of a framework that could be used to evaluate MMAs for reimbursement decision-
making have been identified. Additionally, the findings identify that the current regulatory model for SaMD 
in Australia is unable to properly regulate MMAs to decrease the risks they pose to the population, and 
that a number of policy changes are needed to ensure that proper regulation occurs.  
 
As MMAs are not yet reimbursed as part of clinical services both domestically and internationally, the 
development of this possible implementation pathway (the module) may facilitate the adoption of MMAs 
for this purpose. There are a number of potential benefits that could occur if MMAs were publicly 
reimbursed in Australia. Access and equity within the Australian healthcare system could be facilitated 
with MMAs being truly available to every resident. Furthermore, if the recommendations help limit the 





consumers to make informed choices regarding the use of MMAs that have been proven (reimbursed) to 
be safe and clinically effective. If MMAs are reimbursable it may result in GPs and/or other healthcare 
workers becoming comfortable in prescribing and/or using MMAs as they would be reimbursed for 
using/interpreting the apps and would know that the apps are affordable for patients. Lastly, 
reimbursement itself could stimulate the development of good quality, evidence-based (credible) MMAs.  
 
The recommendations from this thesis – when communicated to policymakers – could put MMA 
reimbursement on the policy agenda. 
8.6 Thesis limitations 
There were various limitations to this thesis. All the limitations related to the individual research articles in 
Chapters 5, 6, and 7 and are detailed in the respective chapters. This sub-section will only explore 
limitations related to the overall thesis. 
 
8.6.1 Research as a whole 
There are two main limitations to the research as a whole. The first is that although the research findings 
may be applicable to similar healthcare jurisdictions, they may not be realistic to implement. This is due 
to the research being focused on the distinctive Australian healthcare context.  The second limitation was 
the fact that the created MMA evaluation framework has not been pilot-tested on a sample of MMAs 
submitted for funding as part of a medical service. This is an area where further research would be 
beneficial.  
 
8.6.2 Timeliness of research  
There was a limitation specifically related the timeliness of this research. MMAs are a dynamic technology 
that is evolving at an incredibly fast pace. This has resulted in a significant amount of changes in the 
technology, regulations, and evaluative methods during the study. This was mitigated with the use of clear 
cut-off dates for time sensitive sections as well as acknowledging where regulations and guidelines were 
under review. However, the use of cut-off dates could have resulted in the information in this thesis being 












9.1 Conclusion of thesis 
In conclusion, it is feasible to tailor Australian regulation and reimbursement processes to evaluate MMAs. 
However, a range of modifications to current processes are needed which will require changes to existing 
policy.  
 
Regulation of software as a medical device (SaMD) needs to be changed so that it is able to assess the 
risks posed by MMAs. The major change includes modifying MMA regulation to evaluate the main harm 
posed by apps - the medical information provided and how this is material is used to inform clinical 
decision-making. Another policy change is the need to create a method to address the cybersecurity 
threats posed to MMAs though their connectivity capabilities, in order to protect user information.  
 
Similarly, policy changes need to be made to current HTA processes in Australia. The current processes 
are inadequate to properly evaluate MMAs. These changes include ensuring the mandatory assessment 
of the ethical domain during an HTA of an MMA, to address concerns about the secure use and handling 
of confidential data and equity issues. Other changes involve the ‘rolling review’, or appraisal and re-
appraisal, of app software updates and how these changes can affect the overall conclusions of an MMA’s 
safety and effectiveness.  
 
This study found that other policy changes would ease the pathway to MMA reimbursement in Australia, 
by increasing stakeholders’ confidence in the technology. These policy changes include: clarifying where 
the responsibly lies regarding the ownership and use of data produced by an MMA; and facilitating the 
digital health literacy of patients, healthcare practitioners, and other possible app users (i.e. carers). 
 
To ensure that the technology specific harms posed by MMAs are properly evaluated by regulators and 
funders, a module was created that was used to modify the current HTA evaluation framework used by 
MSAC.  The adapted process could be used to evaluate MMAs properly, by taking into account their 
mutable digital characteristics and indirect impacts on human health.  
 
All of the policy changes needed to feasibly tailor Australia’s regulatory and reimbursement processes to 
evaluate MMAs can be achieved through the adoption of the MMA evaluation module. The use of the 
module to adapt current HTA frameworks could safeguard the Australian population until broader 







9.2 Recommendations  
There are a variety recommended policy changes which need to be made to ensure it is feasible to tailor 
regulatory and reimbursement processes in Australia to the properly evaluate MMA technology. 
 
9.2.1 Evaluation of MMAs 
Regulatory evaluation  
 The TGA should adopt the risk-classification approach recommended by the IMDRF, to assess 
the indirect harms posed by MMAs (i.e. through misinformation and its impact on clinical decision-
making).  
 
 Attachable hardware which accompanies an MMA should be regulated in accordance with the 
current TGA assessment and risk-classification for physical harm.  
 
 Due to the potential for cybersecurity threats to MMAs, the TGA should consider creating a 
method for penetration testing and risk categorising the information security (cybersecurity) of 
MMAs on different platforms and devices, and where relevant the accompanying hardware.  
 
Reimbursement evaluation  
 Regulatory and reimbursement authorities should work collaboratively on developing evaluation 
processes that are complementary. 
 
 A HTA evaluation of an MMA should include formal consideration of a comparator in terms of 
the standard of care the MMA is likely to replace or supplement.  
 
 Appraisal of the possible harms to human health presented by MMAs - through misinformation 
(i.e. information credibility) and its impact on clinical decision-making - should be included in the 
HTA of the technology. 
 
 Technology specific challenges need to be considered for MMAs. One concern includes how 
software updates, OS, operating platforms, and different generations of same the platform, could 





surveillance and HTA re-assessment should also be considered, to determine whether the 
original assessment still holds despite the software updates that have been applied. 
 
 HTA processes should consider the ethical issues around privacy and confidentiality of data 
(due to concerns around cybersecurity) and the curation of data. 
 
 Organisational issues which would need to be included in an HTA of MMAs include reviewing: if 
training and/or education would be needed for users of MMAs (i.e. practitioners or patients); if 
professional accreditation is needed of medical practitioners to be able to recommend clinical 
care on the basis of data produced by an MMA; and the assessment of whether MMAs can 
interact with health informatics systems utilised by surgeries, hospitals, and clinics throughout 
Australia. 
 
MMA module for HTA and reimbursement purposes 
 The MMA HTA evaluation module should be trialled by international jurisdictions to modify their 
HTA processes to incorporate the technology-specific characteristics of apps.  
 
 The creation of an MMA HTA evaluation framework for Australia, through the adoption of this 
module, means that there is now a roadmap for assessing the challenges presented by apps 
and their unique characteristics. These challenges include evaluating their analytical (reliability) 
validity, impact of software updates, cybersecurity concerns, compatibility issues (e.g. platform 
and operating systems), inclusion of post-market performance data, as well as other app 
specific concerns.  
 
 The module could be used as a permanent or temporary solution, until wider policy solutions 
are found that address the concerns highlighted above.  
 
9.3 Further research 
The findings from my thesis have highlighted a variety of areas for further research. The MMA HTA 
evaluation framework (Chapter 7, Section 2) created through the use of the module, has not been pilot-
tested for use in Australia and would benefit from this. Additional research should be conducted into the 
development of a risk-classification pathway which could be used to assess the harms posed by MMAs 
(and other SaMDs) that produce information, as well as the accompanying hardware. Similarly, there is a 





and any applicable attachable accompanying hardware. Moreover, there is a need for research to be 
conducted which could provide an evidence-base for exploration and clarification of where the various 
aspects of legal responsibility (e.g. data ownership, IP ownership, professional liability, etc.) for MMAs lie. 
Finally, in the long term, research should explore what barriers there are to the robust regulation of MMAs 














Supporting information to thesis background  
 Definitions 
 Medical device regulation 
 Overview of the Medical Service Advisory Committee (MSAC) 






A.1 Definitions  
 
A.1.1 Definition of mobile health (mHealth) 
A sub-set of eHealth, mHealth, is defined by the WHO as public health and medical practices which are 
supported by mobile devices.(42) Mobile devices include: devices that monitor health, mobile phones 
(including smartphones), personal digital assistants (PDA), and other wireless devices such as 
tablets.(42) mHealth utilises and builds upon the core functions of mobile devices, including: short 
messaging services (SMS); global positioning systems (GPS); general packet radio services (GPRS); 
Bluetooth; third generation mobile telecommunications (3G); fourth generation mobile 
telecommunications (4G); as well as other software applications (apps); and complex functionalities to 
support health interventions at a population level.(42, 49) 
 
A.1.2 Definitions telemedicine and electronic health (eHealth) 
It is important that mHealth is not confused with telemedicine. The WHO considers mHealth and 
telemedicine as both individual subsets of the overarching category of eHealth.(42, 43) eHealth is the 
electronic transfer of healthcare and health resources.(44) Telemedicine is the best established and most 
popular of the eHealth services.(43) Telemedicine is defined as “the delivery of health care services, 
where distance is a critical factor, by all health care professionals using information and communication 
technologies for the exchange of valid information for diagnosis, treatment and prevention of disease and 
injuries, research and evaluation, and for the continuing education of health care providers, all in the 
interests of advancing the health of individuals and their communities”(43). There is controversy 
surrounding the difference between telehealth and telemedicine. Some consider telehealth to be 
communication between allied health practitioners and patients and telemedicine to be point to point 
communication between medical doctors and patients.(43) In accordance with the WHO, telehealth and 
telemedicine will be considered interchangeable and the term will include all patient communication with 
any medical practitioners.(43) 
 
A.1.3 Definition of In vitro diagnostic medical device (IVD) 
A medical device is considered to be an IVD “if it is a reagent, calibrator, control material, kit, specimen 
receptacle, software, instrument, apparatus, equipment or system, whether used alone or in combination 
with other diagnostic goods for in vitro use. It must be intended by the manufacturer to be used in vitro for 
the examination of specimens derived from the human body, solely or principally for the purpose of giving 
information about a physiological or pathological state, a congenital abnormality or to determine safety 






A.2 Medical device regulation  
 
A.2.1 Medical device regulation applied to Software 
How software is regulated as an active medical devices or IVDs depends on its intended purpose and 
how it is supplied.(6, 7, 92-94) If a piece of stand-alone software meets the TGA’s definition of a medical 
device, it is regulated as a medical device in its own right. Software that is supplied as part of a medical 
device but which can act on its own without the related device, is also regulated as a stand-alone medical 
device. Similarly, updates to software that are supplied separately are regulated as a standalone medical 
device. Software that is part of a medical device, and is supplied alongside it, is regulated as within the 
device and not separately.  Likewise, software corrections to errors that were supplied with the device 
software are not regulated by the TGA.(6, 7, 92-94) 
 
In the case where an IVD has software built into it, the software is regulated as part of the IVD.(6, 7, 92, 
93) Similarly, software is regulated as an IVD when it is intended not to drive the IVD but to provide 
therapeutic or diagnostic information. An IVD which is supplied separately to the software and is intended 
to influence or operate it, is regulated as a separate and distinct IVD. Whereas, software corrections are 
generally regulated as a correction; however, if it changes the original functionality of the software, such 
as adding a new feature, the software will be regulated as a separate IVD. Furthermore, software used in 
combination with equipment used to manage patient data and information for both non-IVD medical 
devices and IVDs is not regulated by the TGA.(6, 7, 92, 93) 
 
A.2.2 Medical device risk-classification 
Active medical devices  
Both active medical device and IVD risk-classification applies to software and thus to MMAs. The risk-
classification used for non-IVD medical devices is categorised as Classes I, IIa, IIb, III. The classification 
is scaled, so devices that are classified as Class I provide the lowest risk to public health and safety while 
Class III devices offer the highest risk. Software is classified using the categorisation for an active medical 
device (see Figure A.1).(6) Active medical devices which are classified within Class IIa or IIb are devices 
that are used for therapy (exchange or administer energy), diagnosis (supply energy for imaging, 
monitoring physiology process), and remove or administer medicines/substances. An active medical 
device such as standalone software/ MMAs that are not covered by the Class IIa or IIb classification are 





Figure A.1: Active medical device risk-classification 
 
Source: Therapeutic Goods Administration (5) 
 
In vitro medical devices (IVDs) 
IVD risk-classification is slightly different. IVDs are classified as Class 1, 2, 3, or 4. Class 1 posing the 
lowest risk to public health while devices in Class 4 offering the highest risk.(92, 94, 95) See Table 1 
below for how IVDs are classified.   
 
Table A.1: IVD risk-classification  
IVD Risk-classification  Level of risk 
Class 1 No public health risk or low personal risk 
Class 2 Low public health risk or moderate personal risk 
Class 3 Moderate public health risk or high personal risk 
Class 4 High public health risk 






A.3 Medical Services Advisory Committee (MSAC) 
The MSAC is an independent common law committee within the Federal Department of Health. The 
committee makes a none-binding recommendations to the Federal Government Minister of Health on 
whether or not a medical service in Australia’s should publicly funded through the MBS and the 
circumstances in which it can be.(19, 130) If MSAC are going to recommend a service for funding through 
the MBS the committee needs to ensure at the time of the recommendation that: the service in which the 
applicant is apply for public funding is registered on the ARTG; the service has met the HTA core domains 
of being comparatively clinically effective, comparatively cost effective, and comparatively safe; and that 
the services fits the criteria outlined in the Health Insurance act 19734.(19, 26) 
 
There are two sub-committees within MSAC, the Evaluation sub-committee (ESC) and the PICO5 
Advisory Committee (PASC). MSAC has an executive committee that manages actives between the sub-
committees between formal meetings. This executive committee is made up the chairs of PASC and ESC 







   
                                                     
 
4 If needed MSAC can liaise with the Department of Health legal and policy services for advice. 





A.4 Telemedicine reimbursement  
The Federal Government has acknowledged the importance of the eHealth services,(3, 201) and as such, 
enables the reimbursement of telemedicine in Australia. The aim of the scheme is to remove barriers that 
may prevent people from accessing specialist medical services.(130) 
 
A.4.1 Telemedicine MBS items  
There are currently 11 MBS items that enable specialist doctors, consultant physicians, and consultant 
psychologists to claim video consultations. Additionally, there are 23 MBS items for patient-end 
services.(202) These items are also available to nurse practitioners, medical practitioners, aboriginal 
health workers, and practice nurses who provide clinical support to patients during the video consultation 
with the specialist.(130, 202, 203) 
 
A.4.2 Telemedicine eligibility  
There is no formal application process that determines telemedicine reimbursement eligibility in Australia. 
However, there are a number of requirements that need to be met to be considered eligible.(129, 203, 
204) At the time of the video consultation there needs to be at least 15 km by road between the patient 
and practitioner (medical specialist, consultant psychiatrist consultant physician).(203, 204) Eligibility can 
also be affected by the geographic area. Generally, the patient needs to be situated outside of a major 
city (RA1)6.(129, 203) Exceptions to geographic location apply where a patient is a resident of an eligible 
aged care facility, is present at an eligible Aboriginal Medical Services (AMS), or is present at an eligible 
Aboriginal community controlled health services (ACCHS).(129, 202-204) 
  
                                                     
 
6 The Australian Standard Geographic Classification-Remote Area (RA) scales remoteness numerically 








Supporting documentation used in the review of existing MMA regulatory policy  
 Summary of correspondence with international medical device regulatory authorities  
 Summary of Freedom of Information (FOI) Act requests and responses  





B.1 Correspondence with international medical device regulatory authorities  
 
Table B.1 summarises my correspondence with the respective Canadian and American medical device 
regulatory authorities.  
 
Table B.1: Summary of correspondence with international medical device regulatory authorities 
Jurisdictional 
regulatory agency  
E-mail details 






Inquiry about active 
medical device risk 
classification 
8 May 2018 17 May 2018 
U.S Food and Drug 
Administration 
(FDA) 
digitalhealth@fda.hhs.gov Inquiry about present 
and future MMA 
regulation 
13 February 2018 22 February 2018 
U.S Food and Drug 
Administration 
(FDA) 
digitalhealth@fda.hhs.gov Inquiry about MMA and 
software regulation  






B.2 Freedom of Information (FOI) Act requests and responses   
 
Table B.2 summarises the two freedom of information (FOI) Act requests used to acquire the relevant 
information for the case studies in Chapter 5. 
 
Table B.2: Summary of correspondence with Freedom of Information (FOI) Act requests and responses  
 
FOI request number Date of request submission Date documents were released  
059-1718 16 August 2017 15 December 2017 
185-1718 23 January 2018 15 May 2018 
Explanatory Note 







B.3 Data extraction form for submission and/ or clinical evaluation reports 






Data Extraction Form for Mobile Medical Applications (MMA) Submissions 
and/or Clinical Evaluation Report (CER) by the Therapeutic Goods 
Administration (TGA) 
 
Clinical Evaluation Report (CER) 
Title and Date 
 
 
Author of CER  
 
Was the CER performed by an 
independent reviewer  
 
☐Yes 
☐ No  
If no, please state the position of the CER reviewer _____________ 
Name of MMA  
 
Intended Purpose of MMA  
 
 
This document is based on the International Medical Devices Regulators Forum (IMDRF) Software as a Medical Device 
(SaMD): Clinical Evaluation (N41)(22, 116) guidance document. 
 
- This document expands details addressed in N41 that relate to the IMDRF’s SaMD: Possible framework for risk 
categorization and corresponding considerations (N12)(36). 
 
- This document does not include detailed information on the IMDRF’s SaMD: Application of Quality Management 
Systems (N23)(205), as the TGA does not address quality management systems when conducting a clinical 
evaluation of an induvial medical device.  
 






Description and current use of the  technology 
 
Yes Unclear No N/A Comments  
✔ ? ✘ / 
1) Has the name of the MMA been stated in the 
CER? 
     
 
 
2) Has the intended population(s) for the MMA been 
stated in the CER? 
    
 
 
3) Does the CER consider the type(s) of MMA input(s) 
(e.g. digitized content such as: laboratory results, 
image, medical device data, physiological status, 
symptoms)? 
 
    
 
 
4) Does the CER consider the MMA algorithm (e.g. 
logic such as: inferences engine, equations, model 
based logic; affected by reference data, knowledge 
base, criteria, rules)? 
 




5) Does the CER consider the type(s) of MMA 
output(s) (e.g. inform, treat, diagnose)? 
    
 
 
6) Does the CER consider the intended purpose(s) of 
the MMA? 
 
If yes, complete i-iii below, if no stop data extraction. 




i. Does the MMA have therapeutic 
capabilities? 
 
If yes, complete both 7) Valid Clinical Association and 
9) Analytical Validation and sub-sections in the 
effectiveness  section, if no continue on to ii. 






ii. Does the MMA have non-diagnostic 
(aid in diagnosis) capabilities? 
 
If yes, complete both 7) Valid Clinical Association and 
9) Analytical Validation sub-sections in the 
effectiveness  section, if no continue on to iii. 




iii. Does the MMA have diagnostic 
capabilities?  
 
If yes, complete 7) Valid Clinical Association, 8) 
Clinical Validation and 9) Analytical Validation sub-
sections in the effectiveness section; if no, stop data 
extraction. 







CER= Clinical evaluation report 





Effectiveness Yes Unclear No N/A Comments  
✔ ? ✘ /  
7) Valid Clinical Association 
a) Does the CER consider if literature 
searches for scientific validity evidence 
on the MMA have been conducted 
(e.g. peer reviewed articles, clinical 
guidance documents, conference 
proceedings, etc.)? 
 




b) Does the CER consider the 
manufacturers’ experience data (e.g. 
consumer feedback, adverse events, 
real world data, etc.)? 
 




c) Have any purposefully conducted 
scientific validity studies (e.g. RCTs, 
cohort studies, etc.) that establish an 
association between the MMA output 
and the healthcare situation or 
condition, been considered in the 
CER? 
 




d) Does the CER consider the clinical 
equivalency of the MMA? 




e) Does the CER consider studies which 
evaluate the association between the 
MMA input and the output? 




f) Does the CER consider the 
association between the MMA’s output 
and patient health outcomes? 
 
If yes, address  i-ii below apply; if no continue on 
to question 8 and/or 9 depending on the 
intended purpose of the MMA (see question 6 
for clarification). 
    
i. Is the relationship between the 
MMA output and the patient 
heath outcome a well-known 
association? 
 




ii. Is the relationship between the 
MMA output and the patient 
heath outcome a novel 
association? 
 




8) Clinical Validation   Note: this section is only to be completed for MMAs with diagnostic capabilities  
a) Does the CER consider whether the 
information sources used in the MMA 
are relevant to the intended purpose of 
the MMA? 
 
     
b) Does the CER consider whether the 
information provided is of sufficient 
quality to give an objective 
assessment of the MMAs clinical 
performance? 
 





c) Does the CER consider whether the 
data sets are relevant to the MMA in 
question? 
 
     
d) Does the CER consider whether the 
MMA is consistent across multiple 
datasets? 
If yes, complete i  below; if no, continue on to 
part e). 
     
i. Has the reason for the 
difference in the datasets 
been determined? 
 
     
e) Does the CER consider whether the 
MMA affects health related outcomes 
(patient focused)? 




f) Does the CER consider whether the 
MMA affects surrogate health 
outcomes? 
 
If yes, complete i-vii  below;  if no, continue on to 
the  9) Analytical Validation section. 




i. Does the CER consider the 
calculation of the sensitivity of the 
MMA? 




ii. Does the CER consider the 
calculation of the specificity of the 
MMA? 




iii. Does the CER consider whether 
a receiver operating characteristic 
(ROC) curve has been developed 
for the MMA?  
 




iv. Does the CER consider the 
calculation of the positive 
predictive value (PPV) of the 
MMA? 
 




v. Does the CER consider the 
calculation of the negative 
predictive value (NPV) of the 
MMA? 
 




vi. Does the CER consider the 
calculation of the likelihood ratio 
of the MMA?  




vii. Does the CER consider whether 
there are pre-determined  
evidence based diagnostic 
thresholds (cut-off) for the MMA?  
 




9) Analytical Validation 
a) Does the CER verify and validate the 
analytical validate (accuracy) of the 
MMA?  
 





If yes, indicate from i-iv below apply (one or 
more which), if no continue on to the next 
question. 
i. Does the CER consider 
whether the algorithm used 
by the MMA is a recognised 
standard (the current 
standard of care or 
described in the literature 
(e.g. insulin dosing))? 
 
     
ii. Does the CER consider 
whether the MMA accuracy 
is relative to a reference or 
gold standard? 
     
iii. Does the CER consider 
whether the MMA accuracy 
is relative to reference 
material (e.g. International 
normalisation ratio (INR))? 
 
     
iv. Does the CER consider 
whether the MMA is 
comparable to another 
software or device that has 
an association between the 
output and a health 
outcome? 
 
     
b) Has the calculation of the accuracy of 
the MMA’s findings been considered in 
the CER? 




c) Has the calculation of the precision of 
the MMA’s findings been considered in 
the CER? 




d) Has the calculation of the limit of 
detection for the MMA’s findings been 
considered in the CER?  




e) Has the calculation of the linearity of 
associated transfer function for the 
MMA been considered in the CER?  




f) Has the calculation of the analytical 
sensitivity of the MMA’s findings been 
considered in the CER?  











CER= Clinical evaluation report 







Yes Unclear No N/A Comments 
✔ ? ✘ / 
10) Does the CER consider the impact of the 
MMA’s output on the clinical management of the 
patient? 
 
If yes, complete sections a and b below; if no, 
continue on to the question 11) Socio-technical 
and system environment considerations. 
 
 




a) Does the CER consider whether the 
MMA output impacts healthcare 
decision making?  
If yes, complete sections i-iii below; if no, 
continue on to part b). 




i) Does the CER consider whether 
the MMA is used to treat or 
diagnose? 
For example: 
 treat – provide therapy to 
a human body using other 
means; 
 diagnose;  
 detect;  
 screen;  
 prevent;  
 mitigate;  
 lead to an immediate or 
near term action 




ii) Does the CER consider whether 
the MMA is used to drive clinical 
management? 
For example: 
 aid in treatment - provide 
enhanced support to safe 
and effective use of 
medicinal products;  
 aid in diagnosis - help 
predict risk of a disease 
or condition;  
 aid to making a definitive 
diagnosis;  
 triage early signs of a 
disease or condition; 
 identify early signs of a 
disease or condition 
 




iii) Does the CER consider whether 
the MMA is used to inform 
clinical management?  
For example: 
 inform options for 
treatment; 
 inform options for 
diagnosis;   








 inform options for 
prevention 
b) Does the CER consider whether the 
MMA output impacts healthcare 
decision making? 
If yes, complete sections i-iii below, if no, 
continue on to the question 11) Socio-technical 
and system environment considerations . 




i)  Does the CER consider whether 
the MMA has a critical impact on 
healthcare decision making? 
For example: 
 Disease Type/Patient 
Condition  
o Life-threatening  
o Fragile 
 
 Intervention Type 
o Requires major 
therapeutic 
interventions 
o Sometimes time critical 
o Vital to: avoiding 
death; serious 
deterioration of health; 
mitigating public health 
situations or conditions 
 
 User Type 
o Specialised and 
trained users 




ii) Does the CER consider whether 
the MMA has a serious impact 
on healthcare decision making? 
 
For example: 
 Disease Type/Patient 
Condition  
o Moderate in 
progression 
o Often curable 
o Not fragile 
 Intervention Type 
o Does not require 
major therapeutic 
interventions 
o Not expected to be 
time critical 
o Vital to avoiding 
unnecessary 
interventions 
 User Type 
o Either specialized and 
trained users or lay 
users  








iii) Does the CER consider whether 
the MMA has a non-serious 
impact on healthcare decision 
making? 
For example: 
 Disease Type/Patient 
Condition  
o Slow with predictable 
progression of 
disease state 
o Minor chronic illness 
or disease states 
o May not be curable 
o Individuals who may 
not always be patients 
o Can be managed 
effectively  
 Intervention Type 
N/A 
 User Type 
o Either specialized and 
trained users or lay 
users 
 











CER= Clinical evaluation report 






Technical Characteristics Yes Unclear No N/A Comment  
✔ ? ✘ / 
11) Socio-technical and system environment considerations  
a) Does the CER address whether the 
manufacturers of the MMA have been 
transparent about the limitations of the 
MMA (e.g. the algorithms, clinical 
models, assumptions, and quality of 
the data)? 
 
     
b) Does the CER consider whether the 
real-world MMA is integrated into 
clinical workflows with appropriate use 
if safety features? 
 
    
c) Does the CER consider whether the 
MMA is robust enough to withstand 
user configuration in an unintended 
way? 
 
    
d) Does the CER consider the design of 
the MMA user interface? 
 
If yes, address i-iii below; if no, continue on to 
part e). 
    
i. Does the CER consider whether 
the user interface has over 
complex designs (e.g. 
complicated screens)? 
 




ii. Does the CER consider whether 
the design of the user interface is 
appropriate for the intended 
platform (e.g. smartphone, 
smartwatch, tablet) 
     
 
 
iii. Does the CER consider whether 
the MMA data are dynamic (e.g. 
displaying appropriate 
information for an appropriate 
length of time)? 




e) Does the CER consider whether the 
MMA has the appropriate means of 
information display (so that the target 
audience can understand it  (e.g. units 
displayed, language translation))? 
 




f) Does the CER consider whether the 
MMAs can communicate relevant  
information? 
 
If yes, address  i-iii below apply; if no, continue 
on to part g) 




i. Does the CER consider whether 
the user can use the MMA within 
the organisation (in terms of 
available network, data quality 
input, competence, and 
hardware)? 
 
     
ii. Does the CER consider whether 
there is correct installation and 






configuration of the MMA to 
enable the appropriate 





g)  Have possible MMA 
interdependencies (e.g. software, 
hardware) been considered in the 
CER?  
 




h)  Has it been acknowledged in the 
CER that the MMA is not used as a 
specialised medical platform? 




i)  Have potential changes to the 
software (updates) been considered in 
the CER? 
 
If yes, address i-iv below;  if no, continue on to 
the next question part j) 




i. Does the CER consider whether 
these software changes are 
adaptive (e.g. maintains software 
with dynamic environment)? 
 




ii. Does the CER consider whether 
these software changes are 
perfective* (e.g. recoding to 
improve performance)? 
 




iii. Does the CER consider whether 
these software changes are 
corrective (e.g. corrects 
problems)? 




iv. Does the CER consider whether 
these software changes are 
preventive (e.g. corrects latent 
faults before they cause 
operational problems)? 
 




j) Does the CER consider the operating 
platform(s) (e.g. hardware) of the 
MMA(s)? 
 
If yes, address i-vi below apply (one or more), if 
no continue on to the part k) 
     
i. Does the CER note whether the 
MMA uses a tablet interface? 




ii. Does the CER note whether the 
MMA uses a smartphone 
interface? 




iii. Does the CER note whether the 
MMA uses a smartwatch 
interface? 




iv. Does the CER note whether the 
MMA uses a desk top computer 
interface? 








v. Does the CER note whether the 
MMA uses a smart glasses 
interface? 




vi. Does the CER note whether the 
MMA uses another interface? 




k) Has the operating system(s) that the 
MMA(s) are installed on been 
considered in the CER? 
 
If yes, address i-v below if; no, continue on to 
the Question 12 
     




















12) Information Security with respect to safety considerations  
a) Does the CER consider whether a 
formalised and safe method has been 
implemented to convert, transmit, 
and/or store MMA data? 
 




b) Does the CER consider whether 
control measures to address data 
integrity are appropriate, in the 
circumstance where common 
information is accessed by multiple 
applications and user? 
 





c) Does the CER consider whether users 
can safely implement information 
security updates? 




d) Does the CER consider whether there 
are system supports for access and 
control to ensure protection of system 
information for the MMA? 




e) Does the CER consider whether MMA 
design includes robust and resilient 
measures to address potential 
adverse system interactions? 
   
    
f) Does the CER consider whether there 
is a balance in the availability of timely 











g) Does the CER consider whether there 
are instructions for the user to safely 
manage MMA information security 
been? 
 




h) Does the CER consider whether the 
MMA integrates with other software? 
 
    
i) Does the CER consider whether there 
needs to be updated security software 
for use of the MMA with other 
systems, applications or operating 
environments? 
 







CER= Clinical evaluation report 







Continuous learning using real world 
performance data 
 
Yes Unclear No N/A Comments 
✔ ? ✘ / 
13) Does the CER consider if the manufacturer 
monitors the MMA’s real world performance 
data?  
 








i. Does the CER consider if the 
manufacturer has aimed to 
implement the least burdensome 
approach to collect the MMA’s 
performance data? 
     
ii. Does the CER consider whether 
the real world performance data 
collected by the MMA’s 
manufacturer could be used to 
provide evidence that the clinical 
or analytical validity of the MMA 
is inferior or superior to the 
original measures stated in the 
TGA application? 




iii. Does the CER consider whether 
the real world performance data 
collected by the MMA’s 
manufacturer could be used to 
allow for the enablement or 
disablement of a new MMA 
functionality? 











CER= Clinical evaluation report 
MMA= Mobile medical application  
TGA= Therapeutic Goods Administration  
 






Accuracy: Closeness of the quantity’s true value to its measured quantity.(1) 
Adaptive software changes: Maintains the MMA software within a dynamic technological 
environment.(3) 
Algorithm: A model, or set rules, or logic that the MMA is based on (e.g. inferences engine, equations, 
model based logic; affected by reference data, knowledge base, criteria, rules). 
Analytical sensitivity: Degree to which the input data affects the algorithm’s output.(1) 
Analytical validation: The MMAs ability to reliably and accurately produce the intentional output from 
the input data.(1) 
Clinical equivalency: Clinical association of MMA compared to a reference standard (e.g. predicate/ 
comparator device).(1) 
Valid clinical association: A valid association between the MMA’s output which and the targeted medical 
condition (e.g. measurable, clinical outcomes).(1,2) 
Corrective software changes: Corrects existing errors or problems within the current MMA software.(3) 
Cut-off threshold: A scale or indices for a MMA, it should be meaningful and determined prior to 
validation.(1) 
Diagnostic MMA: A MMA’s output that is intended diagnose and/or drive clinical management by 
differentiating patients or their physiological conditions (e.g. screening apps, diagnostic apps, risk 
predicating apps).(1) 
Input: Digitised content fed to the MMA (e.g. laboratory results, image, medical device data, physiological 
status, symptoms).(1,2) 
Likelihood ratio: The likelihood that a test result given by the MMA would be expected in a person with 
the condition compared to a person without it.(1) 
Limit of detection: Ability to distinguish between random patterns that distract from information and 
information bearing patterns of a clinical condition.(1) 
Linearity of associated transfer function: “Behaviour of output across the range of input data that is 
allowed”(1) by the MMA. 
Negative predictive value (NPV): The likelihood that the patient does not have the condition given the 
MMA result is negative.(1) 
Non-diagnostic: A MMA that has a generic functionality which can be used across several healthcare 
conditions or situations (e.g. calculator app, memory test app).(1) 
Novel association:  The MMA has a new input, algorithm, and/or output with a new target population, or 
a new intended target papulation, which are not well-known or established. (1,2) 






Perfective software changes: Recoding of MMA software to improve performance.(3) 
Positive predictive value (PPV): The likelihood that the patient has the condition given the MMA result 
is positive.(1) 
Precision: Under unchanged conditions the degree to which the recurrent measurements generate the 
same result  (e.g. reproducibility, repeatability).(1) 
Preventive software changes: Corrects latent faults in the MMA software before they can cause 
operational problems.(3) 
Receiver operating characteristic (ROC) curve: A graphical plot that illustrates the trade-off between 
sensitivity and specificity.(1) 
Relevant studies: One or multiple studies which evaluate the association between the input and the 
output.(1) 
Clinical Validation: The MMA’s output has a positive impact on the target population in the context of 
care context.(1,2) 
Sensitivity: MMA’s ability to correctly identify a patient’s condition as positive.(1) 
Specificity: A MMA’s ability to correctly identify a patient’s condition as negative.(1) 
Therapeutic MMA: A MMA’s  output that is intended to treat a healthcare condition or situation.(1) 
Well-known association: MMA output has well established association with health condition or 
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Supporting documentation used in the review of existing MMA evaluation frameworks for 
use within HTA and reimbursement decision -making  
 Search strategies  
 Data extraction standardisation tool  






C.1 Search strategies  
Table C.1: Search strategy Embase 
Mobile Medical Applications (MMA) Mobile Platform 
(‘mobile applications’/exp  OR ‘mobile app*’ OR 
‘telehealth’/exp OR telemedicine OR ‘portable electronic 
app*’ OR ‘mHealth app*’ OR ‘portable software app*’ OR 
‘mobile medical app*’ OR ‘mobile health app*’ OR 
‘electronic health app*’ OR ‘eHealth app*’) 
AND (‘mobile phones’/exp OR ‘cell phone*’ OR ‘cellular 
phone*’ OR ‘cellular telephone*’ OR ‘mobile phone*’ OR 
mobile OR ‘mobile device*’ OR ‘mobile platform*’ OR 
‘smartphone’/exp OR smartphone* OR ‘smart phone*’ OR 
android* OR ipad* OR iphone* OR ‘apple watch*’ OR ‘smart 
watch*’ OR tablet* OR iOS OR Blackberr* OR windows OR 




Table C.2: Search strategy Cochrane Library 
 
Table C.3: Search strategy CINAHL 
Mobile Medical Applications (MMA) Mobile Platform 
((MH "Mobile Applications") OR mobile app* OR portable 
electronic app* OR mHealth app* OR portable software 
app* OR mobile medical app* OR mobile health app* OR 
telemedicine app* OR telehealth app* OR electronic 
health app* OR eHealth app* (MH "Telemedicine") OR 
(MH "Telehealth")) 
AND ((MH "Cellular Phone+") OR (MH "Smartphone+") OR 
cell phones OR cellular phone* OR cellular telephone* OR 
mobile phone* OR mobile OR mobile device* OR mobile 
platform* OR smartphone* OR smart phone* OR android* 
OR ipad* OR iphone* OR apple watch* OR smart watch* OR 
tablet* OR iOS OR Blackberr* OR window OR Microsoft or 
google OR apple OR HTC) 
 
 
Mobile Medical Applications (MMA) Mobile Platform 
mobile applications OR mobile app* OR portable 
electronic app*OR mHealth app* OR portable software 
app*OR mobile medical app*OR mobile health app*OR 
telemedicine app* OR telehealth app* OR electronic 
health app* OR eHealth app* 
 
MeSH: Mobile Applications, Telemedicine 
cell phones OR cellular phone* OR cellular telephone* OR 
mobile phone* OR mobile OR mobile device* OR mobile 
platform* OR smartphone* OR smart phone* OR android* 
OR ipad* OR iphone* OR apple watch* OR smart watch* OR 
tablet* OR iOS OR Blackberr* OR window* OR Microsoft or 
google OR apple OR HTC 
 





Table C.4: Search strategy PsycINFO 
Mobile Medical Applications (MMA) Mobile Platform 
 (exp Telemedicine/ OR mobile applications OR mobile 
app$.tw OR portable electronic app$.tw OR mHealth 
app$.tw OR portable software app$.tw OR mobile 
medical app$.tw OR mobile health app$.tw OR 
telemedicine app$.tw OR telehealth app$.tw OR 
electronic health app$.tw OR eHealth app$.tw) 
 
AND (exp Cellular phones/ OR exp Mobile Devices/ OR cell 
phones.tw OR cellular phone$.tw OR cellular telephone$.tw 
OR mobile phone$.tw OR mobile.tw OR mobile device$.tw 
OR mobile platform$.tw OR smartphone$.tw OR smart 
phone$.tw OR android$.tw OR ipad$.tw OR iphone$.tw OR 
apple watch$.tw OR smart watch$.tw OR tablet$.tw OR 
iOS.tw OR Blackberr$.tw OR windows.tw OR Microsoft.tw or 
google.tw OR appl.tw OR HTC.tw) 
 
 
Table C.5: Search strategy Business Source Complete  
  
Mobile Medical Applications (MMA)  Evaluation   Other 
("mobile medical app" OR "mobile 
health app" OR "mobile health 
application" OR "mobile health app" 
OR “telemedicine app” OR 
“telemedicine application” OR 
“mHealth app” OR “mhealth 
application”  OR “eHealth app” OR 
“eHealth application” OR “telehealth 
app” “telehealth application”) 










C.2 Data extraction standardisation tool  
 
  















Evaluation of core domains 
Domain 1: Current use of the technology  




Does the framework have any item(s) that address how the 
current MMA assists the user(s) in managing their health 
concern (population/ clinical indications)? 
✔ ? ✘  
   
Item(s) that address health concerns and current use of the technology could include: 
 
 Item(s) about the medical condition the MMA is intended to aid; 
 
 Item(s) which address the current use (e.g. rates, utilisation, trends) of the MMA; 
 
 Item(s) about the MMA’s intended purpose (e.g. diagnosis, management, treatment);  
 














Domain 2: Description and technical characteristics  
Domain: Description and technical Characteristics Question(s) 
Number 
Does the framework have any item(s) that describe the 
technical characteristics of the MMA? 
✔ ? ✘  
   
Item(s) that address the description and technical characteristics of the technology  could include: 
 
 Item(s) which consider the personalization capabilities of the MMA; 
 
 Item(s) on what type of devices the MMA will be compatible with (e.g. mobile platform, 
operating system, version);  
 
 Item(s) which address if experts were consulted or included during the development of the 
MMA; 
 
 Item(s) that ask about the MMA’s communicative capabilities (e.g. connectivity, 
communication with personal health records (PHR), electronic health records (EHR), 












Domain 3: Effectiveness  
Domain: Effectiveness    Question(s) 
Number 
Does the framework have any item(s) that address the 
clinical effectiveness a MMA?  
✔ ? ✘  
   
Item(s) that address clinical effectiveness could include: 
 
 Item(s) that address if the MMA has been tested or trialed;  
 
a) Item(s) that address the design of the trial; 
 
b) Item(s) which address the number of subjects included in the trial; 
 
c) Item(s) which address the quality of the trial; 
 
d) Item(s) that address if trial results match the conclusion; 
 
 Item(s) that address the therapeutic effectiveness of the MMA;  
 
a) Item(s) answerable by health related outcomes (e.g. mortality, DALYS); 
 
b) Effectiveness item(s) relating to surrogate outcomes (e.g. physiological, 
biochemical, behaviour change) and the corresponding underlying assumption 
used; 
 
c) Item(s) about a meta-analysis on the effectiveness; 
 
d) Item(s) that aimed at publication bias; 
 
e) Item(s) on about heterogeneity; 
 
 Item(s) which address technical efficacy of the MMA; 
 
 Item(s) that address diagnostic accuracy efficacy (e.g. specificity, sensitivity, likelihood ratio) 
of the MMA; 
 
 Item(s) which ask about what intervention is the MMA’s comparator for clinical effectiveness; 
 


















Domain: Safety  Question(s) 
Number 
Does the framework have any items(s) that address the 
safety of the MMA? 
✔ ? ✘  
   
Items(s) that address safety could include: 
 
 Item(s) that address the harms (adverse events) caused by the MMA; 
 
 Item(s) that ask why participant(s) may have left the trial when the MMA was tested; 
 
 Item(s) that ask about the source of the information used in the MMA; 
 
 Item(s) which concern how the MMA information sources were selected; 
 
 Item(s) that address the psychological (fear, anxiety) effects of using the MMA; 
 
 Item(s) which address how users of the MMA may feel stigmatised; 
 











Domain 5: Cost-effectiveness  
Domain: Cost, cost - effectiveness  Question(s) 
Number 
Does the framework have any item(s) that address whether 
the MMA is cost-effective? 
✔ ? ✘  
   
*Item(s) that address cost-effectiveness could include: 
 Item(s) that address if an health economic evaluation of the MMA has been conducted; 
 
a) Item(s) which ask about what type of health economic evaluation was conducted 
and whether it has been justified;  
 Cost-consequence analysis (all health related cost(s) and outcome(s) 
are disaggregated and listed separately)a ; 
 
 Cost-minimisation analysis (multiple health outcomes are viewed as 
similar and the cost is the same as the least cost comparator); 
 
 Cost-effectiveness analysis (compares the relative difference of costs 
and effects of health interventions, and can be summarized in the form 
of the incremental cost-effectiveness ratio (ICER))a; 
 
 Cost-utility analysis (a form of cost-effectiveness analysis in which the 
measure of effectiveness is exclusively in quality adjusted life years 
(QALYS))a; 
 
 Cost-benefit analysis (places monetary value on health care resources 
as well as on health outcomes)a; 
 
b) Item(s) that ask about the perspective (e.g. societal, insurance, social) that the 
economic analysis assumed; 
 
c) Item(s) which ask if the assumption used in the economic analysis can be 
justified (e.g. time horizon, discount rates), and if these had been tested in 
sensitivity analyses; 
 
d) Item(s) which address how the sources of literature for the economic analysis 
were collected (e.g. systematic review), and whether they were appropriate and 
had been tested in sensitivity analysis; 
 Item(s) that address if the sources of the cost are different to the ones 
used for outcomes (effectiveness/safety); 
 








*Economic analysis of a comparable MMAs may be included if the reasoning is provided, 






Domain 6: Organisational aspects 
Domain: Organisational Aspects   Question(s) 
Number 
Does the framework have any Item(s) that address possible 
implications (e.g. professional or organisational) relating to 
the use or recommendation of MMAs?  
✔ ? ✘  
   
Item(s) that address organisational, and professional implications could include: 
 
 Item(s) that address if training is need for users (e.g. medical practitioners, patients, care 
givers, allied health workers); 
 
 Item(s) that address if additional accreditation will be needed for professionals (e.g. medical 
practitioners, allied health workers, technicians); 
 
 Item(s) that address if adopting the MMA will alter the current utilisation of services (e.g. work 
load, work force, compliance); 
 
 Item(s) that address if adopting the MMA will change treatment location (e.g. rural, remote, 
hospital, clinic); 
 















Domain 7: Legal aspects 




Does the framework have any item(s) that address legal 
implications related to the MMA?  
✔ ? ✘  
   
Item(s) that address legal implications could include: 
 
 Item(s) about possible litigation risks to the relevant person(s) associated with the use or 
recommendation of the MMA (e.g. for medical professional or allied health worker); 
 
 Item(s) about how the users’ insurance(s) (e.g. professional indemnity, life, health, income) 












Domain 8: Ethical aspects 




Does the framework have any item(s) that address ethical 
considerations related to MMA?  
✔ ? ✘  
   
Item(s) that address ethical considerations could include: 
 
 Item(s) that address if the MMA has a privacy policy; 
 
 Item(s) that address the contents of the MMA’s privacy policy (e.g. if the user data is owned 
by the company, if the data can be sold without user consent); 
 
 Item(s) about whether the framework has questions that address patient confidentiality; 
 
 Item(s) that address whether the MMA asks for the patients’ consent prior to providing any 
clinical services; 
 
 Item(s) that address MMA access (e.g. cost of device, cost of MMA, subscription cost, 
geographical location); 
 
 Item(s) which consider equity in the use of MMA’s (e.g. socioeconomic status, disability, 
language, age);  
 









a Access in a health care context can be affected by influences demand and supply. Factors which 
influence demand include practices in self-care, attitudes, disease burden, as well as knowledge and 
skill. Influence on supply include cost, service appropriation, and geographical location.  








Domain 9: Social aspect 




Does the framework have any item(s) that address social 
considerations related to MMA? 
✔ ? ✘  
   
Item(s) that address social considerations could include: 
 
 Item(s) about how the MMA may affect the care giver; 
 










C.3 Structure of the data extraction table 









Outline of Framework Intended  
MMA User 
(Population) 












Supporting documentation used in -depth interviews used to determine possible pathways 
and impediments to MMA reimbursement in Australia.  
 Ethics approval 
 Recruitment email 
 Participant information sheet 
 Consent forms 
 Interview schedules  
 
Supporting documentation used to determine the applicabil ity of the MMA HTA 
evaluation module to other jurisdictions  




















D.2 Recruitment e-mail 
From: Magdalena R. Moshi (magdalena.moshi@adelaide.edu.au) 
To: [Insert e-mail address] 
CC: Rebecca Tooher (rebecca.tooher@adelaide.edu.au) 
 
Subject: Recruitment for an in-depth interview on mHealth applications in Australia 
 
Dear [Insert name] 
 
I am a PhD candidate at The University of Adelaide, Australia and I am currently 
conducting research on the feasibility of reimbursing or publicly funding mobile health 
(mHealth) applications in Australia.   
 
To achieve this I will need to talk to professionals such  as  medical practitioners, allied 
health workers, policy makers, and application developers who may be involved in 
recommending, using, regulating, or creating mHealth apps.  
 
Your position on the [interest organization name] enables you to have valuable and 
unique insight into mHealth apps in Australia. Therefore, I am wondering if you would 
be willing to be interviewed about mHealth apps in Australia. The interview will take 
approximately 30-60 minutes ad can be concluded either face to face, by 
teleconferencing, videoconferencing, or by phone-whichever you prefer. Your identity 
will be concealed in any publications or presentations that could result from the 
research. For more information I have attached a participant information sheet. 
 
If you would like to be interviewed please contact: myself; Dr Rebecca Tooher at 
rebecca.tooher@adelaide.edu.au  or on (08) 8313 1316; or Professor Tracy Merlin at  
tracy.merlin@adelaide.edu.au or on (08) 8313 3575. 
 
Similarly, if you know anyone who may be interested and willing to participate in the 
study please forward them this email and/or encourage them to get in contact with 
myself; Dr Rebecca Tooher, or Professor Tracy Merlin. 
 
Furthermore, if you have any questions please feel free to contact myself, Dr Rebecca 





Magdalena R. Moshi   
Ph.D Candidate  
School of Public Health 
The University of Adelaide  
Level 9, Adelaide Health & Medical Sciences Building 
Ph: +61 (8) 8313 6569| Fax: +61 (8) 8313 6899 
Email: magdalena.moshi@adelaide.edu.au 
 
CRICOS Provider Number 00123M 
     
----------------------------------------------------------- 
IMPORTANT: This message may contain confidential or legally privileged information. If you think it was sent to you by mistake, please delete 
all copies and advise the sender. For the purposes of the SPAM Act 2003, this email is authorised by The University of Adelaide. 
 





D.3 Participant information sheet 
PARTICIPANT INFORMATION SHEET 
 
PROJECT TITLE: Feasibility of a Reimbursement Pathway for Mobile Medical 
Applications (MMA) in Australia   
 
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL NUMBER: H-
2017-039 
 
PRINCIPAL INVESTIGATOR: Dr Rebecca Tooher  
 
SENIOR INVESTIGATOR: Professor Tracy Merlin  
 
STUDENT RESEARCHER: Ms Magdalena Moshi 
 









You are invited to participate in the research project described below. 
What is the project about? 
There is currently no public Medicare funding (reimbursement) in Australia available 
for mobile health/medical applications (apps)  (MMAs) that are accessible on portable 
devices like smartphones. There is also no specific method to determine the likely 
eligibility of apps for reimbursement. Before MMA reimbursement can be implemented 
in Australia, a method or process for evaluating MMAs needs to be developed that is 
feasible and equally as rigorous as processes used to evaluate other health 
technologies.  
 
This research aims to determine if reimbursement of MMAs is feasible in Australia and 
develop possible reimbursement implementation pathways.  
Who is undertaking the project? 
This project is being conducted by Magdalena R. Moshi who is a Ph.D candidate at 
the University of Adelaide under the supervision of Dr Rebecca Tooher and Professor 
Tracy Merlin.  
 
 





You have been invited to participate in this study because you are a medical 
practitioner, allied health worker, policy maker, or application developer and are 
currently in the use of mobile health applications within Australia. 
 
What will I be asked to do? 
If you choose to participate you will be interviewed by the student researcher 
Magdalena Moshi via phone, teleconferencing, videoconferencing or in-person. There 




How much time will the project take? 
The interview will last between 30 and 60 minutes.  
Are there any risks associated with participating in this project? 
There may be the potential for reputational and/or professional risk through disclosure 
of information about clinical or regulatory practices. To ensure confidentiality and limit 
any risks associated with participating in this research project, a pseudonym will be 
used instead of your name, any identifying information will be omitted, and  extra steps 
will be taken to maintain that you or your organisation cannot be identified from any 
data extracts used as quotation(s), or from any example(s) included in, written 
publications or presentations.  
What are the benefits of the research project?  
Your participation in the project is not expected to yield any immediate personal 
benefit. However, your input may contribute to determining whether public funding of 
MMA in Australia is feasible. Pathways identified for the implementation of frameworks 
that evaluate MMAs for reimbursement decisions may have a policy impact of some 
significance. 
Can I withdraw from the project? 
Your participation in this project is completely voluntary. If you agree to participate, you 
are free to withdraw your information any time before the submission of the thesis. 
 
What will happen to my information? 
The information you supply during the interview will be de-identified, stored securely, 
and published. The published information will omit any identifiable information and 
pseudonyms will be used in place of participants’ names.  
The digital copies of the voice recording, digital copies of consent forms, and 
accompanying transcripts will be stored within a secure area in the School of Public 
Health at the University of Adelaide. Only personnel affiliated with this particular 
research project will have access to the information you provide. Any storage drives, 
the voice recorder(s), and paper copies related to the research project will be kept in 
a locked drawer or compactus in a secure area within School of Public Health, The 
University of Adelaide. 
The interview recording and transcripts will only be made available to the three 
researchers affiliated with this project. The results from the interviews will be published 





(MM) Ph.D thesis. In the publications or presentations pseudonyms will be used, and 
any identifying  information will be omitted. 
If you are interested in receiving a the copy of the final results please let the student 
researcher know and she will supply you with a copy.  
At the completion of the project, it is not expected that  the raw data will be reused for 
any future research. 
 
Who do I contact if I have questions about the project? 
Principal Investigator   
Dr Rebecca Tooher 
(08) 8313 1316 
rebecca.tooher@adelaide.edu.au 
 
Senior Investigator  
Professor Tracy Merlin 





(08) 8313 6569 
magdalena.moshi@adelaide.edu.au 
 
What if I have a complaint or any concerns? 
The study has been approved by the Human Research Ethics Committee at the 
University of Adelaide (approval number H-2016-xxx). If you have questions or 
problems associated with the practical aspects of your participation in the project, or 
wish to raise a concern or complaint about the project, then you should consult the 
Principal Investigator. If you wish to speak with an independent person regarding a 
concern or complaint, the University’s policy on research involving human participants, 
or your rights as a participant, please contact the Human Research Ethics Committee’s 
Secretariat on:  
 
Phone:  +61 8 8313 6028  
Email: hrec@adelaide.edu.au  
Post: Level 4, Rundle Mall Plaza, 50 Rundle Mall, ADELAIDE SA 5000  
Any complaint or concern will be treated in confidence and fully investigated. You will 
be informed of the outcome. 
If I want to participate, what do I do? 
If you would like to participate in the research project please contact the student 
researcher Magdalena Moshi (08) 83136 569 or magdalena.moshi@adeliade.edu.au 










Dr Rebecca Tooher 
Principal Investigator   
 
Professor Tracy Merlin 
Senior Investigator  
 
Ms Magdalena Moshi 






D.4 Consent forms 
D.4.1 Consent form for interview conducted in person  
Human Research Ethics Committee (HREC) 
CONSENT FORM 
1. I have read the attached Information Sheet and agree to take part in the following research 
project: 
Title: 
Feasibility of a Reimbursement Pathway for Mobile Medical Applications 
(MMA) in Australia   
 Ethics Approval 
Number: 
H-2017-039 
2. I have had the project, so far as it affects me, fully explained to my satisfaction by the 
research worker. My consent is given freely. 
3. I have been given the opportunity to have a member of my family or a friend present while 
the project was explained to me. 
4. Although I understand the purpose of the research project it has also been explained that 
involvement may not be of any benefit to me. 
5. I have been informed that, while information gained during the study may be published, I 
will not be identified and my personal results will not be divulged. 
6. I understand that I am free to withdraw from the project at any time. 
7. I agree to the interview being audio/video recorded.  Yes  No  
8. I am aware that I should keep a copy of this Consent Form, when completed, and the 
attached Information Sheet. 
Participant to complete: 
Name:  _____________________ Signature: _______________________  
Date: _______________________ 
Researcher/Witness to complete: 
I have described the nature of the research 
to
 _________________________________________________________________________  
  (print name of participant) 
and in my opinion she/he understood the explanation. 






D.4.2 Consent form for interview conducted via teleconference  
 
Human Research Ethics Committee (HREC) 
CONSENT FORM 
9. I have read the attached Information Sheet and agree to take part in the following research 
project: 
Title: 
Feasibility of a Reimbursement Pathway for Mobile Medical Applications 
(MMA) in Australia   
 Ethics Approval 
Number: 
H-2017-039 
10. I have had the project, so far as it affects me, fully explained to my satisfaction by the 
research worker. My consent is given freely. 
11. I have been given the opportunity to have a member of my family or a friend present 
while the project was explained to me. 
12. Although I understand the purpose of the research project it has also been explained that 
involvement may not be of any benefit to me. 
13. I have been informed that, while information gained during the study may be published, 
I will not be identified and my personal results will not be divulged. 
14. I understand that I am free to withdraw from the project at any time. 
15. I agree to the interview being 
audio/video recorded.  Yes  No  
16. I am aware that I should keep a copy of this Consent Form, when completed, and the 
attached Information Sheet. 
Participant to complete: 








D.5 Interview schedules  
D.5.1 Interviewers introduction for all interviews 
  
My name is Magdalena Moshi, I am currently a PhD candidate at the University of 
Adelaide and I will be conducting this interview today. It is estimated that the interview 
will take between 30-60 minutes. Thank you for volunteering to be a participant in this 
interview, your participation is greatly appreciated. The aim of this research project is 
to determine the feasibility of publicly funding (reimbursing) mobile health (mHealth) 
applications in Australia.  To achieve this I will need to talk to professionals such as 
yourself (medical practitioners, allied health workers, policy makers, and application 
developers) who are involved in recommending, using, regulating, or creating mHealth 
apps to identifying anything that could potentially affect the evaluation, use and public 
funding of these technologies.  
 
This interview will be recorded to assist in the transcription and analysis of the content 
at a later stage. The copy of the recording will be destroyed after it has been 
transcribed and your name will be changed to a pseudonym. The information you 
provide may be published, but any identifying information will be omitted and a 
pseudonym will be used in place of your name. The information you provide will assist 
the research project, but it will not directly benefit you as an individual. Your 
participation in the project is voluntary and you are free to withdraw at any time as well 
as refuse to answer any questions of your choosing. 
 
You have been provided a copy of the participant information sheet as well as a copy 
of the University of Adelaide consent form. Please read both the consent from and 
participating information sheet so that you understand them. If you have any questions 
regarding either documents please feel free to ask.  
 
Once you have read the sheets and are comfortable with the situation, please sign and 
date a copy of the consent form.  
 
























I will start by asking you some basic questions,  
 







 above 66 
 




 Choose not to specify 
 
Can you tell me a little about your current role? 
Probe: Public, private, community, government role? 
 
Can you talk about your experience with MMAs? 
 
 
Now we will move on to more profession-specific questions, 
 
 
Do you currently recommend MMAs to your patients? 
Probe: Why?/ Why not?/ How do you decide which ones to recommended?/ 
Does the type of medical condition affect how you how you recommend a MMA?  
 
 
Do you currently use MMAs in clinical consultations? 
Probe: Why?/ Why not?/ How do you decide which ones to use?/ Does the type 





by whether it was possible to claim the use in a clinical consultation through the 
Medicare Benefits Scheme (MBS)?/ If the MMA suggested a particular condition 
do you still recommend further testing?/ If the MMA suggested a particular type 
of management would you use other tools to confirm the advice? 
 
Have you used MMAs (e.g. ‘wearables’) to monitor your patients? 
Probe: Why?/ Why not?/ Would being able to claim on the MBS any remote 
monitoring and/or data analysis using the MMA affect your answer? 
 
What is your current understanding of MMA reimbursement through private or public 
funding in Australia?  
 
In the time you have been recommending or using MMAs in clinical practice have you 
checked the Australian Register of  Therapeutic Goods (ARTG) to determine if the 
MMA is registered? 
Probe: Why?/ Why not?/  If the MMA is registered on the ARTG, would this 
affect your recommendation to the patient?  
 
To what extent do you trust MMA results? 
Probe: Would this be affected by the quality of the apps? If MMAs were 
evaluated through the Medical Services Advisory Committee (MSAC) 
evaluation process would your opinion differ? 
 
If MMAs were reimbursable would that change your willingness to recommend them? 
Probe: Why is that?/ Would you say it is due to cost or that the MMA has been 
properly vetted? 
 
In the past, how have your patients reacted to your recommendation of MMAs? 
Probe: Why would you say they reacted in that manner? / Have you noticed a 
difference in the age of the patients and their reaction?/ Have you noticed a 
difference between the socioeconomic status and their reaction?/ Have your 
patients ever asked about the cost of the MMA?  
 
 
 Do you have any concerns about how using or recommending MMAs would affect 
your ability to practice in healthcare? 
 (Clarify:  Australian Health Practitioner Regulatory Agency (APHRA) registration, 
practicing insurances) 
 Probe: Why?/ Why not?  
 
Lastly we will move one to more questions that related to MMA in a broader context, 
 
Can you describe your use of MMAs in your professional context? 
 
What motivated you to get involved with using MMAs in your given profession? 
 
Can you describe any resources you know that assist in using MMAs? 
(Clarify: training to use MMA for yourself or other user (i.e. patient)) 
 






Can you describe any resources you know that would assist with integrating MMAs 
into the current system? 
 
In your experience with MMAs how would you describe user experience with MMAs? 
Probe: affected by age, socioeconomic status? 
 
Does your current work place have an MMA strategy? 
Probe: If yes, what is the current strategy, is it in place, would you say it is 
working? 
 
What place do you think the MMAs should have in the Australian healthcare context? 
 



























I will start by asking you some basic questions,  
 







 above 66 
 




 Choose not to specify 
 
 
Can you tell me a little about your current role? 
Probe: Public, private, community, government role? 
 
Can you talk about your experience with MMAs? 
 
 
Now we will move on to more profession-specific questions, 
 
 
What type of applications ‘apps’ do you develop? 
Probe: Have you developed an app which meets the definition of a MMA?/ How 
does the development of MMAs differ from other types of apps?/ How does the 
evaluation of MMAs differ from other apps? 
 
What is your current understanding of the Therapeutic Goods Administrations (TGA) 





Probe: Would you say there are areas in the TGA’s regulation that of concern/ 
need improvement? 
 
In your opinion, how well does the TGAs MMA regulation address the unique 
challenges presented by the technology? 
 
Before developing an MMA are you concerned about adhering with the TGA’s 
regulations? 
 Probe: Why?/Why not? 
 
In your opinion as an App developer, what defines a good App? 
 Probe: Can you provide an example of what you define as a good apps? 
 
How have you come to these findings? 
 
 Is there a criteria you use? 
Probe: Why?/ Why not?/ How did you come across this criteria? 
 
If public or private MMA reimbursement were available in Australia, how might this 
affect app development? 
Probe: Why?/ Why not?/ How would this affect the overall development cycle of 
an apps or MMA?/ How would it affect cost?/ How would it affect software or 
hardware updates?/ How would it affect the quality of apps or MMAs?   
 
If public or private MMA reimbursement were available in Australia, would you as a 
developer try to adhere to the guidelines for reimbursement? 
Probe: Why/ Why not?/ Would your adherence to these guidelines be affected/ 
dependent on the financer/client of the MMA? 
 
When developing an MMA, what kind of aspects do you focus on? 
Probe: Do reserve any consideration for HTA domains?/ Such as safety (ability 
to do harm), effectiveness, cost-effectiveness? 
 
How much time on average does it require to develop an MMA? 
Probe: How much time goes into background research on content?/ How does 
this compare to other types of apps or MMAs? 
 
How much focus in the MMA development process is on MMA testing/trialing? 
 Probe: What type of testing is done?/ what type of consumer base is used for 
the testing? 
 
How does the development of an app differ between operating systems? 
Probe: How do you address the challenges as developers?/ Would the 




How does the functionality of an app differ  between operating systems (e.g. iOS-
Apples, Android-Google)? 
Probe: How do you address the challenges as developers?/ Would the 
evaluation and/or testing of an MMA’s functionality need to differ depending on 






How does the development of an app differ between devices? 
Probe: How do you address this challenge?/ How would differences in devices 
affect the evaluation of MMAs? 
 
Do MMAs function differently on different devices? 
Probe: How do you address this challenge?/ How would these differences affect 
the evaluation of MMAs? 
 
Apps have a fast turn over time for updates, how would this affect the evaluation of 
MMAs for reimbursement decisions? 
 Probe: Why would you include these specific aspects? 
 
In your opinion, what would the ideal MMA evaluation system contain? 
 Probe: Why have you chosen these specific elements?  
 
























I will start by asking you some basic questions,  
 







 above 66 
 




 Choose not to specify 
 
 
Can you tell me a little about your current role? 
Probe: Public, private, community, government role? 
 
Can you talk about your experience with MMAs? 
 
Now we will move on to more profession-specific questions, 
 
What do you see as the challenges of regulating MMAs? 
 
Are you familiar with the TGA evaluation processes?  
Probe: What about for MMAs? 
 
Do you think this process works for MMAs?  
Probe: what improvements could be made? Can you suggest an alternative 






(Clarify: Depending on familiarity with the TGA process – if participant is not familiar 
briefly describe process) 
 
How well do you think the TGA’s “software as a medical device” works for MMAs? 
 
How does this compare to the “MMA specific” approach used by the Food and Drug 
Administration (FDA) in the USA? 
 
Currently, MMAs can be sold on global app stores without TGA approval 
(registration), can you think of any  
methods that the Australian Government could implement to encourage global apps 
store to comply with TGA policies? 
 
With the increased popularity of MMAs, are you aware of any consideration by the 
relevant authorities of a public funding (reimbursement) pathway?  







D.6 Included documents in the study of the applicability of the MMA HTA 
evaluation module to other jurisdictions  
 
Table D.1: Included documents  
Jurisdiction  Health 
Technology 
Assessment (HTA) 
Agencies   
Document Title  Document 
Type 









Comparators & comparisons: Criteria for 
the choice of the most appropriate 
comparator(s)- Summary of current policies 
and best practice recommendations (173) 
Guideline  2015 
Comparators & comparisons: Direct and 
indirect comparisons (173) 
Guideline 2015 
Endpoints used for relative effectiveness 
assessment: Composite endpoints (173) 
Guideline 2015 
Endpoints used for relative effectiveness 
assessment: Composite endpoints (177)
  
Guideline 2015 
Endpoints used for relative effectiveness 
assessment: Health-related quality of life 
and utility measures (172) 
Guideline 2015 
Endpoints used in relative effectiveness 
assessment- Safety (175) 
Guideline 2015 
Endpoints used in relative effectiveness 
assessment: Surrogate endpoints (174) 
Guideline 2015 
 Evidence submission templates to support 
production of core HTA information and 
rapid assessments: Adaptation notes (206) 
Template 2015 
HTA core model® (179) Website 2018 
 Internal validity of non-randomised studies 
(NRS) on interventions (175) 
Guideline 2015 
 Levels of evidence: Applicability of 
evidence for the context of a relative 
effectiveness assessment (174) 
Guideline 2015 
Meta-analysis of diagnostic test accuracy 
studies(171) 
Guideline 2014 
Methodology guidelines (178) Website   2018 
Methods for health economic evaluations 
- a guideline based on current practices in 
Europe (206) 
Guideline 2015 
Personalised medicine and co-dependent 
technologies, with a special focus on 




Therapeutic medical devices (172) Guideline 2015 
Canada Canadian agency 
for drugs and 
technologies in 
health (CADTH) 
About the health technology assessment 
service(207) 
Website   2019 
Guidelines for authors of 




Guidelines for the economic evaluation of 
health technologies: Canada(170) 
Guideline 2017 




and quality (AHRQ) 
AHRQ Methods for Effective Health 
Care(164) 
Website  2008 
Methodology (166) Website  2013 
Methods guide for effectiveness and 
comparative effectiveness reviews(167) 
Guideline  2014 
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